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ABSTRACT 
The production of Nitric Oxide (NO) under physiological conditions has beneficial roles 
in acting as a key signaling component of many biological processes as well as having 
an anti-microbial effect. However its effects following excess production by the inducible 
NO pathway is potentially detrimental in the pathogenesis of chronic inflammation 
including sepsis and several other inflammatory diseases. Understanding the 
mechanisms that regulate the expression of the inducible nitric oxide synthase (iNOS) 
responsible for producing the excessive amounts of NO in disease states is therefore 
critical. In this regards, experiments were carried out to identify the signaling pathways 
that may mediate this process, focusing specifically on the JAK/STAT cascade. The 
reason for selecting the latter is because our research group, amongst others, has 
carried out extensive work investigating other signaling pathways, including the mitogen 
activated kinases (MAPK). Moreover, studies have also been carried out in an attempt 
to identify the critical role of JAK/STAT signaling for iNOS induction. These studies 
however failed to conclusively demonstrate whether, as with the MAPKs, the 
JAK/STATs may also play an essential role. Furthermore there is indeed controversy in 
the literature with researchers unable to agree whether expression of iNOS does 
require JAK/STAT activation. Thus, the aim of the project described in this thesis was to 
establish unequivocally whether activation of the JAK/STATs preceeds induction of 
iNOS. The studies were extended to L-arginine transport as well because the latter is 
widely reported to be induced in parallel with iNOS and substrate supply to iNOS may 
be critical for sustained NO production. Changes in transporter activity as well as their 
expression profiles were assessed. 
 
All experiments were carried out in either rat aortic smooth muscle cells (RASMCs) or in 
the J774 macrophage cell line. These cell types were selected because RASMCs are 
one of the prime targets for induced NO production in vascular inflammation and the 
macrophages are involved in host defence, acting in part through NO production. To 
establish the role of JAK/STATs, pharmacological and molecular approaches were 
used. Pharmacologically, two inhibitors were used and these were AG490 and JAK 
inhibitor I. The former is reported to be a selective JAK2 inhibitor and the other blocks 
all known JAK proteins. The potential of the GTPases to regulate the induction of iNOS 
was also examined using selective inhibitor known to regulate these proteins. In 
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addition to these drugs, siRNA targeting JAK2 was also exploited and western blotting 
was extensively used to detect expression of various proteins including iNOS, native 
and phosphorylated JAK2 and TYK2. Changes in iNOS activity was monitored by 
determining nitrite production using the Griess assay and L-arginine transport was 
monitored using tritiated arginine (L-[3H]arginine). RASMCs were treated with a 
combination of LPS (100 µg/ml) and IFN- (100 U/ml) and the macrophages with LPS 
(1 µg/ml) to induce iNOS and transporter activity. 
  
Consistent with previous reports, the above treatment of both cell types resulted in the 
expression of iNOS, production of NO and enhanced transport of L-arginine. These 
effects were not affected by AG490 but blocked by JAK inhibitor I. Furthermore, 
although both cell types expressed the key JAKs (JAK2 and TYK2), neither of these 
proteins were phosphorylated under conditions of induced NO production. Moreover, 
siRNA experiments showed that JAK2 expression could be abolished without any 
significant change in NO production, confirming that at least JAK2 may not be required 
for this process. Whether TYK2 is involved still remains to be resolved as the phosphor-
protein could not be detected. However the conclusive siRNA knockdown studies could 
not be carried out due to time and cost constraints. Apart from iNOS and NO 
production, changes in induced L-arginine transport were also not significantly affected 
under the experimental conditions described above suggesting that like with iNOS, 
induction of L-arginine transport is independent of at least JAK2. Interestingly however, 
STAT-1 was phosphorylated and this was blocked by JAK inhibitor I but not AG490. 
Thus, STAT-1 activation may be essential but its activation may be independent of the 
JAKs. One possible alternate upstream activator of STAT-1 may be the GTPases. 
Indeed these proteins have been indicated to phosphorylate STAT-1 independent of the 
JAKs. However, in this project, inhibition of the GTPase pathway enhanced NO 
production and L-arginine transport suggesting that the GTPases downregulate these 
processes. 
 
In conclusion, the studies carried out in this thesis have shown that induction of iNOS, 
NO production and L-arginine transport in both RASMCs and J774 macrophages are 
independent of JAK2 but require STAT-1 activation which may be phosphorylated 
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independently of the JAKs. The role of other JAKs such as TYK2 although unlikely, will 
need to be resolved using a more specific approach such as siRNA. 
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1.1  NITRIC OXIDE 
1.1.1 Physical, chemical and biochemical properties of nitric oxide 
Nitric oxide (NO) is a seamlessly simple (30 Da) diatomic, colourless but very reactive 
molecule implicated in a myriad of cellular and physiological processes in mammals 
including humans. Nitric oxide, also called nitrogen monoxide, is basically two 
molecules consisting of nitrogen and oxygen (see Figure 1.1) combining together to 
form NO. It is a gaseous and hence a diffusible substance, which is generated in 
biological systems by a family of enzymes collectively known as nitric oxide synthases 
(NOS). Under gaseous conditions NO reacts with molecular oxygen forming NO2 gas. 
This molecule is able to spontaneusly dimerize, forming N2O4 which can yield equimolar 
quantities of both NO2
- and NO3
- by spontaneous dismutation in water. However, in 
pure oxygen-containing aqueous solution, NO displays a longer half-life of 500 seconds 
or more (Wink et al., 1993) and yields significant quantities of NO2
- without much NO3
- 
production. These reactions are outlined in Figure 1.2 and other properties of NO are 
summarized in Table 1.1. 
 
The biological actions of NO are fairly diverse and widespread whiles its’ fate is 
significantly dependent on the physiological environment. The often complex nature of 
atherosclerosis and associated inflammation are now considered one of the prime 
underlying pathologies of cardiovascular disease (CVD). The structural elements of the 
vascular endothelium wall are the principal targets. At the center of these myriad of 
events are circulating components including inflammatory cells (such monocytes and 
macrophages) platelets and leukocytes. Evidence from experiments involving intact 
animals, tissues or cells suggest that the excess NO produced is the cause of the 
pathophysiological processes of CVD such as in atherosclerosis (Cooke et al., 1997) 
and associated complications such as in sepsis and septic shock. (Kirkeboen et al., 
1999) In this thesis we shall aim to investigate the regulation of iNOS expression in both 
RASMCs and J774 macrophages. 
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Figure 1.1 Lewis structure of Nitric oxide. 
The unpaired electron on the oxygen atom makes this molecule highly reactive. 
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Figure 1.2 Reactivity of NO under different conditions 
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Table 2.1 Summary of the physical properties of nitric oxide 
 
 
 
 
  
 
PROPERTIES 
 
Molecular formula NO 
 
Molar Mass 30.0061 g/mol 
 
Appearance Colourless gas 
 
Density 
 
1.3 × 103 kg m−3 (liquid) 
1.34 g dm−3 (vapour) 
Melting point 
 
−163.6°C (109.6 K) 
Boiling point 
 
-151.7 °C (121.4 K) 
EU classification 
 
Toxic (T), corrosive (C) 
NFPA 704  
 
FIRE -              0 
HEALTH -        3 
REACTIVITY - 1 
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1.1.2 Historical perspectives of mammalian NO 
Nitric oxide was originally identified as endothelium-derived relaxing factor (EDRF) by 
Furchgott and Zawadzki in 1980. Later, other independent investigators identified NO 
as EDRF (Palmer et al. 1987), which is produced by endothelial cells and induce 
smooth muscle cell relaxation in response to agonists such as acetylcholine (Furchgott 
et al., 1980). This discovery suggested for the first time a physiological role for NO, 
which has since been shown to be the principal target in cardiovascular and immune 
systems. It also has an important role in protein interactions and is a key target in 
normal cellular metabolism. 
 
 
1.1.3 Industrial/Commercial production and uses of nitric oxide 
The inception of NO research goes back as far as 1772 when it was first described as 
an air pollutant. Up until the last centuary, NO has been an important intermediate raw 
material in the chemical industry and was produced on a massive scale as an 
intermediate in the Ostwald process for the synthesis of nitric acid from ammonia  
(http://chemed.chem.purdue.edu/genchem/topicreview/bp/ch10/group5.php). One of the 
leading industrial uses during the first world war was the production of explosives in 
artillery shells and fairly later on, its applications in the semiconductor industry where it 
is used in combination with nitrous oxide to form oxynitride gates in Complementary 
metal–oxide–semiconductor (CMOS) devices; a major class of integrated circuits. In the 
electronic industry, detection of surface radicals on polymers is made possible by the 
use of nitric oxide and the subsequent incorporation of nitrogen. A quantitative measure 
is undertaken by means of X-ray photoelectron spectroscopy (Carley et al., 1979) 
 
It is estimated that about 80% of emitted NO worldwide is primarily from human 
activities such as in farming and its’ associated practises. As an environmental 
pollutant, NO or nitrogen oxides is commonly found in gasoline engine emission 
(Brooks et al., 1993; Wallace et al., 1981) and in cigarette smoke where is it reported to 
significantly affect the expression or activity of eNOS (or type III NOS) (Nadler et al., 
1983; Yang et al., 2007). It is also produced as a result of fossil fuel combustion and 
from other industrial processes (Cao et al., 2008; Frey et al., 2008). In addition, NO is 
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the active compound released under acidic conditions from many meat preservation 
techniques using nitrites and nitrates (Benjamin et al., 1994; Reddy et al., 1983). 
 
In agriculture, the production of nitric acid is closely linked to the manufacture and 
demand for nitrogenous fertilizers. At present fertilizers are sourced as solid urea rather 
than as ammonium nitrate. The influence on plant growth and activities of soil microbes 
maintains a fine balance between microbial mineralization, nitrification, nitrogen fixation, 
and denitrification processes. This consequently is a major factor in determining soil 
nitrogen availability in the natural ecosystem. In plants, NO is released into the soil by 
denitrifying bacteria as a free intermediate between nitrite and N2O (Carr et al., 1990; 
Heiss et al., 1989; Zafiriou et al., 1989) in the roots of leguminous plants whose main 
role is providing plants and the surrounding soil ecosystem with a rich and available 
source of nitrates and nitrites. In addition NO is obtained from dietary intake of fresh 
foods such as lettuce, spinach and beetroot which has a natural abundance of nitrates.  
 
In mammals, NO is produced by the NOS enzymes which are described in more detail 
below (Section 1.1.4 and 1.1.5). In addition, NO is also obtained either from dietary 
intake when accumulated salivary nitrites are acidified in the stomach (Benjamin et al., 
1994; Dykhuizen et al., 1996) or from biosynthesis by the NOS enzymes using the 
amino acid L-arginine as a substrate (see below). 
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1.1.4 Biosynthesis of Nitric Oxide 
All NOS enzymes catalyse a multi-electron oxidation of the terminal guanidine-nitrogen 
of the cationic amino acid L-arginine by performing two separate oxidation cycles 
(Marletta et al., 1988; Palmer et al., 1988b) as illustrated in Figure 1.3. The first of these 
reaction steps (Monooxygenase I) catalyses the oxidation of L-arginine to N-hydroxy-
L-arginine (NHA), whereas the second step (monooxygenase II) catalyses the oxidation 
of NHA to citrulline and NO (as shown in Figure 1.4) (Marletta et al., 1988; Pufahl et al., 
1992; Zembowicz et al., 1991). 
 
During the first monooxygenation, binding of BH4 and L-arginine to the oxygenase 
domain increases haem redox potential forming a ferric haem. On the reductase 
domain, electrons are donated from NADPH and flow via FAD and FMN to the 
oxygenase domain, where they reduce the ferric haem to ferrous haem. Binding of an 
oxygen molecule forms a ferrous-oxy complex which equilibrates with a ferric-
superoxide complex. Simultaneous addition of an electron and a proton from BH4 
reduces the superoxide bound to hydroperoxide. Further protonation induces the 
irreversible breaking of the oxygen-oxygen bond, resulting in a ferryl iron with a protein-
bound cation radical and H2O. This highly oxidizing species rapidly oxygenates L-
arginine to NHA, and the enzyme resting state is regenerated. 
 
Throughout the second monooxygenation reaction, a single electron from the reductase 
domain reduces the ferric haem iron to ferrous-oxy complex allowing binding of 
molecular oxygen and thus generating the ferrous-oxy complex. Finally, this ferrous-oxy 
complex catalyses the NHA oxidation to NO, citrulline and water, and regenerates the 
ferric haem protein again (Andrew et al., 1999). 
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Figure 1.3 The two step consecutive hydroxylation reactions of NOS enzyme on L-
arginine with Nω-hydroxy-L-arginine (NHA) as the intermediate and NO and L-citrulline 
as the products. Adapted from (Abramson et al., 2001)  
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1.1.5 Nitric oxide synthase isoforms 
As already highlighted, NO is synthesized by the NOS family of enzymes (NOSs, EC 
1.14.13.39) of which there are three different isoforms; endothelial NOS (eNOS, NOS1 
or NOSI), neuronal NOS (nNOS or NOS3 or NOSIII) and inducible NOS (iNOS or 
NOS2 or NOSII). These are products of three different genes with a homology between 
isoforms of 50-58% (Janssens et al., 1992; Lamas et al., 1992; Nishida et al., 1992; 
Sessa et al., 1992). The enzymes also show differences in localization, regulation, 
catalytic properties and inhibitor sensitivity (Bredt et al., 1991; Geller et al., 1998; 
Janssens et al., 1992; Lamas et al., 1992; Lowenstein et al., 1992; Lyons et al., 1992; 
Nishida et al., 1992; Sessa et al., 1992; Yui et al., 1991). They were firstly classified by 
their expression pattern as constitutive and inducible isoforms, but are now classified 
according to their expression profile in neuronal, endothelial and inducible tissues 
(Alderton et al., 2001; Andrew et al., 1999; Forstermann et al., 1994; Forstermann et al., 
1995a; Forstermann et al., 1995b; Papapetropoulos et al., 1999).  All three isoforms, 
though structurally  related, differ in their dependence on Ca+ for activity, genetic origin, 
anatomic distribution and physiological role in disease (Wu et al., 2002). 
 
Neuronal NOS (nNOS or NOS1) (Bredt et al., 1991) and endothelial NOS (eNOS or 
NOS3) (Janssens et al., 1992; Lamas et al., 1992) are constitutively expressed, and 
thus known as constitutive NOS (cNOS). While nNOS was first identified in neuronal 
cells from the central and peripheral nervous systems, eNOS was initially discovered in 
endothelial cells. Nonetheless, they are both known to be expressed in various other 
tissues and cell types (Alderton et al., 2001; Anderson, 2003; Forstermann et al., 
1995a; Forstermann et al., 1995b; Papapetropoulos et al., 1999). Both isoforms have 
expression patterns that are quite complex (Boissel et al., 1998). In nNOS, however 
regulation of expression in specific physiological conditions are under promoter control. 
This is reported to involve different transcriptional units containing alternative 
promoters. Both isoforms constitutively produce NO within the low picomolar range and 
participate in the regulation of physiological processes in the neuronal and 
cardiovascular system respectively. Production of NO by these isoforms is regulated 
mainly at the enzymatic level, where changes in the concentration of intracellular 
calcium (Ca2+) play a central role in their regulation by stabilizing calmoduline (CaM) 
binding to its binding site and thereby inducing NO synthesis (Busse et al., 1990). 
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Inducible NOS, in contrast to its constitutive isoforms, is mainly regulated at the 
expressional level and is entirely Ca2+ insensitive probably due to its peculiar non-
covalent association with calmodulin. In particular, expression of iNOS in resting cells is 
usually very low or absent, although it can be induced by hypoxia (Iadecola et al., 1996; 
Nagafuji et al., 1992). Additionally it can be induced by LPS and/or proinflammatory 
cytokines (IL-1, IL-2, IL-6, and TNF- and IFN-) in almost every cell type including 
macrophages, lymphocytes (Kirk et al., 1990), neutrophils (Rimele et al., 1988; Schmidt 
et al., 1989), smooth muscle cells (Beasley et al., 1991) hepathocytes (Mellouk et al., 
1994) and cardiac myocytes (Szabo et al., 1993). Once induced, iNOS expression 
requires a delay of several hours for de novo protein synthesis before the onset of NO 
production. Moreover, once expressed, iNOS produces NO in the high nanomolar 
range (1000-fold larger quantities than the constitutive isoforms) over several hours or 
even days. In addition, iNOS activity is not changed by modulation of calcium [Ca2+] 
probably due to the tight binding of CaM to the enzyme (Cho et al., 1992), thus 
suggesting that iNOS regulation occurs at the transcriptional level (see figure 1.3). 
Nonetheless, limited evidence suggest that regulation of iNOS may also occur at the 
functional level by post-translational modification through phosphorylation (Panaro et 
al., 1999; Salh et al., 1998). 
 
Evidence has been put forward for a fourth NOS isoform, distinct from those described 
above which appears to be of relevance in mitochondrial bioenergetics. This novel 
isoform is referred to as mitochondrial NOS (mtNOS) (Elfering et al., 2002; Ghafourifar 
et al., 1997; Ghafourifar et al., 1999; Giulivi et al., 1998). However, its relationship with 
other isoforms and its regulation is not clearly understood as yet (Adcock et al., 1994; 
Kanai et al., 2004). 
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1.1.6 Structure and molecular characteristics of Nitric Oxide Synthase 
The active NOS enzyme is dimeric and presumed to function as a homodimer during 
activation. It is made up a calmodulin-dependent hemoprotein (homologous to 
cytochrome P450) with both a reductase and oxygenase domains. The presence of 
flavin adenine dinucleotide (FAD) and flavin mononucleotide aids in its ability to carry 
out a 5-electron oxidation of non-aromatic amino acid arginine with the aid of 
tetrahydrobiopterin (BH4). Calmodulin acts as a molecular switch to enable electron flow 
from FAD to heme thereby facilitating the conversion of oxygen and L-arginine to NO 
and citrulline. 
  
The NOS enzymes consists of two domains: an oxygenase and a reductase domain 
(Chen et al., 1996; Ghosh et al., 1995; Sheta et al., 1994) with a CaM binding domain in 
between (Figure 1.4) (Ghosh et al., 1995; Klatt et al., 1995; Maciejewski et al., 1995; 
Marrero et al., 1998) (see Figure 1.4) in one dimer. The reductase or C-terminal domain 
contains binding sites for one molecule of nicotinamide adenine dinucleotide phosphate 
(NADPH), flavin adenine dinucleotide (FAD), and flavin mononucleotide (FMN) (Bredt et 
al., 1992; Cho et al., 1992; Geller et al., 1998; Lowenstein et al., 1992; Nishida et al., 
1992; Sessa et al., 1992). The oxygenase or N-terminal domain binds iron 
protoporphyrin IX (haem, Fe), and (6R)-5, 6, 7, 8-tetrahydrobiopterin (BH4) together 
with the substrate L-Arginine (Bredt et al., 1992; Cho et al., 1992; Geller et al., 1998; 
Lowenstein et al., 1992; McMillan et al., 1992; Nishida et al., 1992; Sessa et al., 1992). 
Both NOS monomers interact by their oxygenase domains leaving the reductase 
domains still attached as independent extensions in a head-to-head manner (Figure 
1.4) (Ghosh et al., 1995; Klatt et al., 1995; Maciejewski et al., 1995; Marrero et al., 
1998). This association requires a large interface, which includes the binding site for 
BH4 and helps to structure the active-site pocket containing the haem and the L-
Arginine binding site (Crane et al., 1998; Fischmann et al., 1999; Ghosh et al., 1995; 
Klatt et al., 1995; Maciejewski et al., 1995; Sahin-Toth et al., 1997). In addition, this 
dimer is further stabilised by two cysteine residues forming either disulphide bridges or 
ligating a zinc ion between monomers (Hemmens et al., 2000; Li et al., 1999), and an 
N-terminal hook swaping between the two monomers (Alderton et al., 2001; Andrew et 
al., 1999; Crane et al., 1999). However, binding of BH4 (Reif et al., 1999; Sahin-Toth et 
al., 1997; Saura et al., 1996), haem and L-Arginine have also been suggested to 
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promote and/or stabilize the active dimeric form, although the different NOS isoforms 
present distinct dimer interaction (Panda et al., 2002). 
 
Nitric oxide could through a negative feedback mechanism involving s-nitrosation (or s-
nitrosylation), regulate NOS expression. There is however substantial evidence 
implicating the rate limiting steps in NO production in some cell to the availability of 
extracellular L-arginine. Both NOS1 and NOS2 can be inactivated by forming ferrous-
nitrosyl complexes in their heme prosthetic groups (Abu-Soud et al., 1995; Buga et al., 
1993). 
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Figure 1.4 Schematic domain structure of the NOS dimer. 
An illustration showing the main cofactors and substrate binding sites of the NOS dimer 
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1.1.7 Physiological properties of Nitric oxide 
The endogenous production of NO as well as its effects on the surrounding tissues 
have led some investigators to hypothesize its role as a secondary mediator. One of the 
principal actions of NO is its role as a biological messenger, targeting soluble guanylyl 
cyclase (sGC) which catalyses the conversion of guanosine triphosphate (GTP) to 
cyclic 3', 5' guanosine monophosphate (cGMP) (Ignarro et al., 1982). Once produced, 
cGMP is able to cause vascular smooth muscle relaxation thus mediating NO-induced 
vascular relaxation (Furchgott et al., 1980; Moncada et al., 1993; Palmer et al., 1988a; 
Radomski et al., 1987). This stems from the slightly faster diffusion coefficient of NO 
[approx. 3800 μm2/s] (Vanderkooi et al., 1994) compared to that of oxygen [2000 μm2/s 
at 25 ºC or 3240 μm2/s at 40 ºC] or carbon dioxide [1600 μm2/s at 25 ºC], and its 
hydrophobicity thus allowing it an accelerated difusion through cells relatively quickly 
(Lancaster, 1994). 
 
Physiological concentrations of NO has also been shown to have anti-platelet actions, 
inhibiting platelet aggregation (Alheid et al., 1987; Furlong et al., 1987; Glusa et al., 
1974; Mellion et al., 1981) and adhesion to vascular endothelium (Benjamin et al., 
1991; Kubes et al., 1991; Radomski et al., 1987; Sneddon et al., 1988), thus avoiding 
blockage of the vasculature through a similar action on sGC (Radomski et al., 1987; 
Yamakado et al., 1982). 
 
Nitric oxide has also been implicated in neuronal signalling, mediating the ability of the 
excitatory neurotransmitter glutamate to stimulate cGMP levels via N-methyl-D-
aspartate (NMDA) receptors in the brain (Bredt et al., 1989; Garthwaite et al., 1989). 
This has led to the implication of NO in long term potentiation (a model of memory and 
learning), where NMDA induces changes in synaptic transmission (Bohme et al., 1991; 
O'Dell et al., 1991; Schumann et al., 1996). Similarly, in the cerebellum, NO may act as 
a messenger in long term depression (a model of motor learning) (Shibuki et al., 1991). 
Furthermore, NO in the peripheral nervous system regulates relaxation of the 
gastroinstestinal tract (Bult et al., 1990; Gibson et al., 1990; Gillespie et al., 1989; 
Ramagopal et al., 1989), penile erection (Bowman et al., 1986; Ignarro et al., 1990), 
and blood flow to the adrenal medulla (Breslow et al., 1992) by acting as a non-
adrenergic non-cholinergic (NANC) neurotransmitter. Within the immune system, NO 
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produced by macrophages may mediate host response immunity to invading organisms 
(Hibbs et al., 1988). 
 
 
1.1.8 Pathological properties of Nitric oxide 
The characteristically high NO output from iNOS following induction means that the 
associated unshared electron(s), mediating cell-to-cell communication, signaling and a 
growing list of biological processes, can often result into pathological events inspite of 
fulfilling some physiological objectives. In some studies however low NO may stimulate 
cell growth and be protective of cells from apoptosis (Kim et al., 2001). To date, 
evidence suggest that the effects of NO overproduction is dependent on concentration 
(µM), tissue type and duration of exposure (overs days to weeks) (Abramson et al., 
2001). These parameters have all been implicated in the pathogenesis of various 
diseases including cancer (Hibbs et al., 1992; Xu et al., 2002), atherosclerosis (Chin et 
al., 1992; Napoli et al., 2006) and in endotoxin (Andoh et al., 2013; Westenberger et al., 
1990), hemorrhagic (Andoh et al., 2013; Thiemermann et al., 1993) and anaphylactic 
shocks (Amir et al., 1991; Evora et al., 2007) or even in the hyperdynamic state such as 
cirrhosis (Benjamin et al., 1994). Similarly, several other immune-associated 
pathologies such as acute (Ialenti et al., 1992) and chronic inflammation (Laroux et al., 
2001), rheumatoid arthritis (Farrell et al., 1992; McCartney-Francis et al., 1993), 
ulcerative colitis (Middleton et al., 1993), inflammatory bowel disease (Singer et al., 
1996), asthma (Kharitonov et al., 1994; Zhou et al., 2006) and diabetes (Kleemann et 
al., 1993; Kroncke et al., 1993) have also been linked to abnormal overproduction of 
NO. These deleterious actions of NO have also been implicated in pathologies within 
the CNS such as cerebral ischemia (Beckman, 1991; Nowicki et al., 1991), epilepsy 
(Beckman, 1991), Huntington's disease (Dawson et al., 1991; Norris et al., 1996), 
multiple sclerosis (Sherman et al., 1992), and the dementia found in acquired 
immunodeficiency syndrome patients. 
 
With iNOS, for instance, its expression in various tissues is associated with pathological 
conditions where overproduction of NO is believed to contribute to the initiation and/or 
progression of the disease. This is particularly true for septic shock which is an 
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inflammatory condition within the vasculature that is mediated, potentially, by excessive 
iNOS-derived NO (Enkhbaatar et al., 2006; Thiemermann et al., 1993; Vallance et al., 
1993) as one of its principal causes. Indeed, studies in animal models have shown that 
the induction of iNOS within the blood vessel wall (especially the smooth muscle layer) 
contributes to vascular collapse caused by NO-induced vasodilatation resulting in 
severe hypotension, poor perfusion of tissues and thus multi organ failure and 
subsequent death (Enkhbaatar et al., 2006; Thiemermann et al., 1993). In addition, 
some patients in intensive care with severe sepsis do suffer from severe hypotension 
with associated cardiovascular collapse and multiple organ dysfunction syndrome 
(MODS) (Vallance et al., 1993). 
 
The expression of iNOS is also only restricted to some tissues where expression 
remains low under normal physiological conditions and only expressed when induced 
by certain factors. Evidence suggests that transcription of iNOS gene is often up-
regulated by pro-inflammatory stimuli including cytokines (TNF- IL-1, IFN-), growth 
factors and endotoxin (LPS) (Moncada et al., 1991; Nathan et al., 1994). This is evident 
from the variety of inflammatory diseases mentioned previously. Expression is also 
upregulated in certain stressful conditions (Fang, 2004) or even, following an infection 
by microbial products such as LPS, Irrespective of the source of triger, the very high 
levels of NO generated has often been associated with an uncontrolled tissue injury. At 
other times, the high NO output could prove too cytotoxic to the bacteria and thereby 
either contribute to abrogation of the bacteria itself or restriction in its rate of growth. In 
summary, there is overwhelming evidence to suggest that inflammation within the 
vasculature together with high NO production are major contributory factors in the 
pathogenesis of diseases such as atherosclerosis (Ross, 1999). 
 
A major factor that mediates these unwanted effects of NO has been the result of its 
free diffusible and highly reactive nature. In addition, the principle determinant of the 
wellbeing of the vasculature is its redox state and NO is a key mediator of endothelial 
function. Both L-arginine and BH4 are very important in maintaining both adequate 
(healthy) vascular function and an active NOS dimer in order to function at its optimum 
level. L-arginine is an absolute subtrate for NO production whiles BH4 functions both as 
allosteric enzyme by improving the binding affinity to l-arginine and as redox cofactor by 
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providing electrons to the heme of eNOS (Gao et al., 2007; Wei et al., 2008). In a state 
of limited L-arginine and BH4 supply, NOS becomes ‘uncoupled’ and the NADPH 
derived electrons instead of being channelled to L-arginine for citrulline and O2 
production are rather added to the latter with subsequent production of ROS. A vicious 
cyle results in further increases in peroxinitrite production with sebsequent restrictions 
in NO production by oxidizing tetrahydrobiopterin (BH4) (Kohnen et al., 2001) to levels 
below physiological levels for optimum eNOS function. Under these circumstances 
eNOS reverts from a NO producing enzyme to superoxide generating one (Xu et al., 
2006). 
 
The high level of NO (at micromolar range) is less often associated with rapid blood 
delivery, glucose uptake, contractility and other exercise associated beneficial effects 
than to the deleterious effects of its chemical reactivity with reactive oxygen species, 
ROS or more specifically, superoxide anion reacts with NO to form the highly reactive 
peroxynitrite. The latter is reported to result in the oxidation of cellular components such 
as proteins (enzymes) in the cell. These effects ultimately lead to altered protein 
structure, especially of enzymes and therefore compromise on protein function, and/or 
catalytic capacity. In addition, it seriously compromises on important physiological and 
biochemical events in cell regulation and function. To this end, various species of ROS 
have been implicated. These include production of high level of NO which reacts with 
reactive oxygen species such as O2
- to generate peroxynitrites (ONOO-) anion in the 
presence of NADPH oxidase (Beckman et al., 1990). In alkaline solutions the 
peroxynitrite becomes stable and rapidly decays once protonated by hydrogen anions. 
However in very acidic environments further reactions of peroxynitrite with ROS species 
and/ or hydrogen peroxides results in further cytotoxic reactions. 
 
The highly reactive peroxynitrite has been implicated in apoptosis of cardiomyocytes 
(Arstall et al., 1999; Dickhout et al., 2005), endothelial (Dickhout et al., 2005; Mihm et 
al., 2000) and vascular smooth muscle cells (Li et al., 2004; Li et al., 2003). It is 
therefore of little surprise that NO under induced conditions is symptomatic of 
pathologies such as sepsis and other associated inflammatory disorders including 
cerebral infarction, diabetes mellitus and neurodegenerative disorders and multiple 
organ dysfunctions. However for the purpose of this thesis, it is the impact of NO 
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overproduction on inflammatory states and septic shock that will be the focus of our 
investigations. 
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1.1.9 Atherosclerosis and inflammation 
There is at present, substantial evidence from clinical trials, laboratory studies and 
through pharmacological interventions to implicate inflammation in the pathophysiology 
of atherosclerosis. The current concept regards both inflammation and immune 
responses as contributory factors to antherogenesis (Lobo et al., 2010). The inciting 
targets for such a remodeling process involve mainly the intima layer, composed mainly 
of SMC and tissue macrophages. Under inflammatory conditions endothelial cells 
undergo activation with the subsequent expression of various adhesion molecules (i.e. 
VCAM-1). The first observable signs leading to atherosclerotic plaque occurs when 
monocyte derived macrophages are recruited and in presence of oxidized lipids 
(oxLDL), chemokines and other inflammatory mediators including NO, ROS and 
peroxynitrites, arterial foam cells, the hallmarks of arterial lesion, are formed. 
 
The clinical manisfestations of a cardiovascular disease (CVD) or events are often 
elicited in the form of a heart attack and/ or stroke. In the early stages of disease 
progression, the reported appearance of a ‘fatty’or yellow streak normally restricted to 
the inner layer of the artery with cholesterol impregnated smooth muscle cells, 
macrophages and lymphocytes are the typical hallmarks of CVD development. Recent 
findings of attenuation in lesion progression in animal models of familial 
hypercholesterolemia following a dietary intake of L-arginine supplements (Javanmard 
et al., 2009; Khazaei et al., 2012) does indicate a direct effect of iNOS. In addition the 
use of NOS inhibitors to reverse this protective effect of L-arginine (Vasdev et al., 2008) 
further reinforces the assertion of a direct involvement of NOS. The events of plaque 
rapture, acute thrombosis and necrosis are also regarded as key events in the natural 
progression of atherosclerosis (Falk et al., 1995) and substantial evidence suggests 
that macrophages might be directly implicated (Woolf, 1990). The high NO production 
following macrophage activation then acts as a source of oxygen free radicals and with 
the aid of powerful proteases, could trigger necrosis and rapture of the plaques (Woolf, 
1990). The associated inflammation has been suggested as the key mediator that 
drives the formation, progression and rupture of the atherosclerotic plaque (van der Wal 
et al., 1994). 
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In summary, the development of atherosclerosis requires several distinct events 
including enhanced cytokines production including interleukin (IL) 1, tumour necrosis 
factor- (TNF)- These cytokines in turn upregulate the induction of adhesion molecule 
VCAM-1,.ICAM-1 and E- and P-selectin expression on endothelial cells (Harari et al., 
1999; McHale et al., 1999). The latter, are responsible for the firm attachment of 
inflammatory cells to the vascular surface, particularly, at the sites of inflammation 
(O'Brien et al., 1996). Presently, various lines of evidence suggest human 
atherosclerotic lesions contain these pro-inflammatory cytokines (Blake et al., 2002; 
Libby, 2002; Ross, 1999) and these findings may well link the high LDL cholesterol 
levels to VCAM-1 expression. 
 
At present, CVD contributes significantly to the proportion of morbidity and mortality in 
the developed world (Murray et al., 1997). Apart from age and family history the causes 
are often associated with development of atherosclerotic lesion, smooth muscle cell 
proliferation and infection by microorganism. In addition, events such as vascular 
remodeling are often initiated by a number of clinical conditions such as excess low 
density lipid (LDL), cholesterol, diabetes mellitus and life style changes. In particular, 
the high LDL levels under the cytotoxic environment in the vasculature results in the 
modification of the lipoprotein and the induction of transcription of adhesion molecules. 
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1.1.10 Sepsis and septic shock; an inflammatory disease 
Despite the use of antibiotics and other associated therapies, severe infection and 
sepsis still remain a leading cause of death in most intensive care units worldwide. The 
generation of NO by iNOS has been implicated in several inflammatory disease states 
with detrimental consequences. Due to the very variable and non-specific nature of the 
signs and symptoms of the septic response following an infection, unraveling the 
complex chain of events associated with this abnormality remains a major goal. 
Currently, endotoxines, certain growth factors and a variety of cytokines, which are 
rapidly produced following sepsis, remain important mediators in the pathophysiology of 
sepsis (Akira et al., 2004; Schulte et al., 2013). 
 
In addition, Toll-like receptors (TLRS) are the principal mediators of LPS mediated 
signaling and act through the nuclear factor kappa B (NF-B) resulting in the 
upregulation of proinflammatory mediators such as TNF-, NO and IL-1 (Knuefermann 
et al., 2002; Ullrich et al., 2000). Further studies have however identified that the 
sustained activity of the iNOS enzyme, and thus NO production, is critically dependent 
on the availability and supply of exogenous L-arginine into the cells (Mori, 2007; 
Wileman et al., 2003). As a result, transport of L-argnine may be a crucial novel target 
for regulating NO synthesis by iNOS in disease states. 
 
The symptoms that accompany septic shock are often high fever following an induction 
by endotoxin and/or cytokines. The actions of these mediators are reported to trigger 
production of proinflammatory mediators, including TNF and IL-1, Chemokines 
postaglandins and ROS. Consequently these compounds induce vasodilation and 
vascular leakage, myocardial suppression, respiratory failure and hyperdynamic shock 
as a result of increased cardiac output (Hirschfeld et al., 1999; Karima et al., 1999; 
Poussin et al., 1998; Romero-Bermejo et al., 2011). These effects result in physiological 
alterations within the vasculature which impacts severely on the normal functioning of 
the vessel. 
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1.2  L-ARGININE 
1.2.1 L-arginine: characteristics and metabolism 
L-arginine has been described as the physiological precursor for NO production by 
NOS (Palmer et al., 1988a; Palmer et al., 1988b), hence its relevance in our studies. It 
is an alpha-amino acid and basic with regard to its properties due to the long 
hydrophobic carbon chain nearest the backbone (Figure 1.4). L-arginine was first 
isolated from lupin seedlings in 1886 by Ernst Schulze, a Swiss chemist and later 
identified as a component of animal proteins by Hedin (1895). This cationic amino acid 
was originally classified as being dispensable (non-essential) in healthy adult humans 
(Rose et al., 1954) but has since been shown to be essential for young, growing 
mammals (Ha et al., 1978; Mertz et al., 1952) and for carnivores (Deshmukh et al., 
1983; Morris et al., 1978). As a result L-arginine is now considered to be a semi-
essential amino acid (Barbul, 1986). 
 
The majority of endogenous synthesis of L-arginine in adults involves an interorgan 
pathway (due to high restriction in the expression of some enzymes) known as the 
intestinal-renal axis. Endogenous L-arginine is synthesized by the sequential action of 
the cytosolic enzymes argininosuccinate synthetase (ASS) and argininosuccinate lyase 
(ASL) from citrulline primarily (a coproduct of the NOS-catalyzed reaction) within the 
epithelial cells of the small intestine. Biosynthesis of citrulline on the other hand is 
derived from multiple sources; from arginine via NOS; ornithine via catabolism of proline 
or glutamine/glutamate; or from asymmetric dimethylarginine (ADMA) via 
dimethylarginine dimethylaminohydrolase (DDAH) into the blood circulation which is 
then primarily extracted by the kidney for conversion into arginine (Dhanakoti et al., 
1990; Featherston et al., 1973). Pathways linking all three sources are bidirectional. 
 
Interestingly, de novo L-arginine synthesis only accounts for 5-15% of endogenous 
arginine flux in adults, and the major contributor to endogenous arginine flux is whole-
body protein turnover (Chu et al., 1998a). The highest rates of L-arginine synthesis 
occurs within the hepatic urea cycle, although the high levels of arginase expressed in 
hepatocytes results in little or no net production of arginine by the liver (Chu et al., 
1998a; Rabier et al., 1991). The complete urea cycle is only expressed in hepatic 
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tissue, although other tissues present a truncated urea cycle known as the arginine-
citrulline cycle (Figure 1.5). This cycle allows recycling of citrulline to arginine by the 
combined action of argininosuccinate synthase (ASS; EC6.3.4.5) and argininosuccinate 
lyase (ASL; EC 4.3.2.1) (MacMicking et al., 1997). 
 
Both ASS and ASL are expressed to some degree in nearly all cell types and seem to 
be co-induced with iNOS (Chu et al., 1998a; Flodstrom et al., 1995; Hattori et al., 1994; 
Mellouk et al., 1994). This co-induction led to the proposition of a citrulline-NO cycle in 
which citrulline is generated as a co-product with NO and in turn converted to L-arginine 
for further NO synthesis (McDonald et al., 1997). Citrulline can therefore at least in part, 
replace arginine in supporting NO synthesis (Flodstrom et al., 1996; Norris et al., 1995; 
Raghavan et al., 2001; Wu et al., 1992). This proposal is however refuted by key 
publications from our group (Baydoun et al., 1994a; Wileman et al., 2003). The findings 
from both showed that citrulline could not sustain maximal production of NO when 
compared to L-arginine. Moreover, other studies have suggested that L-arginine re-
cycled from L-citrulline represent half of that used by eNOS and is much less than that 
required by iNOS (Hrabak et al., 1994). In addition, sustained NO production by iNOS 
has been shown to require extracellular L-arginine (Beasley et al., 1991; Granger et al., 
1990; Granger et al., 1988; Hibbs et al., 1987; Jorens et al., 1991; Schott et al., 1993b) 
which appears to be supplied by L-arginine transport since it is co-induced by pro-
inflammatory mediators (Bogle et al., 1992a; Closs et al., 2000; Sato et al., 1992; 
Schmidlin et al., 1995; Simmons et al., 1996; Wileman et al., 1995). Also, inhibition of L-
arginine entry into cells by blocking transport inhibits NO synthesis (Beasley et al., 
1991; Granger et al., 1990; Granger et al., 1988; Hibbs et al., 1987; Jorens et al., 1991; 
Schott et al., 1993b). This apparent lack of NO and associated endothelial dysfunction 
in some diseases despite the significantly higher (25 to 30 fold) saturating intracellular 
L–arginine within the cells has thus been reported as the L-arginine paradox. Despite 
these, further support has documented substantial improvement in endothelium-
dependent vasomotor response following the administration of L-arginine supplements 
(Tentolouris et al., 2004). Possible mechanism to explain this impasse has been the 
reported likely antagonism between L-arginine and the endogenously produced NOS 
inhibitor, ADMA (Bode-Boger et al., 2007). In addition, inactivation of NO in certain 
disease states with associated high ROS production have been reported as likely 
causes. 
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The recycling of L-arginine in the cytosol is coupled to the mitochondrial citric acid 
cycle. Fumarate, which is produced in the cytosol, (Figure 1.5) enters the citric acid 
cycle in the mitochondria, where it is converted into L-malate by the enzyme, fumarase. 
L-malate is then metabolised to oxaloacetate by the enzyme malate dehydrogenase 
enzyme. Transamination of oxaloacetate by the enzyme aspartate aminotransferase 
forms aspartate, which is transported back to the cytosol. Once in the cytosol, aspartate 
is implicated in the conversion of L-citrulline to L-argininosuccinate, a reaction catalyzed 
by argininosuccinate synthase. Argininosuccinate is then metabolized by 
argininosuccinate ligase to give L-arginine (Chu et al., 1998a). 
 
In summary, L-arginine has a number of physiological roles in addition to NO production 
as illustrated in Figure 1.5. Significant metabolites produced in this cycle include 
citrulline, urea, creatine, ornithine and methylarginine derivatives. Regulation of L-
arginine availability may be controlled by the degree of uptake of the latter by 
transporters into the various cells (McDonald et al., 1997). 
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Figure 1.5 The metabolic fate of L-arginine. 
Arginine also serves as a metabolic precurcor for several metabolites. 
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1.2.2 L-arginine transporter system 
Our current understanding of the pivotal role of substrate availability in controlling NO 
production does provide opportunities in NO modulation and therapy from the effects of 
excessive NO production. Evidence of a substantial increase in iNOS-derived NO and 
elevated nitrates in plasma of patients with chronic heart failure (Habib et al., 1994; 
Toda et al., 2011; Winlaw et al., 1994) or renal failure (Noris et al., 1993; Qian et al., 
2013) together with elevated L-arginine in red blood cells (Mendes Ribeiro et al., 1997; 
Schuster et al., 2012) suggest the involvement of a transport system mediating these 
adaptive changes. 
 
In most mammalian cells, arginine requirements are primarily met by uptake of 
extracellular arginine via specific transporters. These transporter families include the 
widely expressed system y+ and the tissue specific systems b0+, B0+, y+L and b+ (Deves 
et al., 1998c; Kilberg et al., 1993; Palacin et al., 1998). These transporters are a 
member of the solute carrier family 7 (SLC7) which consist of two subfamilies, the 
SLC7A1-4 which is made up of the cationic amino acid transporters (CAT-1, CAT-2A, 
CAT-2B, CAT-3, and CAT-4) family and the SLC7A5-11 (y+LAT1, y+LAT2, b0,+) 
transporter family. The latter are glycoprotein associated amino acid transporters 
comprising of seven proteins (the gpaAT family; also called L (light) chains amino acid 
transporters (LATs). They are characterized as high affinity, broad scope amino acid 
transporters of specifically two homologous proteins, rBAT (Bertran et al., 1992b; Tate 
et al., 1992) and 4F2hc (Bertran et al., 1992a; Wells et al., 1992). On the available 
evidence to date, the gpaAT family which is made up y+LAT1 (SLC7A7), y+LAT2 
(SLC7A6), b0,+ (SLC7A9) and Bo,+ (SLC7A11) genes are implicated in the transport of 
cationic amino acids (Verrey et al., 2004). 
 
Apart from the SLC7A family of transporters the SLC6A14 transporter (Bo+AT) is also 
known to mediate in L-arginine transport via a sodium and chloride dependent 
mechanism (Sloan et al., 1999). Interestingly, of all these transporters, only system y+ 
has been shown to be co-induced with iNOS by proinflammatory mediators in 
macrophages (Bogle et al., 1992b), smooth muscle cells (Durante et al., 1995; Wileman 
et al., 1995), astrocytes (Heid et al., 1996) and cardiac myocytes (Simmons et al., 
1996) amongst others. It has therefore been suggested that enhanced transporter 
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activity may provide a mechanism for increasing substrate supply during sustained 
synthesis of NO by iNOS. Thus, transport of L-arginine through system y+ may play a 
crucial and relevant role in regulating NO synthesis. In support of this hypothesis is the 
evidence already stated above that inhibition of L-arginine transport by other cationic 
amino acids inhibits NO synthesis in cells expressing iNOS (Bogle et al., 1992a; 
Marletta et al., 1988; Wileman et al., 1995). Furthermore, NO synthesis is dramatically 
impaired in mice deficient in system y+ transporters (Nicholson et al., 2001a). 
Nonetheless, new evidence suggests that the broad scope system y+L can also be 
induced by IFN- in human monocytes (Rotoli et al., 2004), although synthesis of NO in 
these cells appear to be independent of L-arginine transport  (Rotoli B.M., unpublished 
data). Since evidence from other studies show that other L-arginine transport systems 
may be implicated in NO production particularly via systems y+, y+L and bo+  this study 
did not exclude their possible involvement in L-arginine-transport systems. 
Nonetheless, the discussion below will focus on system y+ as this appears to be the 
predominant carrier system for cationic amino acids in smooth muscle cells, the cells of 
choice for this thesis. 
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1.2.3 Characteristics of members of system y+: CATs 
System y+ catalyses the high affinity Na+-independent transport of cationic amino acids, 
in addition to it ’s reaction involving neutral amino acids in the presence of Na+ 
(Christensen et al., 1969; Christensen et al., 1968; White et al., 1982). Members of this 
system share a common but unique mode of transport by acquiring substrates through 
coupling their transport mechanism with the with the plasma membrane potential 
(Deves et al., 1998c; Palacin et al., 1998). System y+ is made up of a family of five 
different Cationic Amino acid Transporters (CATs) referred to as CAT-1 (Kim et al., 
1991), CAT2A (Closs et al., 1993a), CAT2B (MacLeod et al., 1990), CAT-3 (Hosokawa 
et al., 1997; Nishiya et al., 1997) and CAT-4. The latter however lacks cationic amino 
acid transport activity (Hammermann et al., 2001; Verrey et al., 2004; Wolf et al., 2002). 
 
The CATs are classified as a glycosylated solute carrier family 7(SLC7 member) and 
displays the characteristic 14 putative transmembrane segments for surface 
expression. Their proteins essentially mediate Na+-independent transport of cationic L-
amino acids such as L-arginine, L-lysine and L-ornithine. In addition, all CATs exhibit 
the characteristic y+ system of trans-stimulation, i.e. concentration dependent 
stimulation of transport by substrate at the opposite site of the membrane. Amongst the 
CATs, CAT-1 has the most pronounced trans-stimulation in contrast to CAT2A, which is 
the least stimulated or is relatively insentive to trans-stimulation (Closs et al., 1993c). 
 
CAT-1 was first identified (Albritton et al., 1989) as the ecotropic murine leukaemia virus 
receptor (ecoR) (Kim et al., 1991; Wang et al., 1991) and was later renamed as CAT-1 
(Closs et al., 1993a). The rat member exhibits 95% homology with the murine (Aulak et 
al., 1996; Wu et al., 1994) and over 85 % with the human homologue. Described as a 
constitutive and widely distributed cationic amino acid transporter, it is formed by a 622 
amino acids (aa) single polypeptide with 12 (Kavanaugh et al., 1994a) to 14 
transmembrane spanning domains (Albritton et al., 1989; Woodard et al., 1994). 
Transport of L-arginine, L-ornithine, and L-lysine by CAT-1 is Na+-independent and 
saturable (Km values 70–100 mM) (Kim et al., 1991; Wang et al., 1991). Neutral amino 
acids (such as glutamine, serine, homoserine, and 2-methylaminoisobutyric acid) can 
only induce currents at very high concentrations and only in the presence of Na+ (Wang 
et al., 1991). Its expression has been shown in all tissues investigated except normal 
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liver, although it is expressed during liver regeneration (Deves et al., 1998c; Kim et al., 
1991; Palacin et al., 1998). Evidence to date suggest that in different cell types 
depletion of their substrate availability results in a coordinated increase in CAT-1 mRNA 
level and y+ mediated transport (Fernandez et al., 2001). In other words there is 
synergistic adaptive regulation of cationic amino acid transport and protein synthesis to 
changes in their substrate availability. 
 
Studies on transcriptional control by amino acid availability depend on the modulation in 
both transcription and mRNA stability. The transcription of two key genes, present on 
the first exon in CAT-1 gene; an amino acid response element (AARE) and 
CCAAT/enhancer binding protein (CEBP) homologus gene (GTGATGCAAT) are prime 
targets. These two genes are induced by amino acid depletion, potential transcription 
factors and their target cis-DNA elements. 
 
A second member of the CAT family, CAT2, has been identified in different mammalian 
species for which two main splice variants have been characterized in the y+ transport 
system. The two variants, referred to as CAT2A and CAT2B have been described to be 
structurally homologous to CAT-1 but different in kinetic properties, tissue distribution 
and expression patterns in the body. Both transporters are products of the same gene 
generated by alternative splicing (Finley et al., 1995) although they produce two distinct 
proteins. These proteins have a 97% homology, only differing in 20 amino acids within a 
stretch of 41 base pairs (Closs et al., 1997). This difference in their sequences may 
account for the differences in affinity and kinetic properties of these two proteins. 
 
CAT2B, described as an inducible carrier, is usually co-expressed with CAT-1, and its 
expression has been documented in lung, brain (Deves et al., 1998b; Palacin et al., 
1998), activated cells such as macrophages (Closs et al., 2000), astrocytes (Heid et al., 
1996) and aortic vascular smooth muscle cells (Baydoun et al., 1999). It is also 
normally induced together with iNOS (Hattori et al., 1999; Heid et al., 1996; Schwartz et 
al., 2002; Simmons et al., 1996), and it has been suggested that it may have a specific 
role in delivering substrate to iNOS (Closs et al., 2000; Hammermann et al., 2001; 
Manner et al., 2003; Nicholson et al., 2001a; Schwartz et al., 2002). However, other 
studies suggests that CAT2B is not essential for NO production by iNOS (Cui et al., 
2005). In contrast to CAT2B, CAT2A is a low affinity carrier of cationic substrates (Km = 
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2-5 mM) and appear to be less sensitive to trans-stimulation (Closs et al., 1993a). The 
tissue distribution pattern of this carrier is also different from CAT2B, being found 
mainly in liver, skeletal muscle, skin, ovary, stomach (Deves et al., 1998c; Palacin et al., 
1998) and smooth muscle cells (Baydoun et al., 1999). 
 
CAT-3 is another sodium-independent carrier for L-arginine that has been described to 
be expressed exclusively in the brain (Hosokawa et al., 1997; Nishiya et al., 1997). The 
619 aa peptide CAT-3 is a Na+-independent L-arginine  transporter (Km = 103 μM), 
which is not affected by neutral amino acids and can be inhibited by K+-induced 
depolarization (Hosokawa et al., 1997; Nishiya et al., 1997). 
 
Several other amino acid transport systems with differing amino acid specificity, cell 
type and sodium ion-dependence have been characterised so far (Christensen, 1990; 
Collarini et al., 1987). There is substantial evidence to implicate CAT transporters in the 
transport of l-arginine following NO synthesis which will partly form our focus on this 
thesis. 
  
 49 
1.2.4 Requirements of L-arginine transport in NO synthesis 
To understand the close association between L-arginine and NO, one needs to recall 
the requirements for NO production. As previously stated (in section 1.1.2) NO is 
formed from the N-guanido terminal of L-arginine and oxygen by NOS enzymes of 
which various isoforms exits. Various lines of evidence to date have pointed to the 
requirement of an external L-arginine (the precursor of nitric oxide) for nitric oxide 
production. In particular, evidence from clinical studies does suggest that intravenous 
administration of L-arginine can improve endothelium-dependent vasodilatation in 
coronary artery disease (Dubois-Rande et al., 1992) and in patients with septic shock 
(Reade et al., 2002). Also in a double-blind randomized crossover trial of ten men (41 
+/- 2 years), oral administration of L-arginine has been found to improve endothelium-
dependent dilatation and a reduction in monocyte/endothelial cell adhesion (Adams et 
al., 1997). Patients with various pathologies have been observed to have a dysfunction 
in L-arginine transport where the entry of L-arginine into cells is impaired (Chin-Dusting 
et al., 2007). 
 
In animal models, similar observations show that inhibition of transport attenuates NO 
synthesis in blood vessels of endotoximic rats (Schott et al., 1993c) and in SMCs 
exposed to pro-inflammatory stimuli (Hattori et al., 1999; Wileman et al., 2003). 
Similarly, knockout studies in mice have indicated that limitation in L-arginine through 
blockade of CAT-2B results in a marked attenuation in NO production (Nicholson et al., 
2001a). These observations have also been demonstrated in in vitro cultured cells 
systems such SMCs (Durante et al., 1995; Hattori et al., 1999; Wileman et al., 1995) 
and in experimental models of endotoxin-induced shock in vivo (Hattori et al., 1999; 
Huang et al., 2004a; Yang et al., 2005). 
 
All available evidence to date does point to an absolute stereo-specificity in the 
requirements of an exogenous arginine. When L- and D-arginine intracoronary infusions 
were administered to patients, there was significant dilatation of stenosis of the proximal 
seqments of both normal and diseased arteries with L-arginine (Schott et al., 1993a) 
compared to D-arginine (Tousoulis et al., 1999) which remained largely unaffected. 
However, extracellular L-arginine had no effect on nitrite production by eNOS in the 
absence iNOS induction or any cardiovascular disease (Schott et al., 1993a). In 
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diseased coronary arteries, evidence also suggests that administration of L-arginine 
reversed the effects of the non selective NOS inhibitor L-NG-monomethyl arginine 
(LNMMA) which in addition achieved a greater degree of dilatation in diseased hearts 
(Tousoulis et al., 1999). 
 
Taken together, these findings strongly indicate an important functional link between L-
arginine transport and iNOS mediated NO synthesis. Since the supply of arginine is 
rate-limiting for NO production, there is substantial support for the cooperative 
existence of both processes during inflammatory disease states. Selectively modulating 
this process can therefore provide the therapeutic means of controlling the excessive 
NO production in the various inflammatory disease phenotypes so far mentioned. 
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1.2.5 Regulation of the inducible L-arginine-NO pathway 
1.2.5.1 Regulation of iNOS gene expression 
In view of the central role of iNOS in disease states and the close coupling between 
iNOS–induced NO production and L-arginine transport, several groups including ours 
have focused on understanding the mechanisms that mediate the induction of these 
processes in various cell systems. These studies should shed light on the 
cellular/molecular mechanisms that regulate induction of the enzyme and upregulation 
of L-arginine transport into cells. The findings may provide alternative mechanisms for 
regulating over production of NO and potentially regulating disease states associated 
with the latter. 
 
There have been many challenges in designing specific iNOS inhibitors to target their 
active sites in order to block their function. While all three isoforms produce nitric oxide 
from L-arginine and possess a common modular architecture with a conserved active 
site, it is of particular significance that iNOS is primarily responsible for the high NO 
output attributed to diseases such as rheumatoid arthritis, cancer, sepsis and 
associated cardiovascular complications as earlier discussed. Despite their intricate 
regulation, attempts to limit iNOS induced nitrite production without affecting the 
beneficial aspects of NO from the other isoforms have been a major challenge for 
years. Previous attempts on the use of amino acid precursor to nitric oxide, arginine or 
nitric oxide pro-drug, nitroglycerin have resulted in associated peroxynitrites (Axelsen et 
al., 2011; Smith et al., 1997) and its accompanying byproduct with long term harmful 
effects. 
 
One alternative approach that has been intensely investigated was in the use of 
pharmacological inhibitors of the enzyme to achieve therapeutic outcomes. Several 
small molecule inhibitors have been identified including L-arginine analogues such as 
the endogenous (N (G)-monomethyl-L-arginine (L-NMMA)) (de Meirelles et al., 2007) 
and the highly selective N-iminoethyl-L-ornithine and L-N (6)-(1-iminoethyl)-lysine (L-
NIL) (Budzinski et al., 2000; Ulhaq et al., 1999). Another highly selective inhibitor with 
added attributes of time, concentration and NADP-dependent irreversible inactivator of 
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iNOS is N-(3-(Aminomethyl) benzyl) acetamidine (1400W) has been reported (Zhu et 
al., 2005). 
 
Other non-amino acid-based inhibitors include the guanidines, benzoxazolones, 2-
amino-pyridines and isothioureas of which various levels of selectivity and potency have 
also been developed (Cochran et al., 1996; Nakane et al., 1995). The uses of some of 
these molecules in various animal studies have indicated some benefit. For instance, 
aminoguanidine provides beneficial effects in a rodent model of endotoxic shock 
(Pedoto et al., 1998) and protects against brain injury after cerebral ischemia (Iadecola 
et al., 1997; Zhang et al., 1998a). Similarly, selective inhibition of iNOS using L-NIL 
improved survival in sepsis-induced renal dysfunction in rats (Asakura et al., 2005). 
There is however concern over the specificity of these inhibitors for other NOS 
isoforms, their potential cytotoxic effects and also about the high concentrations 
required for these drugs to be effective in vivo. Additionally, effective therapies in man 
targeting iNOS overproduction with pharmacological interventions are yet to be 
developed. Thus, looking at alternative targets such as the cellular/molecular pathways 
that regulate the expression of iNOS and the accompanying increase in L-arginine 
transport are required. 
 
Regulation of iNOS is mainly achieved at the expressional level. Studies on the 5’-
upstream sequence of iNOS (considered as the promoter region) have shown that this 
region contains a number of transcription factor binding sites including copies for IFN- 
regulatory factor (IRF), gamma-activated site (GAS), nuclear factor-κB (NF-B), IFN-
stimulated response element (ISRE), activating protein-1 (AP-1), tumor necrosis factor 
(TNF) response element and CAAT box element (Beck et al., 1998; Chu et al., 1998b; 
Lowenstein et al., 1993; Niwa et al., 1997; Xie et al., 1993; Yang et al., 1998; Zhang et 
al., 1996). Studies investigating the role of these nuclear factors have revealed that 
binding of STAT-1α and IRF-1 to GAS and ISRE binding sites, respectively, was 
required for optimal induction of the iNOS gene (Kamijo et al., 1994; Kleinert et al., 
1998; Martin et al., 1994).  Additional studies reported NF-kB as an essential element 
for iNOS expression (Forstermann et al., 1995a; Martin et al., 1994; Xie et al., 1994; Xie 
et al., 1993; Yang et al., 1998), although it has been suggested that NF-kB and AP-1 
are not sufficient for iNOS expression (Adcock et al., 1994; Beck et al., 1998; Chu et al., 
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1998a; Nathan et al., 2005; Taylor et al., 1998; Xie et al., 1994; Yang et al., 1998). In 
addition, other studies have suggested that AP-1 could act as an inhibitory regulator of 
iNOS expression (Kleinert et al., 1998). Other alternative studies have suggested that 
CAAT box/enhancer binding protein (C/EBP) and cAMP responsive element binding 
protein (CREB) may have synergistic effects on iNOS induction via the CAAT box 
(Kinugawa et al., 1997). 
 
Activation of these nuclear factors are frequently associated with exposure of tissues or 
cells to proinflammatory mediators including LPS and/or cytokines (Beasley et al., 1991; 
Kirk et al., 1990; Mellouk et al., 1994; Rimele et al., 1988; Schmidt et al., 1989; Szabo 
et al., 1993). These proinflammatory mediators often act synergistically, by activating a 
substantial array of signalling pathways that feed into the activation of nuclear factors 
essential for iNOS gene transcription. In addition, several protein kinases have also 
been identified as being critical for activation of iNOS gene transcription. Amongst these 
proteins, tyrosine kinase (PTK) inhibition with pharmacological inhibitors has been 
consistently shown to inhibit LPS and/or cytokine induced iNOS expression (Baydoun et 
al., 1999; Hellendall et al., 1997; Kong et al., 1996; Lee et al., 1997; Marczin et al., 
1993; Paul et al., 1995). Thus, indicating that activation of these proteins may be 
essential. In contrast, the specific role of protein kinase C (PKC) is less convincing with 
some reports suggesting that activation of this family of serine/threonine kinases either 
potentiates (Hellendall et al., 1997; Hortelano et al., 1993; Oda et al., 2003; Paul et al., 
1997; Scott-Burden et al., 1994), inhibits (Zhou et al., 2006) or is of no consequence 
(Baydoun et al., 1999; Lee et al., 1997; Marczin et al., 1993; Yoon et al., 1994). 
Similarly, studies on phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB or 
Akt) appear controversial with reports suggesting an exclusive role in iNOS post-
translational modifications (Salh et al., 1998) and others suggesting both a negative and 
positive regulation of iNOS induction (Diaz-Guerra et al., 1999; Park et al., 1997). 
Furthermore, previous studies on protein kinase A (PKA) do suggest that although it 
may not be involved in iNOS signalling transduction (Hellendall et al., 1997; Lee et al., 
1997), it may have a role in iNOS mRNA stability.  
 
Several reports (Doi et al., 2000) have also implicated the mitogen activated protein 
kinases (MAPKs) as a critical signalling cascade activated by cytokine in inducing iNOS 
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expression. The MAPK family includes several members which are grouped into three 
subfamilies: 
  
1. Extracellular signal-regulated kinases (ERKs): p44 MAPK (ERK1) and p42 
MAPK (ERK2) 
 
2. Stress-activated protein kinases (SAPKs), also referred to as c-Jun N-terminal 
kinases (JNKs), which include p54 SAPK (SAPK α / β JNK2) and p45 SAPK 
(SAPK γ, JNK1) 
 
3. p38 MAPKS (, ,  and ) 
 
In addition, reports in the literature have provided evidence implicating one or more of 
these pathways in the induction of iNOS but this seem to be dependent on the cell 
system being examined (Bellmann et al., 2000; Blanchette et al., 2003a; Caivano, 1998; 
Chan et al., 1998; Chan et al., 2001c; Ignarro et al., 1982; Morikawa et al., 2000). In 
smooth muscle cells, for instance, the p38 MAPKs may be more relevant as its 
inhibition by SB203580, a potent inhibitor of this enzyme activity, abolished iNOS 
production while ERK1/2 seems to have little effect (Baydoun et al., 1999). On the 
contrary, ERK1/2 appears to play a partial role in the induction of iNOS in J774 
macrophages where p38 was found not to be involved (Feng et al., 1999). 
 
Another signalling pathway that may be involved but as yet not unequivocally implicated 
in the induction of iNOS is that associated with JAK-STAT signalling. This is the main 
focus of this thesis and is discussed further in the sections below. The interest in these 
proteins have come from evidence suggesting that induction of iNOS and indeed CATs 
in vascular smooth muscle cells requires their exposure to IFN-which is a potent 
activator of JAK signalling. 
 
In addition to the above events, several reports have also implicated the JAK/STATs in 
supporting cytokine induction of iNOS expression as summarised in Figure 1.6. 
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Figure 1.6 Schematic representation of the regulation of iNOS production 
Illustration showing proposed (shown by broken lines) activation via the JAK/STAT and 
other pathways. Plausible cross-talk between the signaling pathways is also indicated. 
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1.2.6 Regulation of CAT expression 
In contrast to iNOS, the mechanisms that regulate the induction of CATs are still poorly 
understood with limited data implicating the p38 MAPKs as perhaps being critical for 
this process (Baydoun et al., 1999). Moreover, very little work has been carried out on 
cloning the promoter regions of CATs and as a result there is limited data available in 
the literature on the regulatory elements that may be present. Studies looking at the 
regulation of iNOS expression would clearly benefit from exploring the mechanisms that 
regulate the CATs in parallel and this is one of the focused areas of this thesis. There is 
at present a myriad of potential targets that could be investigated as potential regulators 
of the induction of not only iNOS but the CATs as well. Some attempts have therefore 
been made in this thesis to establish what role the JAK/STAT signalling plays in 
regulating CAT expression and function in parallel with iNOS expression. 
 
Earlier studies have looked at the impact of proinflammatory compounds such as LPS 
and IFN- in different cell systems on CAT2A or CAT2B transporter expressions. 
However such studies have not addressed the relative impact of other comparable 
forms of CAA transport under these same conditions or in comparison with different cell 
systems under the same conditions. In fact there is evidence to suggest that transport 
contribution from system y+ is marginal compared to y+L under normal conditions 
(Reade et al., 2002). In addition most studies have concentrated their investigations on 
murine macrophages only. However reports suggest that CAA transport is species 
specific as demonstrated in an earlier investigation between murine and human models 
(Deves et al., 1998b). In this thesis, we examined the effect of such proinflammtory 
compounds in both RASMCs and macrophages. 
 
We also investigated transport in relation to NO production as evidence suggest that in 
several cell systems so far examined that produce excess NO there was co-induction of 
CAA transport (Bogle et al., 1992b; Closs et al., 1993b; Nicholson et al., 2001b; 
Rothenberg et al., 2006). Examination of the regulation in CAT2B and iNOS induction in 
rat astrocytes and mouse microglia cells have demonstrated that both iNOS and CAT-
2B were co-induced either with LPS in combination with IFN- (Kawahara et al., 2001; 
Stevens et al., 1996) or with LPS alone (Hammermann et al., 2000) repectively. 
However earlier investigations have shown conflicting reports on the latter assertion 
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demonstrating different induction patterns when both J774 macropahges and 
RAW264.7 murine macrophages were stimulated with LPS alone (Closs et al., 2000). 
 
Various reports have also shown that presences of certain mediators are contributory to 
the difference in induction patterns. In particular the plasma concentrations of TNF- 
(Stathopulos et al., 2001), treatment with apolipoprotein E (Colton et al., 2001), 
tetrahydrobiopterin (Schwartz et al., 2001) or treatment with rapamycin, an inhibitor of 
mTOR kinase (Visigalli et al., 2007) have all been associated with increased induction 
in CAT2B expression. Signaling via NF-B and p38 MAPK have been reported to be 
essential for both CAT2B and iNOS induction (Baydoun et al., 1999; Hammermann et 
al., 2000). However, requirement for protein kinase C (PKC) mediated signaling has 
also been reported to be essential for iNOS induction in RASMCs (Baydoun et al., 
1999). 
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1.2.7 The JAK/STAT pathway 
The Janus kinase (JAK)/ signal transducers and activators of transcription (STATs) 
pathway is a very widely used transduction pathway by vertebrates including mammals 
to relay responses from extracellular ligands to targets within the cells. 
 
This pathway is expressed in a wide variety of cells and tissues specific to 
hematopoietic cell development such as in stem cells as well as in other cellular 
developmental processes undergoing cell proliferation migration and differentiation. 
These processes are carried out by a vast array of cells including SMCs (Madamanchi 
et al., 2005), embryonic fibroblasts (Zheng et al., 2011), bone marrow cells (Li, 2013), 
immune cells such as in macrophages (Hu et al., 2007), in order to mediate various 
immunological responses. Perhaps the greatest burden on cells of hematopeiotic 
lineage is manisfested in the wide range of disorders associated with JAK/STAT 
dysfunction or dysregulation. These responses are important for normal cell function 
and physiology and in certain pathological conditions. They include response by 
cytokines and growth factors on apoptosis, cell growth, proliferation and differentiation. 
 
The classical JAK/STAT pathway is activated by cytokines (IFNs), endotoxin (LPS), 
growth factors, hormones and other polypeptide ligands. Much characterization has 
been undertaken over the years with respect to cytokines (see Figure 1.7). Cytokines 
receptors inherently do not have any intrinsic tyrosine kinase activity but do 
constitutively associate with the JAKS. Evidence suggest that the resulting bond is via 
the presence of common receptor subunits called the src homology 2 (SH-2) domains 
which induces a conformational change with the subsequent activation of the JAKs. The 
Janus kinase (JAKs) family which include JAK1, JAK2, JAK3 and TYK2, have a 
molecular weight of between 120-140 kDa (Pellegrini et al., 1997; Schindler, 2002). The 
family consists of a group of intracellular protein–tyrosine kinases (PTK) that are 
constitutively associated with the cytokine receptors on the membrane following 
cytokine stimulation. 
 
With the exception of JAK3 which is mainly confined to hematopoietic cells, the rest of 
the JAKs are widely expressed in most tissues. The JAKs have also been implicated in 
signal transduction mechanisms involving growth hormones (Argetsinger et al., 1993; 
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Herrington et al., 2000) and interferons (Silvennoinen et al., 1993b). Consequently, they 
are said to form a critical component of the cytokine signaling system. The signaling 
cascade involves interacting with receptor components to undergo intracellular 
phosphorylation and enzymatic activation upon ligand binding (Darnell, 1997). However 
the signaling aspects of the reaction components and cascade tiers are yet to be fully 
understood despite the role played by a multitude of components whose nature or 
character have to a large extent been well defined. Evidence to date acknowledged that 
these reactions are principally mediated via STAT proteins which through either homo 
or heterodimerization generate docking sites via their respective SH2 domains. 
 
 
 
Figure 1.7 Schematic representation of the classical JAK/STAT pathway 
This is an Illustration of the main components and the cascade of events linking 
extracellualr ligands (LPS and cytokines) to intracellular events in the cell. 
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The JAKs undergo either autophosphorylation or transphosphorylation at specific 
tyrosine (or serine/threonine) residues at the carboxyl end of the molecule. A complex is 
formed which acts as a docking site to further recruit STAT proteins via their SH-2 
domains. STATs then in turn become phosphorylated, dimerize, move into the nucleus 
and bind to specific DNA sequences (GAS) in the promoter region of designated genes 
to activate transcription (Schindler et al., 1995). 
 
It is significant to note that other pathways are indirectly involved in STAT 
phosphorylation. Evidence suggest that dephosphorylation of the JAKs (Starr et al., 
1999) could also trigger the activation of the MAPK pathway to modulate STAT activity 
via serine-phosphorylation. 
  
Despite their vast reviews in many publications, it is still unclear as to the role of this 
family of signalling molecules referred to as the JAKs. The interest in these proteins is 
due to the fact that induction of iNOS and indeed CATs in vascular smooth muscle cells 
requires the exposure of these cells to IFN, a potent activator of JAKs. 
 
Interferons in general exert pleiotropic effects in key cellular functions such as induction 
of differentiation, modulation of the immune system and inhibition of both angiogensis 
and cell proliferation via multiple signaling pathways (Pestka et al., 1987; Pfeffer et al., 
1998; Stark et al., 1998). As cytokines, they play a complex and central role in 
mammalian resistance to pathogens (Boehm et al., 1997). There are two major groups 
of interferons that share very different homologies with very unique receptors (Pestka et 
al., 1987; Stark et al., 1998); type I (made up of IFN- - and) and type II (IFN ) 
interferons. 
 
Type I interferons are derived from virus-infected cells and bind to the Type I IFN 
receptor. They consist of two distinct structural subunits; IFNAR1 (110 kDa protein) and 
IFNAR2 (occurs in two splice variant – a long 100 kDa IFNAR2c and a short 51kDa 
IFNAR2b) (Uze et al., 1995). 
 
Type II interferons (IFN-) are from thymus-derived (T) cells and natural killer (NK) cells. 
In addition, IFN-transmit signals to the cell interior through a distinct Type II IFN 
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receptor which is made up of two subunits, IFNGRI (110 kDa) and IFNGRII (62 kDa) 
(Bach et al., 1997; Pestka et al., 2004). 
 
The effects of IFN- signaling are extensive and diverse and include nearly all aspects 
on host defense, inflammation and autoimmunity. In order to mediate signaling the IFN 
receptor subunits need to associate with members of the JAK family at some stage in 
the cascade of signaling reactions. What is uncertain at this stage is how far 
downstream that stage is. 
 
 
1.2.5.2 Stucture and functional role of the JAKs in cytokine induced 
nitric oxide signaling 
A recent review (Ivashkiv et al., 2004) suggest that following ligand induced stimulation 
of the IFN receptors at the cell surface, there is activation of the receptor associated 
JAKs by phosphorylation. In addition, the target receptor associated with Tyk2 is the 
100-kDa longer splice variant of interferon receptor-2 (IFNAR2c) subunit  (Bach et al., 
1997). Of the four members of the mammalian JAKS (JAK-1, -2, -3 and TYK2) only 
three (JAK-1, JAK-2 and TYK2) are reported to undergo tyrosine phosphorylation of 
receptors and thereby creating binding sites for specialized domain sites on STAT 
proteins called SH domains. Both Tyk2 and JAK2 share with other members of the JAK 
family, a unique structural framework made up of seven conserved JAK homology (JH) 
regions (Wilks et al., 1991) as shown in Figure 1.8 below. In addition reports suggest 
that JAK2 kinase is implicated in cross-talk of the JAK/STAT pathway (Argetsinger et 
al., 1993; McWhinney et al., 1998). 
 
Src homology 2 (SH2) domains are specialized motif regions, containing approximately 
about 100 amino acids (Moran et al., 1990) which are found in a variety of proteins 
including JAKs and STATs. They are intricately linked to signal transduction which 
involves cell surface signal initiators on the membrane to changes in gene expression. 
In addition SH2 contain unique binding sites for phosphotyrosine residues (Tyr-P) and a 
binding specificity with the associated SH2 motif domain. The association between the 
SH2 domain with the phosphotyrosine binding sites provides the framework for signal 
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transducer complex formation. To effect the changes in gene expression they convert 
the changes in protein-tyrosine phosphorylation into altered protein-serine/ threonine 
phosphorylation. 
 
From the above, we can surmise that the Janus kinase/signal transducers and 
activators of transcription (JAK/STAT) pathway play an essential intracellular 
mechanism that controls expression of certain target genes. 
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Figure 1.8 A schematic structural representation of the JAK structure. 
An illustration of the comparative domains (Figure A) and the relative positions of the 
different JAK Homology (JH) domains (Figure B). 
 
 
JAKs share 7 regions of high homology JH1 to JH7. JH2 represents a pseudokinase 
domain and appears to regulate JH1, the kinase domain that has catalytic activities. 
JH3 to JH7 region mediates receptor association. (N represents receptor mediator 
region or amino terminal region; KL, pseudokinase or kinase-like domain; TK, tyrosine 
kinase domain; C, carboxyl terminal tail). Figure B is a more detailed representation of 
JAK and comprise FERM, SH2, pseudokinase, and kinase domains. The FERM domain 
mediates receptor interactions. Both the FERM and pseudokinase domains regulate 
catalytic activity. 
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1.2.5.3 Structure and functional role of the STATs proteins in nitric 
oxide signaling 
STATs are latent cytoplasmic transcription factors which following receptor activation 
dimerizes and translocates into the nucleus. They are induced by a variety of growth 
factors and cytokines (Ihle, 1996). They are activated by tyrosine phosphorylation 
though an additional serine phosphorylation in some STATs appears to enhance 
transcription of some target genes (Decker et al., 2000). 
 
They are approximately 80 – 95 kDa in size. In mammals, seven genes encoding 
different STAT proteins (STAT-1, STAT2, STAT3, STAT4, STAT5a, STAT5b and 
STAT6) have so far been identified (Aaronson et al., 2002). Just as in the JAKs, the 
STATs share a highly conserved structural and functional domain as shown in Figure 
1.9  
 
 
 
 
Figure 1.9 Schematic structural representation of STAT-1 
An illustration of the homologies between STAT-1 and STAT-1  and the relative 
positions of the respective STAT-1 domains (TAD is Transactivation domain). 
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These domains include an amino-terminal domain (NH2), the coil-coil domain (CCD), a 
DNA binding domain (DBA), the linker domain and the SH2/tyrosine activation domain. 
All the STATs do however share a divergent but unique carboxy-terminal domain called 
the carboxy-terminal transcriptional activation domain (TAD). There are two isoforms of 
STAT-1, STAT-1 and STAT-1The latter lacks a 38 amino acid residue at the 
carboxy-terminal end compared to the STAT-1 (as shown in Figure1.9). 
 
The JAK/STAT pathway plays an essential role in vascular smooth muscle cell 
proliferation following cytokine activation (Darnell et al., 1994; Ihle, 1995). The classical 
transduction mechanism involving the JAKS and STATs involves the homo- and 
heterodimerization via their src homology 2 (SH2) domains. In support of this concept, 
evidence suggest that reductions in JAK/STAT activity either through mutations or 
mutations that constitutively activate or fail to regulate its associated JAK signaling 
properly can lead to inflammatory and other associated diseases (Igaz et al., 2001; 
O'Shea et al., 2002). In general, phosphorylation of the STATs enable them to then 
undergo homo- and or heterodimerization and translocate into the nucleus, to activate 
IFN-stimulated response elements (ISREs, AGTTTCNNTTTCNC/T) in order to 
transcribe the appropriate genes associated with this signalling cascade (Chen et al., 
2004). 
 
STATs activate transcription by binding to a DNA motif, TTCNNNGAA, in the promoter 
region of target gene. This motif represents a specific response element within the gene 
promoter. One of their well-characterized response element GAS is expressed in the 
iNOS gene promoter and may be essential for iNOS gene induction (Schindler et al., 
1995). Of the STAT proteins thus far investigated, STAT-1 is known to undergo 
homodimerization of phosphorylated STAT-1. 
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1.2.5.4 Activation of STATs independent of JAKs; Role of the 
GTPases 
 
Most of the responses to cytokines in cells result in the activation of JAKs through 
tyrosine phosphorylation of STAT-1 (Ihle, 1995; Yeh et al., 1999) on tyrosine-701 (Tyr-
701) residue. This may also be achieved independently of JAKs with other upstream 
signaling molecules directly phosphorylating STAT1 and thus initiate iNOS gene 
transcription. In this regard, protein tyrosine kinases (PTK) as well as serine and 
threonine kinases with much broader substrate specificity have also been implicated. 
Other cell surface receptors such as G-protein coupled receptors (GPCR) have also 
been shown to activate the STATs through tyrosine phosphorylation and induce STAT 
DNA binding in cells (Bhat et al., 1994; Marrero et al., 1995; Rodriguez-Linares et al., 
1994). However the cascade of events by which G-proteins activate the JAK/STAT 
pathway are far from certain. 
 
During iNOS mediated expression the majority of the signal cascades by kinases are 
orchestrated mainly by protein tyrosine kinases (PTK) though serine and threonine 
kinases with much broader substrate specificity have also been implicated. In addition, 
many of the cytokine (IFN-) or endotoxin (LPS) mediated stimuli do activate multiple 
signal transduction cascades. For example, PTK receptors are reported to activate both 
PI3K-Akt and MAPK pathways, following induction by cell proliferation associated 
stimuli (Muto et al., 2007). The phosphorylated PTK receptor activates PI3K via 
cytokines and other extracellular ligands. Consequently considerable overlap and 
cross-talk between many of these cytokine mediated signaling pathways have been 
reported (Tachado et al., 2005; Wang et al., 2006). We envisage that these interactions 
may provide the cooperation and coordinated interactions that are important in STAT-1 
activation via the GTPases and independent of the JAKs. 
 
Many extracellular ligands including endotoxins (LPS) cytokines (IFN-) are reported to 
activate multiple signal transduction cascades. For example, PTK receptors have been 
reported to activate the PI3K-Akt pathway in addition to the MAPK pathway, when 
stimulated by signals that induce cell proliferation and cell survival. What has been 
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clearly defined is the extent and diversity in the IFN- mediated interaction across 
distinct but synergistic pathways. In macrophages IFN- mediated NO production has 
been evident not only in the JAK/STAT pathway but also reported in the ERK1/2 and 
MAPK pathways. Further downstream of the JAK/STAT cascade, IFN- is also reported 
to activate class II trans-activator (CIITA) CCAAT enhancer-binding protein (Roy et al., 
2000), and interferon-responsive factors (IRFs). 
 
Other cell surface receptors such as G-protein coupled receptors (GPCR) have been 
shown to also activate the STATs through tyrosine phosphorylation and induce STAT 
DNA binding in cells (Bhat et al., 1994; Marrero et al., 1995; Pelletier et al., 2003; 
Rodriguez-Linares et al., 1994). However the cascade of events through which G-
proteins activate the JAK/STAT pathway are far from certain but G-proteins such as 
Rho GTPases can activate STAT-1 and induce its transcriptional activity (Pelletier et al., 
2003). These G-proteins may also induce expression of cytokines through parallel 
pathways involving the transcription factor, nuclear factor (NF)-B (Goodman et al., 
1982; Okusawa et al., 1987; Okusawa et al., 1988) suggesting a multiple cascade of 
effects of which some may be STAT-dependent. 
 
Small GTPases comprises a functionally diverse group of proteins (G proteins) 
responsible for a range of cellular processes important in almost all organisms including 
prokaryotes and eukaryotes. They regulate processes by functioning as molecular 
switch from GDP bound form (inactive or off position) to GTP bound form (active or on 
position) as shown in Figure 1.10 below. 
 
Of particular importance is their involvement in the regulation of a diverse range of 
processes including cell proliferation, cell migration, transport inflammation (Laufs et al., 
1998; Muniyappa et al., 2000) amongst others. In addition, at least one other report 
suggest that most of the inflammatory cytokines and extracellular stimuli which induce 
iNOS are also implicated in the activation of G-proteins associated with the Ras/Rho 
family (Kjoller et al., 1999). In particular, there is evidence supporting this concept 
demonstrated that Rho signaling down regulated iNOS expression in RASMCs 
(Muniyappa et al., 2000). In view of these findings, our examination of iNOS regulation 
will also take into account components of the of the Rho GTPase pathway. 
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Figure 1.10 Regulation of small G protein activity. 
Schematic representation of the molecular switching role of the small GTPases showing 
the GTP bound (active state) and GDP bound (inactive state). 
 
GTPases control many aspects of cell activities by cycling between an inactive (GDP-
bound) to an active (GTP-bound) conformational state following hydrolysis of guanine 
triphospahate (GTP) (Boguski et al., 1993). It is only in the latter conformational state 
that GTPases are able to interact with effector molecules (GEF) in order to mediate in 
cellular processes. 
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Figure 1.11 Schematic representation of the Mevalonate pathway and its 
downstream signalling 
The figure illustrates the main intermediates in the mevalonate pathway and highlights 
key targets for some of the pharmacological inhibitors used in this study. The 
convergence of the different pathways is proposed to link JAK/STATs to GTPases and 
transcription factors further downstream. (Broken lines are plausible links that are yet to 
be determined). 
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1.2.8 GTPase Inhibitors as potential regulators of induced nitric oxide 
production 
The compound Y27632 ((+)-(R) trans-4-(1-aminoethyl)-N-(4-pyridyl) 
cyclohexanecarboxamide dihydrochloride) is a synthetic compound reported to inhibit 
the ROCK family of kinases. Y-27632 is used to investigate the possible involvement of 
small GTpases in the signaling transduction upstream of the JAKs. This compound has 
been reported to inhibit agonist-induced contraction of both vascular and bronchial 
SMCs through blocking the calcium sensitized SMC contractions (Bai et al., 2006; 
Lazaar, 2002). The main targets are the Rho-associated coiled-coil forming protein 
serine/threonine kinase (ROCK) family, which acts on downstream effector targets in 
small GTPases The ROCK family consist of p160ROCK (ROCK-I) (Ishizaki et al., 1996) 
and ROKα/Rho-kinase/ROCK-II (Leung et al., 1995). 
 
The potency of its reaction is reported to be over 100 times more when compared to 
other naturally occurring kinases including protein kinase C, cAMP-dependent kinase 
and myosin light chain kinase. These targets are implicated in Rho-induced formation of 
actin stress fibers and focal adhesions (Amano et al., 1997; Ishizaki et al., 1997; Leung 
et al., 1996) and the down regulation of myosin phosphatases (Kimura et al., 1996). 
 
In our experimental setup, the inhibitor, Y-27632 was used, to assess the role of Rho 
pathway in the induction iNOS with LPS and IFN- in RASMCs and LPS alone in J774 
macrophages. 
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AIM 
The main aim of this thesis was to confirm unequivocally whether JAK/STAT signalling 
play a critical role in the induction of the inducible L-arginine-NO pathway in either 
smooth muscle cells or J774 macrophages. Furthermore, the project was also aimed at 
identifying changes in the profile of expression of CATs in induced cells with a view to 
establishing the critical role played by each transporter in sustaining substrate supply 
into cells for sustained NO synthesis. To achieve these aims, studies were carried out 
using both pharmacological and molecular approaches to dissect the specific JAK 
and/or STAT signalling that may be associated with the expression of iNOS and/or 
CATs. Gene silencing using siRNA knockdown was also attempted to establish the role 
of JAK2 as this has been the most studied and often the most implicated JAK protein 
for iNOS induction, but with inconclusive outcomes. 
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Chapter 2. MATERIALS AND METHODS 
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All substances used in cell culture experiments were handled in accordance with the 
regulation for the Control of Substances Hazardous to Health (COSHH) guidelines. 
Solutions and apparatuses were autoclaved and experiments were carried out in a 
laminar flow cabinet using aseptic techniques when required. 
 
2.1 Preparation of cell culture medium 
Dulbecco´s Modified Eagle´s Medium (DMEM; without sodium pyruvate, with 1000 mg-
1 glucose, and with pyridoxine HCl) was used throughout these studies as the culture 
medium. The media was supplemented with penicillin (100 Uml-1) and streptomycin 
(100 µg ml-1) plus 10% foetal bovine serum (FBS). Once prepared, the complete 
growth medium (referred to here on as complete DMEM) was stored at 4ºC and used 
within a period of no more than 2 weeks. 
2.2 Culture of J774 macrophages 
The murine monocyte/macrophage cell line J774 macrophage was a generous gift from 
Neil Foxwell (Wolfson Institute for Biomedical Research, University College London-The 
Cruciform Building). J774 macrophages cells were maintained in continuous culture in 
T75 tissue culture flasks containing complete DMEM. Cells were harvested by gentle 
scraping and passaged every 3-6 days by dilution of a suspension of the cells in media 
in a ratio of 1:4. Once every two months, old cells were discarded and new cells were 
defrosted and brought to confluence for use. 
 
2.3 Isolation of Rat Aortic Smooth Muscle Cells (RASMCs) 
Vascular smooth muscle cells were obtained from rat aortic explants as described 
previously by Wileman et al (Wileman et al., 1995). Essentially, male Wistar rats (from 
Charles Rivers) were asphyxiated by CO2 and the thoracic aorta dissected out into a 
Petri dish containing complete DMEM. Following removal of the connective tissue on 
the adventitia, the aorta was cut open and the monolayer of endothelial cells removed 
by gentle scraping. Each aorta was cut into approximately 2 mm2 segments and placed 
in a T-25 Falcon flask containing 5 ml of complete media with the intimae facing the 
flask surface. Flasks were placed upright in a tissue culture incubator (100% humidity 
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and 5% CO2) overnight to allow adherence of the explants to the plastic surface. After 
24 hours, flasks were gently placed flat and explants were left in culture for 14 days. 
Over this period, rapidly dividing and migrating cells were harvested and cultured to 
confluence in a T-75 Falcon flask. 
 
2.4 Sub-culturing of RASMCs 
Proliferating cells that had migrated from the explants were harvested with trypsin-
EDTA (0.01/0.02 %) diluted in phosphate buffered saline (PBS; mM: NaCl, 140; KCl, 
2.7; Na2HPO4, 8.1; KH2PO4, 1.5; pH 7.4). Following aspiration of the growth medium, 
cells were washed at least twice with pre-warm (37ºC) PBS (X1) in order to remove any 
trace of protease inhibitors present in the serum from the complete media. The pre-
warm (37ºC) trypsin-EDTA solution was added (1 ml per 25 cm2 of surface area) to the 
cell monolayer and distributed uniformly. Detachment of SMC was monitored under an 
inverted light microscope at 2 minutes intervals. When most of the cells acquired a 
round shape the flask was gently tapped to help cell detachment and 13 ml of complete 
DMEM was added to re-suspend the cells and inactivate trypsin. Cells were then gently 
dispersed with a Pasteur pipette before being transferred into a sterile T-75 tissue 
culture flask. RASMCs were passaged weekly and only cells between passages 3 to 5 
were used in the experiments described in this report. 
 
2.5 Characterisation of RASMCs 
Cells extracted from the Wistar rat aorta were routinely identified and characterised as 
smooth muscle cells by immunostaining of smooth-muscle α-actin (Skalli et al., 1986) 
as described by Wileman and co-workers (Wileman et al., 1995). Briefly, cells at 
passages 2 to 5 were plated at sub-confluent density in a culture chamber slide and 
grown in complete DMEM. All cultures were grown in a 100% humidified incubator at 
37°C under 5% CO2 in air. After 2 days of growth, cells were washed twice with PBS to 
eliminate serum contamination prior to being fixed with ice-cold methanol for 45 
seconds. Fixed cells were blocked with 5% bovine serum albumin (BSA) in PBS for 20 
minutes before incubation with an anti-α-actin antibody (1:50 dilution) for 1 hour. Excess 
primary antibody was eliminated following several wash cycles (four times) with PBS for 
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5 minutes each wash. Cells were then incubated with an anti-mouse IgG-FITC 
conjugated secondary antibody (1:50 dilution) for 1 hour in the dark. Subsequently, cells 
were treated with increasing dilutions of glycerol (30%, 50%, and 80%) in PBS for 15 
seconds each time. Cells were finally mounted in 100% glycerol prior to placing a cover 
slip over the cells and sealing with standard nail vanish. Cells were visualized under UV 
light using a Nikon EFD3, LABOPHOT-2 Light Microscope at 400X magnification. An 
example of routine cultures stained with α-actin is shown in Figure 2.1. 
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Figure 2.1 Representative photograph showing positive immunostaining of 
smooth muscle α-actin in cells extracted from rat aortas  
 
Sub-confluent cultures of RASMCs, extracted from rat aorta were immunostained with 
-actin antibodies (Sigma, UK). Cells were viewed under UV-light using a Nikon EFD3, 
LABOPHOT-2 Light Microscope at 400X magnification. The characteristic elongated 
shape of RASMCs is not observed in this picture but rather they adopt a star shape or 
polyhedral conformation under sub-confluent culture conditions due to the lowconfluent 
nature of the cells. 
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2.6 Cell counting 
Cell density was estimated using a haemocytometer. Briefly, cell suspensions were 
obtained as previously described. Cell suspension was mixed with 0.4% trypan blue 
solution in a 1:1 ratio and 10 μl of thoroughly mixed cell suspension loaded into each 
chamber. The haemocytometer was then placed on the microscope stage and the total 
number of cells was determined by counting the cells inside each large square, 
ensuring that only cells touching the top and left borders were counted. The average 
cell count was estimated and used to determine total cell number. Therefore, the 
number of cells per ml was determined by multiplying the number of cells obtained by 
10000. The final number of cells in each suspension was then obtained using equation 
3.1. 
 
 
 
 
Where: 
 
Number of cells is the total number of cell counted. 
Square counted is the number of squares counted in order to get an average. 
Conversion factor corresponds to 104 as explained above. 
 
To get the total number of cells harvested the number of cells determined per ml was 
multiplied by the original volume of medium in which the cells were suspended in. 
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2.7 Plating of cells for experimentation 
Confluent monolayer of J774 macrophages were gently scraped and counted as 
described above. Cells were then diluted to the required concentration and plated at a 
seeding density of 2.5 x 104 cells ml-1. Plates were incubated overnight in a tissue 
culture incubator to allow cell adherence and growth. For RASMCs, confluent 
monolayer in T-75 flasks were trypsinised and counted as described above. Cells were 
then seeded at 3 x 104 cells ml-1 and allowed to grow to confluence for approximately 
three days in a tissue culture incubator at 37°C under 5% CO2 in air. 
 
 
2.8 Treating of plated cells with inhibitors 
In order to characterize the role of JAK/STAT signalling in iNOS induction and nitrite 
production as well as L-arginine transport we used a pharmacological approach. In this 
thesis, the two main pharmacological inhibitors of JAKs used were JAK inhibitor I and 
AG490 inhibitor: 
 
JAK inhibitor I: [2-(1,1-Dimethylethyl)-9-fluoro-3,6 dihydro-7H-benz[h]-imidaz[4,5-
f]isoquinolin-7-one P6 Pyridone 6]. 
 
 
C18H16FN3O (309.34 MW) 
Figure 2.2 Chemical structure of JAK inhibitor I  
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JAK inhibitor I is a clear, colourless but potent inhibitor of the JAKs. It is prepared from 
the photochemical cyclization of Pyridone 5 to 6. The resulting product under steady 
state conditions is a reversible inhibitor that is competitive with respect to ATP and non-
competitive with respect to the peptide substrate. It displays potent inhibitory activity 
against JAK1 (IC50 = 15 nM for murine JAK1), JAK2 IC50 = 1 nM), JAK3 (Ki = 5 nM), 
and Tyk2 (IC50 = 1 nM). It inhibits other kinases only at much higher concentrations 
and shows specificity for the JAK family of Protein Tyrosine Kinase (PTK) over other 
kinases. JAK inhibitor I however has limited selectivity amongst the JAKs. Both JAK2 
and TYK2 (IC50=1 nM) are inhibited slightly more potently than JAK3 and JAK1 
(IC50=5 and 15 nM, respectively) (Thompson et al., 2002). 
 
Tyrphostin B42 (AG490): [alpha-Cyano-(3, 4-dihydroxy)-N-benzylcinnamide] 
 
 
 
C17H14N2O3; (Mol. Wt., 294.3) 
 
Figure 2.3 Chemical structure of Tyrphostin B42 (AG490) 
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Tyrphostin B42 (AG490) is a specific synthetically derived member of the class of drugs 
collectively called Tyrphostins which are derived from benzylidenemalononitrile nucleus. 
Erbstatin, which is the smallest competitive PTK inhibitor together with other small 
tyrosine-containing peptides have provided the structural backbone from which all other 
tyrphostins have been developed. AG490 is regarded as a protein PTK inhibitor or 
blocker. It is also regarded as potential antiproliferative agent and therefore a potential 
therapeutic agent for diseases caused by the hyperactivity of PTK. AG490 is reported to 
selectively block JAK2 thus making it’s a specific inhibitor of the protein over the others 
in the group (Levitzki, 1992; Meydan et al., 1996). When used, each inhibitor was 
incubated with cells at the appropriate concentration for 30 min prior to activation with 
the respective stimuli. The cell culture medium was collected for nitrite measurement 
and the cell monolayer used for either L-arginine transport studies of for western 
blotting. 
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2.9 Measurement of nitrite as an indicator of NO production 
As nitrite is a major breakdown product of NO in both mouse and rat (Ignarro et al., 
1993; Marletta et al., 1988) we used the Griess assay to measure nitrite in solution as 
an indicator of NO production as described by (Seguin et al., 1994; Wileman et al., 
1995). In these studies, RASMC or J774 macrophage cells were seeded at 3.0 x 104 
cells ml-1 and 2.5 x 104 cells ml-1 respectively in 96 well plates and cultured in a 
humidified cell culture incubator at 37”C until they reached confluence. Confluent 
monolayer of RASMCs were activated for a further 24 hours with LPS (100 µg/ml) and 
IFN- (100 U/ml) while macrophages were activated with LPS (1.0 µg/ml) alone. As 
indicated above, drugs were added to cells 30 min prior induction with the respective 
stimulus. 
 
A stock of Griess reagent A (2% sulfanilamide amine) and Griess reagent B (0.2% 
napthylethylenediamine plus 10% phosphoric acid) were prepared and stored at 4ºC.  
When required, both reagents were mixed in a 1 to 1 ratio before performing the assay 
on the bench at room temperature. The inner wells of a non sterile 96-well plate were 
used to transfer 100 μl of medium from the cell cultures and the outer wells were used 
to add standards of sodium nitrite in a final volume of 100 μl. Both samples and 
standards in the wells were incubated with 100 μl of Griess reagent and incubated at 
room temperature for 10 minutes.  
 
Absorbances were measured using a Multiskan II plate reader (Ascent, Nitrite protocol) 
set at a wavelength of 540 nm. Sodium nitrite standard concentrations were used to 
produce a standard curve (as shown in Figure 3.2) from which the concentrations of 
nitrite in samples were determined. 
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Figure 2.4 Nitrite Standard Curve  
 
The standard curve was constructed as described above using serially diluted solutions 
of sodium nitrite made up in complete DMEM at the concentrations shown on the graph. 
The graphs often show linearity over the concentration ranges of 1 to 10 nmole nitrite 
100 μl-1 (equivalent to 0.01 to 0.1 mM nitrite). 
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2.10 Measurement of L-[3H] arginine transport 
Both RASMCs and J774 macrophages were seeded at 3.0 x 104 and 2.5 x 104 cells/ ml 
respectively. Transport studies were carried out on the cell monolayer after removing 
the culture medium for analysis of nitrite concentrations. Prior to initiating transport of L-
arginine, cells were washed three times with warm HEPES-buffered Krebs solution. 
Special care was taken to ensure complete removal of buffer at the end of each wash 
cycle. Cells were then incubated in a ‘Hot Box’ at 37ºC with 50 µl of transport buffer 
containing 1 µCi/ ml L-[3H] arginine plus 100 µM of unlabelled (non-radioactive) L-
arginine. Incubations were terminated after 2 min by placing the 96-well plates on ice 
and immediately washing  three times with 200 µl of ice-cold Na+-free Kreb’s buffer 
containing 10 mM excess unlabelled L-arginine. Cells were subsequently lysed using 
50 µl of distilled water and protein content assessed using BCA assay as described 
earlier. Full content of each well was then transferred into scintillation vials containing 4 
ml of scintillation fluid. The -vials were sealed and transferred onto a scintillation 
counter (Beckman Coulter™ LS6500 β-Scintillation counter). The levels of radioactivity 
in samples were determined by scintillation counting and the disintegrations per minute 
(DPM) converted to pmol µg protein-1 min-1 using the following equation: 
 
 
 
 
Where: 
R is the amount of L-arginine in cell lysates expressed in pmole 
 
5000 is the amount of cold L-arginine in pmole present in 50 µl of a 100 µM solution 
used in the transport studies 
 
Dc is the DPM in the cell lysates 
 
M is the DPM in 50 µl of 100 µM L-arginine solution + 1 µCi ml-1 L-[3H] arginine 
 84 
 
Y is the total protein content of the cell lysates counted. 
 
 
 
2.11 Measurement of total cell protein using bicinchoninic acid assay 
The bicinchoninic acid protein assay is based on the two step process of an initial, 
biuret reaction involving a reduction of copper (Cu) to cupric ions (Cu2+) in alkaline 
environment containing sodium potassium tartrate when bound to a peptide containing 
at least 3 amino acid residues. The resulting structure is a light blue to violet 
colouration. The intensity of the colouration is directly proportional to the amount of 
protein. This is subsequently followed by a second step involving formation of a 
complex with the reduced cupric ions. The resulting complex can then be 
colorimetrically determined by measuring absorbance at 640 nm. 
 
Cell protein was determined using the commercially available Bicinchoninic Acid (BCA) 
protein assay reagent kit from Pierce (Smith et al., 1985). The monolayer of cells was 
rinsed twice with PBS in order to eliminate any contamination from extracellular proteins 
(e.g. serum proteins contained in the culture media). Cells were subsequently lysed by 
the addition of X 1 lysis buffer solution (10 mM TRIS, 10 % sodium dodecyl sulphate 
(SDS), pH 7.4) containing 200 μM sodium orthovanadate (Na3VO4), 200 μM phenyl 
methyl sulfonyl fluoride (PMSF) and 1 mM sodium fluoride (NaF). BSA standard 
concentrations were prepared from a bovine serum albumin (BSA) stock solution (1 
mg/ml) in double distilled water (DDW). Preparation of BSA standards is as shown in 
Table 2.1: 
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TABLE 2.1 PREPARATION OF BSA STANDARDS 
 
 
 
 
A 96-well plate format was used to measure the absorbance of our protein lysates and 
BSA standards. Standard wells were filled with 10 µl BSA standard to give the 
concentration range (0.0 to 0.75 g/µl) shown in Table 2.1. 10 µl of lysate from each 
sample was added in triplicate to the inner sixty wells. BCA stock reagent A (containing 
sodium carbonate, sodium bicarbonate, Bicinchoninic acid and sodium tartrate in 0.1M 
sodium bicarbonate) and B (containing 4%[w/v] Copper(II)sulphate pentahydrate 
(CuSO4.5H20)) were mixed in 1:50 dilution, according to manufacturer’s instructions 
(200 µl BCA reagent B in 9.8 ml BCA reagent A). Each well was then incubated with 
100 µl of the mixture for 30 minutes at room temperature. Absorbance readings were 
measured by using a Multiskan II plate reader (Ascent, BCA protocol) set at a 
wavelength of 620 nm. Protein concentration of each sample was determined from the 
standard curve. A representative standard curve is shown in Figure 2.5 below. 
 
 
Volume (µl) 1 mg/ml BCA 
Working stock 
 
Volume of Lysis Buffer 
(µl) 
 
Final BSA CONC. 
(µg/µl) 
 
0 
 
1000 
 
0 
 
10 
 
990 
 
0.01 
 
20 
 
980 
 
0.02 
 
40 
 
960 
 
0.04 
 
100 
 
900 
 
0.1 
 
250 
 
750 
 
0.25 
 
500 
 
750 
 
500 
 
250 
 
0.5 
 
0.75 
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Figure 2.5 Protein Standard Curve  
An example of a BSA standard curve used to determine protein concentration. Protein 
levels in samples were determined by using a standard curve with increasing 
concentrations of BSA (from 1 to 1000 μg well-1) prepared in distilled water. The graph 
is linear from 1 to 1000 μg well -1. 
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2.12 Determination of changes in cell viability 
The MTT cell cytotoxicity assay is based on the reduction of 3-[4, 5-Dimethylthiazol-
2yl]-2, 5-diphenyl tetrazolium bromide (MTT), a tetrazole by the mitochondrial enzyme, 
succinate reductase (EC 1.3.99.1) in the respiratory chain of metabolically active cells 
as shown in Figure 2.4. 
 
 
 
 
 
Figure 2.6 Reduction reaction of MTT to Formazan by mitochondrial reductase 
enzymes. 
 
The principle behind this action is that when viable cells are incubated in media 
containing the yellow tetrazolium compound, MTT is reduced by mitochondrial 
reductase enzymes in metabolically active cells to an insoluble purple formazan in the 
mitochondria. This reduction is thus directly related to the number of viable active cells. 
The insoluble formazan crystals are subsequently dissolved by the addition of an 
organic solvent such as isopropanol (Slater et al., 1963). Briefly, 5.0 mg of MTT was 
weighed and made up to a volume of 10 ml with PBS (final concentration, 0.5 mg ml-1) 
in a laminar flow cabinet under sterile conditions. After a 24 hour treatment of confluent 
cells in 96-well plates with activation media and/or compounds of interest, 100 µl of 
media was removed from each well and used to determine nitrate production. 10 µl of 
MTT stock solution was added to the remaining 100 µl of medium in each well and cells 
incubated for 4 hours at 37ºC in a cell culture incubator at 5% CO2. The medium was 
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subsequently removed by aspiration, cells lysed and formazan crystals solubilized by 
the addition of 100 µl of isopropanol to each well and allowed to incubate for 1 hour. 
The extent of reduction of MTT to formazan was quantified by measuring the 
absorbance at 540 nm in a Multiskan II plate reader (Ascent, MTT protocol). 
 
The cell viability in the untreated control was taken as 100% and the viability under 
other conditions was calculated as a percentage of the control (untreated) cells. Viability 
was expressed using the following equation: 
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2.13 Western Blot analysis 
Confluent monolayers of J774 macrophages or RASMCs in 6-well culture plates were 
pre-incubated for 30 min with media alone or media containing inhibitor prior to 
activation. Incubations were terminated after 24 hours by rapid aspiration of the media 
followed by several washes in ice cold phosphate buffered solution (PBS) 
supplemented with sodium orthovanadate (2 mM). For the detection of non-
phosphorylated protein, cells were lysed in hot lysis buffer containing 20 mM Tris-HCL 
(pH 7.4), 1% sodium dodecyl sulphate (SDS) and 150 mM NaCl. 
 
For phospho-protein detection, cells were lysed in ice cold lysis buffer  consisting of: 1% 
Triton X, 150 mM NaCl, 50 mM Tris pH 7.5, 1 mM EDTA, 1 mM 4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF), 2 mM sodium orthovanadate, 80 μM 
leupeptin, 1 μg/mL aprotinin, 1.0 mM Sodium Fluoride (NaF), 2.0 mM sodium 
pyrophosphate and 0.25% sodium deoxycholate. 
 
The resulting cell lysates were transferred into microcentrifuge tube heated at 95 ºC for 
5 minutes and then sonicated for 2-3 minutes and followed by further centrifugation at 
10,000 RPM at 4 °C. The upper clear supernatant was transferred into fresh clean 
microcentrifuge tubes for storage at -20 °C. Total protein in lysates was determined by 
the BCA assay as previously described (see Section 2.11). Cell lysates were prepared 
with sample buffer as previously described (see Section 2.12) and Western blotting 
carried out immediately or samples stored at -20 °C for future western blot analysis. 
 
 
1. Sample Preparation 
An equal volume of cell lysates containing 20 µg of total proteins was added to an equal 
volume of 2X concentrated sample buffer containing Tris-HCl, pH 6.8 (120mM), SDS 
(4%), Glycerol (10%), β-mercaptoethanol (2%) and bromophenol blue 0.006%). Lysates 
in eppendorf tubes were boiled at 95 ºC for 3 to 5 minutes, centrifuged and loaded onto 
the polyacrylamide gels. 
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2. SDS Gel Electrophoresis 
Two types of gels were prepared: a resolving gel followed by a stacking gel. The 
resolving gel was prepared by mixing 5 ml of the 8.0% acrylamide gel (enough for one 
mini blot) with the following components: double distilled water (2.34ml), 30% 
acrylamide/bisacrylamide 37.5:1 (1.30ml), 1.5M Tris, pH8.8 (1.25ml), 10% SDS 
(0.050ml), 10% APS (0.025ml) and TEMED (0.005ml). 
 
After completion of polymerization of the above gel, 5% stacking gel was prepared with 
the following components: water (2.84ml), 30% acrylamide/bisacrylamide 37.5:1 
(0.83ml), 0.5M Tris-HCl pH6.8 (1.25ml), 10% SDS (0.050ml), 10% APS (0.025ml) and 
TEMED (0.005ml). The stacking gel was poured on top of the resolving gel and this was 
allowed to polymerize completely. 
 
The gel cast containing the gel was transferred into an electrophoresis tank and a X1 
electrophoretic buffer was prepared from a 10X stock solution containing the following 
components: 30.28 g/L of Tris base (0.25M), 144.0 g/L of glycine (1.92M), 100ml of 
10% SDS (1%) with the pH adjusted to 8.3. Electrophoresis buffer was added to the gel 
tank and allowed to cover the top of the gel. The samples and biotinylated molecular 
weight protein ladder (NEB, UK) were heated at 95°C for 5 minutes and then loaded 
onto the gel. The gel was run at a constant voltage of 100V until the bromophenol blue 
dye reached the bottom of the gel. 
 
 
3. Protein Transfer from Gel to PVDF Membrane 
Following SDS-PAGE, a PVDF membrane (Amersham, UK) was cut to the size of the 
gel and soaked in methanol for up to 15 - 30 seconds, washed with distilled water and 
then equilibrated in 1X transfer buffer for a further 15 minutes. The transfer Buffer was 
prepared from a 10X concentrated stock containing: 58.2 g/L of Tris base (0.48M; pH 
8.3), 29.3 g/L of glycine (0.39M), and 3.75 ml of 10% SDS (0.038%)). Briefly, 100 ml of 
the above was diluted down ten fold with 200ml methanol (20%) and 700ml dH2O. 
Precut extra thick blotting paper (Bio-Rad) was soaked in the diluted transfer buffer and 
two of the blot papers were placed on the semi-dry transfer system. The PVDF 
membrane was then laid on top of the soaked blot paper on the blotter. A reference for 
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the protein side of membrane was made by cutting a small notch in one corner of the 
membrane. The gel was removed from the gel cast and laid on top of the membrane 
followed by 2 pieces of soaked blot papers placed on top of the gel. An illustration of the 
transfer setup of gels, PVDF membrane and blotting paper is shown in Figure 2.7 
below. Air bubbles between the gel and the blot papers were removed by gently rolling 
a clean 25ml pipette over the surface of the membrane. To initiate protein transfer, a 
constant current of 0.8mA/cm2 was applied to the gel for 60 minutes. 
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Figure 2.7 Transfer of proteins to PVDF membrane 
 
The diagram illustrate the construction of the gel ‘sandwich’ with the membrane at the 
anode or bottom side relative to the gel. 
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4. Membrane Blocking 
The PVDF membrane was incubated in 5% non fat milk (Marvel Brand) in 1x TBS (Tris-
buffered saline; TBS) containing 0.1% Tween-20 (Sigma, UK) for 1 hour at room 
temperature or overnight at 4oC. The TBS (1litre) was prepared prior to use by making 
a 1:10 dilution of a 10X stock solution with the following components: 24.2 g/L of Tris 
base (20 mM; pH 7.5) and 87.7 g/L of NaCl (150mM). For phosphorylated protein 
detection the PVDF membrane was blocked in 5% BSA instead of non-fat milk. The 
incubation in the blocking buffer blocks hydrophobic binding sites on the membrane. 
Blocking also reduces background and prevents binding of the primary antibody to the 
non-specific areas or sites of the membrane itself. 
 
5. Primary antibody incubation 
After blocking, the membranes were incubated, using gentle agitation on a shaker, with 
the primary antibody in a sealed plastic bag. The primary antibody used to probe the 
blots were rabbit monoclonal antibody to TYK2, phospho-TYK2 (1:2500), phospho-
JAK2 or JAK2 (1:2500) in blocking buffer (All antibodies were purchased from InSight 
Biotechnology, UK). 
 
Following primary antibody incubation, the blot were washed three times (each wash 
lasting for 5 minutes on a shaker) in wash buffer (TBS containing 0.1% Tween 20). The 
incubations and post incubation washes as detailed for the primary antibody were 
repeated goat anti-rabbit IgG conjugated to horseradish peroxidase secondary antibody 
(1:5000) (New England Biolabs, UK). An anti-biotin antibody (1:2000) (New England 
Biolabs, UK) also conjugated to horseradish peroxidase was added in order to detect 
the molecular weight ladder. 
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6. Detection of protein bands by Enhanced Chemiluminescence 
(ECL) detection 
Protein band detection was carried using the enhanced chemiluminescence (ECL) 
detection system. Equal volumes of reagent 1 (5 ml) and 2 ( 5 ml) in the ECL Western 
Blotting Detection kit (Amersham, UK) were mixed and added to the blot as per 
manufacturer’s instructions and incubated for 1 minute at room temperature. The 
excess detection reagent was drained from the membrane using a folded tissue paper. 
The blot was covered with cling film, ensuring all trapped air bubbles were gently 
smoothened out. A sheet of autoradiographic film, Hyperfilm ECL (Amersham, UK) was 
placed on top of the wrapped blot in an x-ray cassette holder and the film was exposed 
for 5 minutes, developed, fixed, rinsed under running tap water and then dried in air at 
room temperature. 
 
7. Quantification of Proteins on ECL Western Blots 
The developed protein bands on the film were scanned and the intensities of the 
scanned image were measured using the densitometry software, Syngene Gene Tools 
(version 3.00). 
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2.14 Gene silencing using small interference RNA (siRNA) 
 
2.14.1 siRNA knockdown of GAPDH 
Small interference RNA (siRNA) was intended as a tool to knock down targeted genes 
including that for JAK2 in order to determine unequivocally the role played by these 
proteins in the induction of iNOS. The protocol for using siRNA was optimized in J774 
macrophages using the lipid-based siPORT NeoFX transfection agent (Ambion, UK), 
GAPDH siRNA including negative control siRNA mixtures (CAT #: AM4624 Silencer® 
GAPDH siRNA (Human, Mouse, Rat) and 5 nmol + 2 nmol Negative Control 50 µM). 
Confluent monolayer of J774 macrophages in T25 flasks were resuspended by 
scrapping cells in 10 ml, complete DMEM. A 15µl of siPORT NeoFX transfection agent 
was diluted in 300 µl of OPTI-MEM I medium and incubated for 10 minutes at room 
temperature. Pre-designed GAPDH siRNA (RefSeq NM_002046 (human), 
NM_001001303 (mouse), and NM_017008 (rat)) and negative control siRNA (Ambion’s 
validated scrambled sequence siRNA) which has limited sequence similarity to the 
human, mouse, or rat genomes were both separately diluted in OPTI-MEM I medium to 
achieve a final concentration of 1 µM. The reaction mixtures of media and target siRNA 
were subsequently combined and incubated for 10 min to allow transfection complexes 
to form. The transfection complex (200µl/well) was then dispensed into a clean 6-well 
culture plate. The re-suspended J774 macrophages (2300 µl) cells were gently overlaid 
over the transfection complex mixture, a procedure referred to as reverse transfection. 
Culture plates were then gently tilted back and forth to achieve a uniform distribution of 
the transfection complex and cells in the plate. 
 
Culture plates were eventually transferred into an incubator at 37°C and maintained 
under normal cell culture conditions for 24 hour. The existing media was replaced after 
24 hrs with fresh complete DMEM and the cultures incubated for a further 24 hours. 
Cells from respective wells were harvested and total RNA extracted as previously 
described. Extracted RNA was treated with RNAse-free DNAse (Ambion) to get rid of 
residual DNA prior to RT assay. In addition a no “RT” and “water control” was included 
in the RT reaction. The resulting cDNAs were then subjected to real time PCR as 
previously described. 
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2.14.2 siRNA knockdown of JAK2 
To investigate the effect of JAK2 knockdown in RASMCs were initially cultivated at 
passage 2 or 3 in a T-75 flask at 37ºC, 5% CO2 until confluent. Cell were then 
trypsinized and plated out at three plating densities (5 x 103, 1 x 104, 2.5 x 104 cells per 
well) so as to determine the optimal seeding density for the most efficient delivery of 
siRNA into cell. Within this parameter, we also investigated the concentration of DhF-2 
that will achieve the most effective delivery of siRNA into each cell. All the cells were 
serum starved (1%FBS) in Opti-MEM (Invitrogen) media and cultured in both 96-well 
and 12-well plate formats. These cells were used to optimize conditions for siRNA 
delivery into cell in the complete absence of penicillin/streptomycin. After day two when 
cells had achieved 70-90 % confluency, media was changed and cells were transfected 
with 0.125 nM DharmaFECT (DhF) transfection reagent-2 in Opti-MEM containing 
1%FBS. 
 
Prior to the transfection studies, the MTT assay was carried out to determine the toxicity 
of DharmaFECT transfection reagent-2 on RASMCs. This was to establish the most 
appropriate concentration that could be used in the transfection experiments without 
resulting in cytotoxicity. 
 
Using the forward transfection (FT) approach for gene silencing, RASMCs were seeded 
at 2.5x104 cells/L for 48 hours in cell culture incubator. On day 3, transfection complex 
were prepared as per manufacturer’s instructions. Briefly, the following transfection 
mixes were prepared: 
 
Tube A containing diluted 0.125 nM DharmaFECT (DhF) transfection reagent-2 in Opti-
MEM with 1%FBS. 
Tube B containing JAK2 siRNA (100 nM) diluted in Opti-MEM with 1%FBS. 
 
Cells were incubated at 37 ºC in 5% CO2 for 24 hours and the transfection media 
replaced with fresh complete media for a further 24 hours prior to protein analysis. 
Lysates were prepared for western blotting as described in section 2.14 and JAK2 
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protein expression was assessed using a selective anti-JAK2 primary antibody (Santa 
Cruz Biotechnology, UK). 
 
2.15 Total RNA Isolation 
Total RNA was prepared from confluent monolayers of cells using the RNA STAT60 
reagent (AMC Biotechnology) as per manufacturers’ instructions. This involved adding 
2 ml of RNA STAT-60 to each T25 plate and incubating at room temperature for 10 min 
to allow lysis and complete dissociation of nucleoprotein complexes. Cell lysates were 
transferred into eppendorf tubes and 200 µl of chloroform per ml of RNA STAT-60 
added to each tube. The mixture was then incubated for a further 5 min at room 
temperature. Each tube was vortexed for 15-20 sec, incubated for 10 min at room 
temperature and centrifuged at 4ºC for 25 min at 12,000 rpm. The upper clear aqueous 
phase containing RNA was carefully removed and transferred into a new eppendorf 
tube. Total RNA was precipitated by adding 500 µl of isopropyl alcohol per ml of RNA 
STAT-60 to the clear supernatant and samples incubated at room temperature for 10 
min before centrifuging at 4ºC for 20 min at 10,000 rpm. The RNA pellet was washed 
three times with 75% ethanol, briefly air dried in the fume cupboard and re-dissolved in 
50 to 100 µl of DNAse free treated water depending on size of pellet. The quantity of 
RNA concentration was assessed using a UV spectrophotometer (Eppendorf 
Biophotometer, Germany) as described below. 
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Spectrophotometric quantification of isolated RNA 
RNA quantity and purity was determined using a spectrophotometer by determining the 
ratio of absorbance at 260 nm and at 280 nm (A260/A280) in DDW. Absorbances were 
determined using a UV spectrophotometer (Eppendorf Biophotometer, Germany) at 260 
(OD260) and 280 (OD280) nm and concentrations of RNA determined using the 
following equation: 
 
 
 
 
Where 
Aλ260 is Absorbance of RNA 
40 represent the concentration in μg ml-1 of RNA in a solution with an OD λ260 of 1. 
 
Measurements were carried out in triplicate, and had an average Coefficient Variation 
(CV) of less than 10%. The average purity (OD260/ OD280) of the samples was 
consistently above 1.75. RNA integrity was verified by electrophoresis in a 1% agarose 
gel in TAE buffer containing ethidium bromide. Each sample containing RNA was 
warmed up to 70o C for one minute and immediately placed on ice. RNA sample was 
then carefully loaded into designated wells. Gel electrophoresis was carried out at 10 
V/cm to avoid RNA degradation during electrophoresis. The gel slab was then placed in 
a UV Gel Scan apparatus and examined for the presence of clear  bands of 4.5 and 2.0 
kb which represent 28S and 18S rRNA. 
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Determination of RNA integrity by gel electrophoresis 
Aliquots of extracted total RNA (1 to 2.5 µg) were run on a 1% non-denaturing agarose 
gel in Tris Borate EDTA buffer (TBE) (89 mM Tris-HCl pH 7.8, 89 mM borate, 2 mM 
EDTA) for 60 min at 80 volts. The gel was then stained with 0.5 µg/ml ethidium bromide 
to visualise the 28S and 18S ribosomal bands. RNA bands were visualized under UV 
light and image captured using a Syngene (Cambridge, UK) Gel Documentation Unit 
system which incorporates Syngene’s software (GeneTools) for analysing the band 
quantities in 1D gel images. 
2.16 PCR Primer design 
Primers for use in PCR analysis of iNOS and CATs were designed together with those 
for the house keeping genes including glyceraldehyde-3- phosphate dehydrogenase, 
(GAPDH) and Beta-2-microglobulin (B2M). These were all designed from respective 
published sequences obtained from the murine database with cross-reference to the 
National Center for Biotechnology Information (NCBI). The sequences retrieved are 
shown in Table 6.3: 
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TABLE 2.2 Source of primers designed from NCBI database with 
GenBank Accession references. 
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Primers were designed with a melting temperature (Tm) of 60°C ± 2°C using the 
FASTPCR and Molecular Beacon programs, ensuring the GC content of all primers was 
within the range of 40 – 60% and the primer length was no more than 18 -23 base 
pairs. Sequences generated (see Tables 6.4 and 6.5) were checked for hairpins, 
maximum permissible local alignment score between primer pairs or the primer itself (3’ 
complementarity and self-complementarity) using the Oligoucleotide Properties 
calculator software. In addition the specificity of primers was assessed using BLAST 
and/or ClustaW. 
 
The designed primer sequences used in both mouse and rat gene expressions are 
shown in Tables 6.4 and 6.5 respectively. Except for GAPDH and -2-microglobulin all 
other housekeeping genes used in this thesis were purchased from PrimerDesign (UK). 
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TABLE 2.3 Mouse primer sequence used in PCR analysis 
 
 
 
Note: All other Housekeeping primers used in this thesis were purchased from 
PrimerDesign (UK). 
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TABLE 2.4 Rat primer sequences used in PCR analysis 
 
 
 
Note: All other Housekeeping primers used in this thesis were purchased from 
PrimerDesign (UK). 
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2.17 Reverse Transcription 
Reverse transcription in combination with polymerase chain reaction is a powerful 
method currently used to quantify the level of gene expression (Bustin et al., 2013; 
Horikoshi et al., 1992; Murphy et al., 1990). Ribonucleases are ubitiquous and are often 
the leading cause of RNA degradation during RNA isolation. Before the resulting RNA 
could be converted to cDNA we had to ensure that the extracted RNA is of high quality, 
intact and free of DNA contamination. To achieve this, the extracted RNA was initially 
treated with (2 U) RNase-free DNase 1 and 0.1 volumes of 10X DNase I Buffer to 
eliminate DNA from the RNA sample. Reverse transcription was then carried out using 
the ImProm-II Reverse Transcription System (Applied Biosystems). The first-strand was 
synthesised in 20 µl total reaction mixture in the presence of 1 U/µl recombinant RNasin 
ribonuclease inhibitor (20 U), although the addition of this enzyme is optional. 
 
The RT reaction master mix was prepared by combining the following: 
Reaction buffer (10X concentration) -    2.0 µl 
ImProm-II™ Reverse transcriptase -    2.0 µl 
Magnesium chloride -     3.5 µl 
dNTPs        2.0 µl 
Nuclease-free water -      5.5 µl 
 
The mixture was carefully mixed with a pipette and briefly spun at 9000 rpm. A working 
stock of RNA was also generated by diluting RNA with nuclease-free water to create a 
working concentration of 0.1 mg/ml to 1µg RNA. Transcription was first initiated by 
heating the template RNA (2.5 µl) and random hexamers (2.5 µl) for 5 minutes at 70ºC 
to facilitate annealing of the random hexamers to the template. Each tube was quickly 
chilled on ice after a brief spin at 9000 rpm. This was then added to the RT master mix 
and subjected to 60 min incubation at 42 ºC, followed by denaturing at 72oC for 10 min 
in order to deactivate the transcriptase enzyme. 
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2.18 Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) was carried out after reverse transcription using the 
fluorogenic minor groove binding dye, Sybr green, in a reaction mixture (20 µl) 
consisting of 10 µl Power Sybr green master mix, 2 µl each of both sense and 
antisense primers, 2 µl of template cDNA (from 1 in 5 dilution of original stock cDNA 
generated) together with 4 µl of DNA free water. 
 
PCRs were performed on a Quantica real time machine (Techne. UK) using the ‘hot-
start’ approach as follows: 
  
AmpliTaq Gold polymerase activation at 95°C for 10 min 
Template cDNA denaturing at 95°C for 15 sec 
Annealing for 30 sec between 59 to 61°C (mean TM used was 60 °C) depending on the 
primer used  
Extension at 72°C for 10 sec  
 
The annealing/extensions were allowed to progress through a maximum of 45 cycles, 
followed by dissociation at 58°C to 95°C and a final hold at 4°C 
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Quantitative PCR analysis of Cationic amino acid transporters in both 
RASMCs and J774 macrophages 
To investigate changes in target gene expression levels we used the relative 
quantification strategy to analyze the data generated from our PCR results. In these 
studies, it was mandatory to relate the changes in gene expression of the target gene to 
changes in control or non-treated cells. In addition both target gene in treated cells 
(activated cells) and control are normalized to a housekeeping (or Reference) gene 
(HKG). These HKGs are normally cellular maintenance genes selected from a panel 
using a procedure called normalization and is commonly used to normalize for the 
variability between samples. The relative quantities can thus be compared across 
multiple real time PCR experiments (Orlando et al., 1998). 
 
Analysis of the Q-PCR results was carried out by the comparative Threshold cycle (CT) 
method, also called the Delta-Delta CT method (2-ΔΔCT) where 
 
 
 
Where  
 
[Delta] Ct (sample) is Ct values of test sample which has been normalized to the 
endogenous HKG or reference gene 
 
[Delta] Ct (reference) is Ct values of non-treated (control) sample which has been 
normalized to the endogenous HKG or reference gene 
 
To ensure validity to the above equation both amplification efficiencies of the target 
gene and the HKG must be very similar. 
 
The threshold cycle value represents the cycle at which there is an observable 
fluorescence emission far in excess of the background emission (Higuchi et al., 1993). 
The threshold cycle analysis involves comparing threshold cycle (Ct) values of both the 
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target gene and the housekeeping gene. The threshold cycle value represents the cycle 
at which  there is an observable fluorescence emission far in excess of the background 
emission (Higuchi et al., 1993). By comparison, the Delta-Delta CT method assumes 
that PCR amplification is the same in both control and activated cells. In addition it is 
assumed that both have the same amplification profile. To further improve our 
amplification profile, we incorporate a mathematical model and analysed our data by 
adjusting for PCR efficiency differences as described by Pfaffl (Pfaffl, 2001). 
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2.19 Normalization of Housekeeping genes 
At present real time RT-PCR is the most sensitive, precise and reproducible means of 
measuring target gene expression by using specific mRNA sequences (Bustin, 2000). It 
is also imperative in normalizing target gene expression that the housekeeping genes 
used for normalization shows minimal variation in its expression profile irrespective of 
the treatment or experimental conditions being employed. In effect, expression of the 
housekeeping gene must be stable and free from any form of influence from the 
existing experimental conditions. To determine which housekeeping gene was suitable 
for use in our studies, we investigated the expression pattern of nine commonly used 
housekeeping genes in both RASMCs and J774 macrophages. As shown in Table 2.5, 
these included 2-microglobulin, glyceraldehyde-3-phosphate dehydrogenase, 
cyclophilin-, hypoxanthine ribosyltransferase, tyrosine 3-monooxygenase /tryptophan 
5-monooxygenase activation protein zeta, calnexin, alpha Actin, ribosomal protein 
L13A, and Ubiquitin C. All except for the first two, HKGs were designed in house. 
 
In this thesis, monolayer of cells with varying treatment conditions were subjected to 
RNA extraction and DNase I treatment (Ambion, UK) following manufacturer’s 
instructions. Briefly, extracted total RNA samples from RASMCs were initially diluted in 
0.2 µg/µl of nuclease-free water. Prior to treatment, 50 µl of resuspended RNA solution 
(0.2 µg/µl) was aliquoted into a 0.5 ml reaction microcentrifuge tube and initially treated 
with 5 µl of DNase I Buffer (0.1 volume) and 1 µl of rDNase. The solution was mixed 
thoroughly and incubated a 37 ºC for 30 minutes. For rigorous DNase treatment a 
further 1 µl of rDNase was added, mixed and the incubation step repeated. 
Resuspended DNase Inactivation Reagent (0.1 volume) was added to resulting 
solution, gently mixed and incubated at room temperature for 2 minutes. Finally, the 
mixture was centrifuged at 10, 000 x g for 1.5 minutes and the upper layer containing 
pure RNA transferred into a fresh tube. 
 
The RNA was quantified spectrophotometrically at 260 nm and its purity assessed 
using the 260/280 ratio. The integrity was determined by 1% agarose gel 
electrophoresis. Reverse transcription of DNase treated RNA samples followed by q-
PCR analysis were subsequently carried out. Generated CT values of respective genes 
were analysed using Quansoft system software and the resulting data transformed 
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using their delta CT (∆CT) values into relative quantification data using geNORM 
analysis procedures. Real time reactions of the different products were assessed by 
dissociation curve or melting point analysis after each reaction. 
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TABLE 2.5 Housekeeping genes used for normalisation in both murine 
J774 macrophages and RASMCs and their respective functions 
 
 
 
 
  
MOUSE RAT FUNCTION
1 2-Microglobulin
(B2M)
2-Microglobulin
(B2M)
Component of  Major 
histocompatibility complex
2 Cyclophilin
(CYC)
Cyclophilin
(CYC)
Protein folding-serine-threonine 
phosphatase inhibitor
3 Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH)
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH)
Glycolytic pathway
4 Hypoxanthine ribosyltransferase 
(HPRT):
Hypoxanthine ribosyltransferase 
(HPRT):
metabolic salvage of  nucleotides-
translational control
5 Tyrosine 3-monooxygenase 
/tryptophan 5-monooxygenase 
activation protein, zeta 
(YWHAZ)
Tyrosine 3-monooxygenase 
/tryptophan 5-monooxygenase 
activation protein, zeta 
(YWHAZ)
Role in regulating insulin 
sensitivity
6 Calnexin 
(CANX)
Calnexin 
[CANX)
MHC binding protein [p88]
7 Alpha Actin
(-Actin)
Alpha Actin
(-Actin)
Major component of  the cell 
cytoskeleton
8 Ribosomal protein L13A
(RPL13A)
Ribosomal protein L13A
(RPL13A)
Translational control in eukaryotic 
cells
9 Ubiquitin C
(UBC)
Ubiquitin C
(UBC)
Cell metabolism
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2.20 STATISTICAL ANALYSIS 
All experiments were performed at least three times and data expressed as means ± 
SEM as indicated. For data with multiple comparisons, data were analyzed by one-way 
ANOVA followed by Dunnett’s test (in order to compare each treatment to control 
value). Where required, Student’s t-tests were used for single comparisons between 
treatment and control. A difference was considered to be statistically significant when 
the P value was less than 0.05 (P < 0.05). 
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Chapter 3. The effects of JAK inhibitors on the induction of nitric oxide 
synthesis and L-arginine transport 
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3.1 INTRODUCTION 
As highlighted in our main introduction (section 1.1.7 & 1.1.8), NO is an important 
mediator, widely involved in both the physiology and pathophysiology of the 
cardiovascular, nervous and immune systems (Moncada et al., 1993; Nathan, 1992). 
Under normal physiological conditions NO production is at basal level but increase 
significantly in different pathophysiological states such as during local inflammation (i.e. 
atherosclerosis) or in systemic inflammation (sepsis and septic shock) (Titheradge, 
1999). The main enzymes responsible for NO production include the constitutive 
isoforms, eNOS and nNOS, and the inducible isoform, iNOS. The former two are 
predominantly regulated through intracellular calcium/calmodulin following stimulation 
by various agents. The inducible NOS which is expressed and regulated following 
induction by cytokines, LPS or other pro-inflammatory mediators and its regulation 
seems to be predominantly transcriptional, involving an ever growing list of signaling 
kinases since it is not constitutively expressed in tissues except when induced. It is 
implicated in lethal and often very debilitating diseases including chronic Inflammation, 
sepsis, stroke, diabetes, arthritis and therefore a key therapeutic target. Unravelling the 
cascade of reactions leading to its expression and subsequent NO production could 
prove essential in developing strategies for treating disease states associated with this 
enzyme. 
 
In this regard, considerable progress has been made in identifying key signaling 
molecules such as the MAPKs (Bhat et al., 1999; Bhat et al., 1998; Da Silva et al., 
1997), PKC (Bhatt et al., 2010; Nakai et al., 1998; Yoon et al., 1994) and P13Ks (Guha 
et al., 2002; Park et al., 1997). Another pathway which may be important but as yet 
inconclusive is that involving the JAK/STAT pathway. 
 
The JAK/STATs may be considered essential molecules through which cytokine induce 
iNOS expression. However, at present it is still unclear as to whether activation of the 
JAK/STAT pathway is critical for the induction of iNOS or indeed L-arginine transport 
which is co-induced with the enzymes in different cell systems. Although there is 
evidence that activation of JAK/STATs may be essential in LPS and IFN- induced 
astrogial cells (Dell'Albani et al., 2001) and in IL-1 and TNF- induced rat VSMCs (Doi 
et al., 2002) the extent and main components in the intracellular signals mediating iNOS 
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expression is far from being fully characterized. Moreover, preliminary studies in our 
group have demonstrated that AG490, a selective inhibitor of JAK2 (Meydan et al., 
1996) was without effect in activated smooth muscle cells. This indicates, at least in our 
hands, that JAK2 may not be essential for iNOS induction. This is however not in 
agreement with the studies highlighted above where a case for JAK2 involvement has 
been made. There are however three other JAK proteins and whilst JAK-1 or JAK-3 
may not be required for iNOS expression the fourth, Tyk-2, remains a candidate which 
is yet to be implicated. To explore this, previous studies with AG490 have been 
extended using another pharmacological inhibitor, JAK inhibitor I which inhibits all four 
JAK proteins including Tyk-2 (Thompson et al., 2002). 
 
To establish unambiguously the role of the JAK/STAT pathway in our system, studies 
were conducted repeating those carried out previously using AG490 and in addition by 
using JAK inhibitor I which is a potent inhibitor of all four JAK family members. 
Furthermore, the activated status of JAK2 and Tyk-2, the two most likely kinases of this 
family likely to mediate the induction of iNOS, were also examined under different 
experimental conditions. 
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3.2 METHOD 
3.2.1 Experimental conditions 
Both RASMCs and J774 macrophages were cultured and maintained in complete 
DMEM as described in Chapter 2. When needed, cells were plated at the appropriate 
seeding densities and allowed to grow to confluence in either 96-or 6-well plates for 
nitrite measurement and L-arginine transport studies or for Western blotting 
respectively.  
 
Each plate was pre-treated with either AG490 (0 to 10 µM) or JAK inhibitor-I (0 to 10 
µM) for 30 minutes prior to stimulation with 100 µg/ml LPS and 100 U/ml IFN- 
(RASMCs) or 1 µg/ml LPS alone (J774 macrophages) for a further 24 hours. 
 
 
3.2.2 Determination of drug effects on nitrite production 
The effects of AG490 or JAK inhibitor I on induced NO production was assessed by 
determining changes in accumulated nitrite levels at the end of each incubation period 
using the Griess assay described in Section 2.9 (Chapter 2). 
 
 
3.2.3 Drug effects on L-arginine transport 
Changes in L-arginine transport were assessed on the cell monolayer as described in 
Section 2.10 (Chapter 2). These studies were carried out after removing the culture 
medium for nitrite measurements and further investigations were carried out in parallel 
with those aimed at determining the effects of AG490 and JAK inhibitor I on NO 
synthesis. 
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3.2.4 Drug effects on iNOS expression by western blotting 
At indicated time points, cells were rapidly washed with ice-cold phosphate-buffered 
saline (PBS) containing 2 mM sodium orthovanadate. For Phospho-JAK2 and Phospho-
TYK2 western blot, the cells were solubilized in cold lysis buffer containing 1% Triton X-
100, 150 mM NaCl, 50 mM Tris pH 7.5, 1.0 mM EDTA, 1.0 mM 
phenylmethylsulfonylfluoride, 2 mM sodium orthovanadate, 80 μM leupeptin, 1 μg/mL 
aprotinin, 1 mM NaF , 2 mM sodium pyrophosphate, 0.25% sodium deoxycholate. 
Lysates generated were processed and subjected to western blotting as described in 
Section 2.13 (Chapter 2) 
 
 
3.2.5 Determination of drug cytotoxicity 
In these studies, cells were incubated at the end of the 24 hour activation period with 
0.5 mg/ml MTT diluted in complete DMEM. Cell viability was subsequently determined 
by the MTT assay as described in Section 2.12 (Chapter 2). 
 
 
3.3 STATISTICAL ANALYSIS 
All experiments were performed three times and data expressed as means ± SEM as 
indicated. For data with multiple comparisons, statistical analysis was carried out with 
Graph Pad Prism (Graph Pad software, USA) and analyzed by using one-way ANOVA 
followed by Dunnett’s test (in order to compare each treatment to control value). Where 
required, Student’s t-tests were used for single comparisons between treated and 
control groups. Statistical significance was established at P<0.05. 
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3.4 RESULTS 
3.4.1 Morphological characterization of J774 macrophage cells 
The characterization of the J774 macrophages was through identification of their 
characteristic rounded shape, their pattern of growth and general morphology. 
Following initial plating of cells in T-75 Flask, cells quickly attached within 1-2 hours and 
started to divide within 12-24 hours especially in areas where they formed clusters 
(Figure 3.1). This growth pattern was observed in all cultures and cells reached 60-70% 
confluency within 2-3 days. 
 
 
 
 
Figure 3.1 Inverted phase contrast micrograph showing the morphology of 
murine J774 macrophage cells cultured in complete DMEM. 
J774 macrophage cells were cultured in DMEM supplemented with 10% FBS, 100 U/ 
ml penicillin and 100 µg/ ml streptomycin in T-75 tissue culture flask. Cultures were 
viewed using a Nikon TMS inverted microscope at 200X magnification and the figure 
above represents the morphology of the cells in culture. 
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3.4.2 Morphological and biochemical characterization of rat cultured 
aortic smooth muscle cells (RASMCs) 
Rat smooth muscle cells were identified on the basis of their growth pattern and 
morphological characteristics. Cells attached within 1-3 hrs following initial plating and 
started to divide within 18-24 hours especially in areas where they formed clusters and 
reaching between 60 to 70% confluent within 2-3 days. In terms of their morphology, 
the cells looked spindle shaped and showed the characteristic ‘hill and valley’-like 
pattern with increasing density. These were observed in all cultures of RASMCs. 
Further biochemical characterization was carried out to ensure specificity of the cell 
type. Cells were characterized by immunoassaying for -actin. As shown in Figure 3.3, 
cultures routinely isolated stained positively for -actin confirming these cells as being 
smooth muscle. Cross staining of the cells with Dil-labelled acetylated low density 
lipoproteins (Dil-Ac-LDL) proved negative, discounting any possible cross 
contamination with endothelial cells and thus confirmed isolated pure populations of 
smooth muscle cells in our experiments. 
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Figure 3.2 Inverted phase contrast micrograph showing the morphological 
characteristics of rat smooth muscle cells cultured in complete DMEM. 
Isolated cells were cultured in DMEM supplemented with 5% FBS, 100 U/ml penicillin 
and 100µg/ml streptomycin in T-75 tissue culture flask. Cultures were examined using a 
Nikon TMS inverted microscope at 200X magnification and the figure above represents 
the morphology of the cells in culture. 
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Figure 3.3 Positive identification of rat cultured smooth muscle cells by 
staining for alpha-actin. 
Cultures of rat aortic smooth muscle cell routinely isolated were stained for -actin 
expression using the FITC labelled -actin monoclonal antibody as previously 
described in Methods (Section 2.6). The above figure was taken using a Nikon 
Quadfluor Episcopic Fluorescence EFD-3 microscope under UV with a FITC Filter at 
400X magnification. The picture is representative of at least four experiments carried 
out randomly over the period of the studies. 
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3.4.3 Nitrite production following activaton of both J774 macrophages and 
RASMCs 
The effects of IFN- and/or LPS or LPS alone on nitrite production in RASMCs and 
J774 macrophages were assessed respectively. Nitrite accumulation in the cell culture 
media was used as an indication of NO production. Treatment of RASMCs with LPS 
and IFN- or J774 macrophages with LPS alone resulted in significant increases despite 
marked differences in levels of nitrite production. The results obtained in Figure 3.4 
showed that stimulation of RASMCs with LPS (100 µg/ml) together with IFN- (100 
U/ml) resulted in a significant increase in nitrite levels (p<0.05) with peak levels of about 
55.0 nM after a 24-hour incubation period. Basal levels of nitrite under control 
experimental conditions average not more than 5.0 nM. By comparison, activation of 
RASMCs with either LPS (100 µg/ml) or IFN- (100 U/ml) alone caused a small but 
statistically non-significant increase in nitrite production (p> 0.05) when compared to 
control cells. Activation of cells with either LPS or IFN- alone resulted in an average 
nitrite production of 8.0 nM and 13 nM respectively (Figure 3.4). 
 
Control J774 macrophages (as shown in Figure 3.5) produced, on average, 3 nM nitrite 
under basal conditions. Activation of these cells with 1.0 µg/ml LPS produced a peak 
average nitrite of up to 85.0 nM. This represents roughly a two-fold increase in 
comparison with that in RASMCs. However activation of cells with IFN- alone induced 
marginal production of nitrite which was not statistically different from the basal control 
levels (p> 0.05). When macrophages were activated with 10 µg/ml LPS there was a 
significant increase (90.0 nM; p<0.001) in nitrite production above basal. This increase 
was however only marginally higher than that seen with 1.0 µg/ml LPS (as shown in 
Figure 3.5) and at 10 µg/ml LPS caused significant cytotoxicity in cells. The 
concentrations used in further studies in this thesis were therefore limited to 1 µg/ml in 
macrophages. 
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Figure 3.4 Comparison of different activators on nitrite production in RASMCs. 
Confluent monolayer of RASMCs in complete DMEM were stimulated with LPS (100 
µg/ml) alone, IFN- alone (100 U/ml) or a combination of both LPS (100 µg/ml) and IFN-
 100 U/ml for 24 hours. Controls were incubated in complete DMEM only. The stable 
NO metabolite, nitrite, present in the medium was analysed using the Greiss assay as 
described in Method (Section 2.9). The data represents the mean ± S.E.M. obtained 
from three independent experiments, each with six replicates. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. * denotes 
P<0.001 when compared to untreated control. 
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Figure 3.5 Effects of different activators on nitrite production in J774 
macrophages. 
Confluent monolayer of J774 macrophages in complete DMEM were stimulated with 
IFN- 10.0 U/mlor with LPS (1.0 µg/ml or 10.0µg/ml) for 24 hours. Controls were 
incubated in complete culture medium only. The stable NO metabolite, nitrite, present in 
the medium was analysed using the Greiss assay as described in Method (Section 2.9). 
The data represents the mean ± S.E.M. obtained from three independent experiments, 
each performed with five replicates. Statistical differences between means were 
determined using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data. * & ** denotes P<0.05 and P<0.001 
respectively when compared to untreated controls. 
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3.4.4 Inducible Nitric Oxide Synthase expression in J774 macrophages 
and RASMCs following activation 
The expression of iNOS protein increased progressively following the induction by LPS 
and IFN- or by LPS alone. Results from western blots shown below demonstrate that 
iNOS expression is induced in both RASMCs (Figure 3.6) and J774 macrophages 
(Figure 3.7) following a 24 hours incubation with a combination of IFN- (100 U/ml) and 
LPS (100 µg/ml) or LPS (1.0 µg/ml) alone respectively. As expected, there was 
negligible or no expression of iNOS in control cells. 
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Figure 3.6 Induction of iNOS expression in control and activated RASMCs. 
Confluent monolayer of RASMCs in 6-well plates were incubated with either complete 
DMEM alone (Controls=Lanes 1 and 2) or in complete DMEM with a combination of 
LPS (100 µg/ml) and IFN- (100 U/ml) (Activated cells=Lanes 3 and 4) for a further 24 
hours. Whole cell lysates (20 µg) generated were subjected to western blotting using a 
specific anti-iNOS antibody as described in the Methods (section 2.13). A 
representative western blot is shown in Figure A. Respective band intensities were 
quantified by densitometric analysis and normalized to -actin protein (Figure B). The 
data is transformed and presented as percentage of relative intensity of the maximum 
expression of iNOS protein. Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. * denotes P<0.001 when compared to untreated controls. 
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Figure 3.7 Induction of iNOS expression in both control and activated J774 
macrophages. 
Confluent monolayer of J774 macrophages in 6-well plates were incubated with either 
complete DMEM alone (Control=Lane 1) or in complete DMEM with LPS (1.0 µg/ml) 
(Activated=Lane 2) for further 24 hours. Whole cell lysates (20 µg) generated from cells 
with respective treatment conditions were subjected to western blotting using a specific 
anti-iNOS antibody as described in the Methods (section 2.13). A representative 
western blot is shown in Figure A. Respective band intensities were quantified by 
densitometric analysis and normalized to -actin protein (Figure B). The data is 
transformed and presented as percentage of relative intensity of the maximum 
expression of iNOS protein. Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. * denotes P<0.05 when compared to untreated controls. 
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3.4.5 Time course induction of iNOS and NO production in activated 
RASMCs and J774 macrophages 
The induction of both iNOS and NO production in activated RASMCs and J774 
macrophages followed a time course. As illustrated in Figures 3.8A and 3.9A, the time 
course of activation of NOS peaked after 24 hours following stimulation in both 
RASMCs and J774 macrophages. In J774 macrophages basal expression of iNOS 
following stimulation was detected after 9 hours of exposure to LPS (1.0 µg/ml). In 
contrast iNOS expression in RASMCs was apparent after only 6 hours following 
induction LPS (100 µg/ml) and IFN- (100 U/ml). 
 
NO production also showed a similar trend as shown in Figures 3.8B and 3.9B, by 
increasing its production with time and peaked at 24 hours in both J774 macrophages 
and RASMCs. This occured after a lag phase of about six hours and increased 
significantly thereafter till 24 hours after activation. 
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Figure 3.8 Time dependent increase in iNOS expression [A] and nitrite 
production [B] in activated J774 macrophages. 
Confluent monolayer of J774 macrophage in 6-well plates in complete DMEM were 
stimulated with LPS (1.0 µg/ml) alone at different time point as indicated above. Cells 
were lysed at the respective time points and 40 µg of total protein subjected to western 
blotting as described in the Methods (section 2.13). The stable NO metabolite, nitrite, 
present in the medium at the indicated time points was analysed using the Greiss assay 
(Figure B) as described in the Method (Section 2.9). The data is presented as 
percentage of nitrite production by activated cells. Data represent the mean ± S.E.M. 
from three independent experiments with five replicates in each. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. * denotes 
P<0.05 when compared to non activated control. 
 
iNOS, 130 kDa
0 6 9 12 15 18 24
A
B
 129 
 
 
Figure 3.9 Time dependent increase in iNOS expression [A] and nitrite 
production [B] in activated RASMCs. 
Confluent monolayer of RASMCs in 6-well plate in complete DMEM were stimulated 
with a combination of LPS (100 µg/ml) and IFN- 100 U/ml at different time point as 
indicated above. Cells were lysed at the respective time points and 40 µg protein 
subjected to western blotting as described in the Methods (section 2.13). The blot 
(Figure A) is representative of iNOS expression three independent experiments. The 
stable NO metabolite, nitrite, present in the medium at the indicated time points was 
analysed using the Greiss assay (Figure B) as described in the Methods (Section 2.9). 
Data represent the mean ± S.E.M. from at least three independent experiments with 
five replicates in each. Statistical differences between means were determined using 
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test 
of the normalized data. * & ** denotes P<0.05 and P<0.01 respectively when compared 
to non activated control. 
 
 
 
 
  
 130 
3.4.6 Effects of JAK inhibitor I and AG490 on nitrite production in both 
RASMCs and J774 macrophages 
In order to further characterize the involvement of the JAK/STAT pathway in iNOS 
induction we used a pharmacological approach and investigated the effects of JAK 
inhibitor I or AG490 on nitrite production in both RASMCs and J774 macrophages. The 
results obtained indicate that treatment of RASMCs with JAK inhibitor I (0.01 to 10.0 
µM) for 30 minutes prior to activation with LPS (100 µg/ml) and IFN- (100 U/ml) 
resulted in a significant decrease (p<0.01) in nitrite production. This occurred in a 
concentration dependent manner and the most significant decrease (approximately 
down to 38.6%) was with a concentration of 10.0 µM (Figure 3.10). Similarly, JAK 
inhibitor I concentration-dependently inhibited nitrite production in LPS (1 µg/ml) 
activated J774 macrophages, reducing this by 85 % at 10 µM (Figure 3.11). In contrast 
AG490 was without effect in both cell types with very marginal (15% reduction) non-
concentration dependent inhibition of nitrite production in either RASMCs (Figure 3.12) 
or J774 macrophages (Figure 3.13). In addition there was no significant change in 
nitrite production in non-activated cells incubated with either JAK inhibitor I (Figures 
3.10 and 3.11) or with AG490 (Figures 3.12 and 3.13) in respective cells. 
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Figure 3.10 Concentration-dependent effect of JAK Inhibitor I on nitrite 
production in both control and activated RASMCs. 
Confluent monolayers of RASMCs in 6-well plates in either complete DMEM alone 
(Controls) or in complete DMEM with different concentrations of JAK inhibitor I (0.01 to 
10 µM) for 30 minutes prior to activation. Cells were activated with LPS (100 µg/ml) and 
IFN- (100 U/ml) in the absence and continued presence of JAK inhibitor I for 24hours. 
The stable NO metabolite, nitrite, present in the medium was analysed using the Greiss 
assay as described in the Methods (section 2.9). The data is presented as percentage 
of nitrite production by activated cell (activated control). Data represent the mean ± 
S.E.M. from at least three independent experiments, each with five replicates. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. * & ** 
denotes P<0.05 and P<0.01 respectively when compared to untreated activated control. 
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Figure 3.11 Concentration-dependent effect of JAK-inhibitor I on nitrite 
production in both control and activated J774 macrophages. 
Confluent monolayers of J774 macrophages in 6 well plates in either complete DMEM 
alone (Controls) or in complete DMEM with different concentrations JAK inhibitor I (0.01 
to 10 µM) for 30 minutes prior to activation. Cells were activated with LPS (1.0 µg/ml) in 
the absence and continued presence of JAK inhibitor I for 24hours. The stable NO 
metabolite, nitrite, present in the medium was analysed using the Greiss assay as 
described in the Methods (Section 2.9). The data is presented as percentage of nitrite 
production by activated cell (activated control). Data represent the mean ± S.E.M. from 
three independent experiments with five replicates. Statistical differences between 
means were determind using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data. * & ** denotes P<0.05 and 
P<0.001 respectively when compared to untreatedactivated control. 
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Figure 3.12 Concentration-dependent effect of AG490 on nitrite production in 
both control and activated RASMCs. 
Confluent monolayer of RASMCs in 6 well plates was treated in either complete DMEM 
alone (Controls) or in complete DMEM with different concentrations of AG490 (0.01 to 
10 µM) for 30 minutes prior to activation. Cells were activated with LPS (100.0 µg/ml) 
and IFN- 100.0 U/ml) in the absence and continued presence of AG490 for 24 hours. 
The stable NO metabolite, nitrite, present in the medium was analysed using the Greiss 
assay as described in the Methods (section 2.9). The data is presented as percentage 
of nitrite production by activated cell (activated control). Data represent the mean ± 
S.E.M. from three independent experiments each with 5 replicates. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. 
P>0.05 confirmed there was no significant difference when compared to 
untreatedactivated control. 
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Figure 3.13 Concentration-dependent effect of AG490 in nitrite production in 
both control and activated J774 macrophages. 
Confluent monolayers of J774 macrophages in 6 well plate in either complete DMEM 
alone (Controls) or in complete DMEM with different concentrations AG490 (0.01 to 10 
µM) for 30 minutes prior to activation. Cells were activated with LPS (1.0 µg/ml) in the 
absence and continued presence of AG490 inhibitor for 24hours. The stable NO 
metabolite, nitrite, present in the medium was analysed using the Greiss assay as 
described in the methods. The data presented as percentage of nitrite production by 
activated cell without inhibitor treatment (activated control). Data represent the mean ± 
S.E.M. from three independent experiments each with five replicates. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. 
P>0.05 confirmed there was no significant difference when compared to untreated 
activated control. 
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3.4.7 Effects of JAK inhibitor I and AG490 on iNOS expression in RASMCs 
and J774 macrophages 
Western blot analysis was carried out to determine whether JAK inhibitor I or AG490 
altered expression of iNOS in RASMCs. Our earlier results showed that stimulation of 
RASMCs with LPS (100 µg/ml) and IFN- (100 U/ml) resulted in the induction of iNOS 
protein expression (Figure 3.6) which was not detectable in control non-activated cells. 
Pre-treatment of cells with JAK inhibitor I prior to activation concentration dependently 
inhibited iNOS expression (Figure 3.14) in RASMCs and this occurred over the same 
concentration range that inhibited nitrite production. However in non-activated cells, 
pre-treatment with JAK inhibitor I (Figure 3.15) resulted in complete lack of iNOS 
protein expression. In contrast, pre-treatment with AG490 followed by activation with 
LPS (100 µg/ml) and IFN- (100 U/ml) caused no significant change in iNOS expression 
(Figure 3.16). This is also consistent with its lack of effect on nitrite production as 
described earlier. There was in addition no iNOS protein expression in non activated 
RASMCs following treatment with AG490 (as shown in Figure 3.17). 
 
Similarly, J774 macrophages exposure to LPS (1 0 µg/ml) resulted in iNOS expression 
(Figure 3.18) which as in RASMCs was not detected in non-activated controls (Figure 
3.19). Treatment of these cells with JAK inhibitor I prior to activation with LPS (1 0 
µg/ml) resulted in a significant (p<0.001) concentration dependent decrease in iNOS 
expression (Figure 3.20). There was in addition, no significant change in iNOS 
expression when macrophages were treated with AG490 inhibitor, 30 min prior to 
activation with LPS (1.0 µg/ml) (Figure 3.24). With both inhibitors, there was no change 
in iNOS expression in non activated controls (Figure 3.23 and Figure 3.25). 
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Figure 3.14 Effects of JAK inhibitor I on iNOS expression in activated RASMCs  
Confluent monolayer of RASMCs in 6-well plate were pre-treated with complete DMEM 
alone (Controls) and in complete DMEM with different concentrations of JAK inhibitor I 
(0.01 to 10 µM) for 30 minutes prior to activation. Cells were activated with both LPS 
(100 µg/ml) and IFN- (100 U/ml) in the absence and continued presence of JAK 
inhibitor I. After 24 hours, cell lysates were generated as previously described in the 
Methods (Section 2.13). Equal quantities of lysates (40 µg) were subjected to western 
blotting using a specific anti-iNOS antibody. The above western blot (Figure A) is 
representative of at least three independent experiments. Respective band intensities 
were quantified by densitometric analysis and normalized to -actin protein (Figure B). 
The data is presented as a percentage of relative intensity of the maximum expression 
of iNOS protein. Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. * & ** denotes P<0.05 and P<0.001 respectively when compared to 
untreated activated control. 
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Figure 3.15 Effects of JAK inhibitor I on iNOS expression in control RASMCs 
Confluent monolayer of RASMCs in 6-well plates were incubated in complete DMEM 
and pre-treated with different concentrations of JAK inhibitor I (0.01 to 10.0 µM) for 30 
min. Cells were cultured in continued presence of JAK inhibitor I for a further 24 hours. 
Cell lysates were generated as previously described in the Methods (Section 2.13). 
Equal quantities of lysates (40 µg) were subjected to western blotting using a specific 
anti-iNOS antibody. The housekeeping protein, -Actin (42 kDa) was used as a loading 
control. The above western blot is representative of at least three independent 
experiments. 
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Figure 3.16 Effects of AG490 on iNOS expression in activated RASMCs 
Confluent monolayer of RASMCs in 6-well plates were pre-treated with complete 
DMEM alone (Controls) and in complete DMEM with different concentrations of AG490 
(0.01 to 10.0 µM: Lane 6) for 30 min prior to activation. Cells were activated with both 
LPS (100 µg/ml) and IFN- (100 U/ml) in the absence and in continued presence of 
AG490 inhibitor. After 24 hours cell lysates were generated as previously described in 
the Methods (Section 2.13). Equal quantities of lysates (40 µg) were subjected to 
western blotting using a specific anti-iNOS antibody. The above western blot (Figure A) 
is representative of at least three independent experiments. Respective band intensities 
were quantified by densitometric analysis and normalized to -actin protein (Figure B). 
The data is presented as a percentage of relative intensity of the maximum expression 
of iNOS protein. Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. P>0.05 confirmed there was no significant difference when compared 
to untreated activated control. 
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Figure 3.17 Effects of AG490 on iNOS expression in control RASMCs 
Confluent monolayer of RASMCs in 6-well plates were incubated in complete DMEM 
and pre-treated with different concentrations of AG490 (0.01 to 10.0 µM) for 30 min 
prior to activation. Cells were cultured in continued presence of AG490 inhibitor for a 
further 24 hours. Cell lysates were generated as previously described in the Methods 
(Section 2.13). Equal quantities of lysates (40 µg) were subjected to western blotting 
using a specific anti-iNOS antibody. The housekeeping protein, -Actin (42 kDa) was 
used as a loading control. The above western blot is representative of at least three 
independent experiments. 
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Figure 3.18 Effects of JAK Inhibitor I on iNOS expression in control J774 
macrophages. 
Confluent monolayer of J774 macrophages in 6-well plates were incubated with either 
DMEM alone (Control; Lane 1) or in complete DMEM with different concentrations of 
JAK inhibitor I (0.01 to 10.0 µM) for 30 min prior to activation. Cells were stimulated with 
LPS (1.0 µg/ml) for a further 24 hour incubation. Equal quantities of lysates (40 µg) 
were subjected to western blotting using a specific anti-iNOS antibody (Figure A) using 
a specific anti-iNOS antibody as described in the Methods (section 2.13). Respective 
band intensities were quantified by densitometric analysis and normalized to -actin 
protein (Figure B). The data is transformed as a percentage of relative intensity of the 
maximum expression of iNOS protein. Data represents the mean ± S.E.M. of 
densitometric values obtained from three independent experiments. Statistical 
differences between means were determind using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. * & ** 
denotes P<0.05 and P<0.001 respectively when compared to untreated activated 
controls. 
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Figure 3.19 Effects of JAK Inhibitor I on iNOS expression in control J774 
macrophages 
Confluent monolayer of J774 macrophages in 6-well plates were incubated in complete 
DMEM and pre-treated with different concentrations of JAK inhibitor I (0.01 to 10.0 µM) 
for 30 min. Cells were cultured in continued presence of JAK inhibitor I for a further 24 
hours. Cell lysates were generated as previously described in the Methods (Section 
2.13). Equal quantities of lysates (40 µg) were subjected to western blotting using a 
specific anti-iNOS antibody. The housekeeping protein, -Actin (42 kDa) was used as a 
loading control. The above western blot is representative of at least three independent 
experiments. 
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Figure 3.20 Effects of AG490 inhibitor on iNOS expression in activated J774 
macrophages 
Confluent monolayer of J774 macrophages in 6-well plates were pre-treated with either 
complete DMEM alone (as Control) or in complete DMEM with different concentrations 
of AG490 inhibitor for 30 min prior to activation. Cells were activated with LPS (1.0 
µg/ml) in the absence and in continued presence of AG490 inhibitor. After 24 hours cell 
lysates were generated as previously described in the Methods (Section 2.13). Equal 
quantities of lysates (40 µg) were subjected to western blotting using a specific anti-
iNOS antibody. The above western blot (Figure A) is representative of at least three 
independent experiments. Respective band intensities were quantified by densitometric 
analysis and normalized to -actin protein (Figure B). The data is presented as a 
percentage of relative intensity of the maximum expression of iNOS protein. Data 
represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. 
P>0.05 confirmed there was no significant difference when compared to untreated 
activated control. 
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Figure 3.21 Effects of AG490 inhibitor on iNOS expression in control J774 
macrophages 
Confluent monolayer of J774 macrophages in 6-well plates were incubated in complete 
DMEM and pre-treated with different concentrations of AG490 (0.01 to 10.0 µM) for 30 
min. Cells were cultured in continued presence of AG490 inhibitor for a further 24 
hours. Cell lysates were generated as previously described in the Methods (Section 
2.13). Equal quantities of lysates (40 µg) were subjected to western blotting using a 
specific anti-iNOS antibody. The housekeeping protein, -Actin (42 kDa) was used as a 
loading control. The above western blot is representative of at least three independent 
experiments. 
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3.4.8 Effects of JAK inhibitor I and AG490 on L-arginine transport in 
RASMCs and J774 macrophages 
The dependence of NO production on L-arginine uptake in both activated RASMCs and 
J774 macrophages led us to characterise further the effects of JAK inhibitor I and 
AG490 on L-arginine transport in both cell models. Our results confirm earlier findings 
that activation of RASMCs with a combination of LPS (100 µg/m) and IFN- (100 U/ml) 
or J774 macrophages with LPS (1.0 µg/m) alone resulted in an increase not only in 
nitrite production but also in L-arginine transport. In the presence of JAK inhibitor I, L-
arginine transport was inhibited in a concentration dependent manner in RASMCs but 
only in activated cells (Figure 3.22). 
 
In J774 macrophages, JAK inhibitor I showed inhibition which was concentration 
dependent. This was significantly evident in activated cells where induced transport was 
reduced back to basal levels in the presence of 0.1 µM inhibitor (Figure 3.23). In 
contrast, AG490 caused no significant change in L-arginine uptake in either RASMCs 
(Figure 3.24) or J774 macrophages (Figure 3.25) under activated or control conditions. 
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Figure 3.22 Concentration dependent effect of JAK inhibitor I on L-arginine 
transport in both control and activated RASMCs 
Confluent monolayer of RASMCs in 96-well plate were pre-treated in either complete 
DMEM alone (Controls) or in complete DMEM with different concentrations of JAK 
inhibitor I (0.1 to 10 µM) for 30 min prior to activation. Cells were activated with both 
LPS (100 µg/ml) and IFN- (100 U/ml) in the absence and continued presence of JAK 
inhibitor I. After 24 hour incubation period, nitrite and protein content of sample wells 
were assessed by the Greiss and BCA assays respectively as described in the methods 
(Sections 2.9 and 2.11 respectively). Transport of 3[H] L-arginine was assessed over 2 
min in both control and activated cells as described in the Methods (Section 2.10). 
Open bars represent controls and closed grey bars represent activated cells. Data are 
presented as percentage of 3[H] L-arginine transport by activated controls without 
inhibitor. Data represent the mean ± S.E.M. from at least three independent 
experiments with five replicates in each. Statistical differences between means were 
determined using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data. * denotes P < 0.05 when compared to 
untreated activated controls. 
 
 
*
*
*
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Figure 3.23 Concentration dependent effect of JAK inhibitor I on L-arginine 
transport in both control and activated J774 macrophages. 
Confluent monolayer of J774 macrophages in 96-well plate were pre-treated with either 
complete DMEM alone (Controls) or in complete DMEM with different concentrations of 
JAK inhibitor I (0.1 to 10 µM) for 30 min prior to activation. Cells were activated with 
LPS (1.0 µg/ml) in the absence and in continued presence of JAK inhibitor I. After 24 
hour incubation period, nitrite and protein content of respective wells were assessed by 
the Greiss and BCA assays respectively as described in the methods (Sections 2.9 and 
2.11 respectively). Transport of 3[H] L-arginine was assessed over 2 min in both control 
and activated cells as described in the methods (Section 2.10). Open bars represent 
controls and closed grey bars represent activated cells. Data are presented as 
percentage of 3[H] L-arginine transport by activated controls without inhibitor. Data 
represent the mean ± S.E.M. from three independent experiments with five replicates in 
each. Statistical differences between means were determined using one-way analysis 
of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the normalized 
data. * & ** denotes P < 0.05 and P < 0.01 respectively when compared to untreated 
activated control. 
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Figure 3.24 Concentration dependent effect of AG490 on L-arginine Transport in 
both control and activated RASMCs. 
Confluent monolayer of RASMCs in 96-well plate were pre-incubated with either 
complete DMEM alone (Controls) or in complete DMEM with varying concentrations of 
AG490 (0.01 to 10.0 µM) for 30 min prior to activation. Cells were activated with LPS 
(100 µg/ml) and IFN- (100 U/ml). After 24 hour incubation period, nitrite and protein 
content of respective wells were assessed by use of Greiss and BCA assays 
respectively as earlier described in Methods (Sections 2.9 and 2.11 respectively). 
Transport of 3[H] L-arginine was assessed over 2 min in both control and activated cells 
as described in the Methods (Section 2.10). Open bars represent controls and closed 
grey bars represent activated cells. Data are presented as percentage of 3[H] L-arginine 
transport by activated controls without inhibitor. Data represent the mean ± S.E.M. from 
three independent experiments with five replicates in each. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. P>0.05 
confirmed there was no significant difference when compared to untreated activated 
control. 
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Figure 3.25 Concentration dependent effect of AG490 on L-arginine Transport in 
both control and activated J774 macrophages. 
Confluent monolayer of cells were were pre-treatted in either complete DMEM alone 
(Controls) or in complete DMEM with varying concentrations of AG490 (0.01 to 10.0 
µM) for 30 min prior to activation. Cells were activated with LPS (1.0 µg/ml). After 24 
hour incubation period, nitrite and protein content of respective wells were assessed by 
use of Greiss and BCA assays respectively as earlier described in Methods (Sections 
2.9 and 2.11 respectively). Transport of 3[H] L-arginine was assessed over 2 min in both 
control and activated cells as described in the methods (Section 2.10). Open bars 
represent controls and closed bars represent activated cells. Data are presented as 
percentage of 3[H] L-arginine transport of activated controls without inhibitor. Data 
represent the mean ± S.E.M. from three independent experiments with five replicates in 
each. Statistical differences between means were determined using one-way analysis 
of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the normalized 
data. P>0.05 confirmed there was no significant difference when compared to untreated 
activated control. 
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3.4.9 Cell viability assays on inhibitors in both RASMCs and J774 
macrophages 
The cytotoxic effects of JAK inhibitor I and AG490 were assessed by measuring 
mitochondrial dependent reduction of MTT to formazan as described in the Methods 
(Section 2.12). The results obtained showed there was no alteration in the reduction of 
MTT in LPS and IFN- stimulated RASMCs pre-treated with JAK inhibitor I (Figure 
3.26A) when compared to control cells. Similarly, metabolism of MTT was also 
unaffected in both controls and LPS stimulated J774 macrophages (Figure 3.27A) when 
exposed to JAK inhibitor I. 
 
Parallel investigations with AG490 showed that in RASMCs there was a slight decrease 
in the reduction of MTT in both LPS and IFN- activated cells and controls at 10 µM 
concentration (Figure 3.26B). These effects were however not statistically significant. In 
addition there was no apparent cytotoxic effect of AG490 in control J774 macrophages 
when compared to LPS activated cells (Figure 3.27B). 
 
 
 
 
 
 
 
 
 
 
 
  
 151 
 
 
Figure 3.26 Concentration-dependent effect of JAK inhibitor I and AG490 on 
RASMCs viability. 
Confluent monolayer of RASMCs in 96 well plates were pre-treated with either 
complete DMEM alone (Controls) or in complete DMEM with different concentrations of 
JAK Inhibitor I (0.01 to 10 µM; Figure A) or AG490 (0.01 to 10 µM; Figure B) for 30 
minutes. Cells were then activated with LPS (100 µg/ml) and IFN- (100 U/ml) in the 
absence and continued presence of JAK Inhibitor I or AG490 for 24 hours. MTT 
metabolism by cells was determined colorimetrically as described in the Methods 
Section 2.12). Open bars represent untreated non-activated cells (Controls) and closed 
bars represent treated activated cells. Data represent the mean ± S.E.M. from three 
independent experiments with five replicates in each. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data. P>0.05 confirmed there 
was no significant difference when compared to non activated control. 
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Figure 3.27 Concentration-dependent effect of JAK inhibitor I and AG490 on 
viability of J774 macrophages. 
Confluent monolayers of J774 macrophages in 96 well plates were pre-treated with 
either complete DMEM alone (Controls) or in complete DMEM with different 
concentrations of JAK Inhibitor I (0.01 to 10 µM; Figure A) or AG490 (0.01 to 10 µM; 
Figure B) for 30 minutes. Cells were then activated with LPS (1µg/ml) in the absence 
and continued presence of JAK Inhibitor I or AG490 for 24 hours. MTT metabolism by 
cells was determined colorimetrically as described in the Methods (Section 2.12). Open 
bars represent untreated non-activated cells (Controls) and closed bars represent 
treated activated cells. Data represent the mean ± S.E.M. from three independent 
experiments, each with five replicates. Statistical differences between means were 
determined using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data. P>0.05 confirmed there was no significant 
difference when compared to non activated control. 
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3.4.10 Expression of JAK2, Tyk-2 and their phosphorylated proteins in 
RASMCs and J774 macrophages 
In view of the lack of effect with AG490 it was essential to demonstrate whether 
RASMCs and J774 macrophages express JAK2, TYK2 and their phosphorylated 
proteins; the latter following activation of cells. As shown in Figure 3.28, JAK2 was 
detectable in both cells examined but more predominant in RASMCs. By comparison, 
TYK2 was also detectable in both cell types but with an apparent difference in protein 
expression (Figure 3.29) as determined by western blotting. Our results suggest there is 
a comparatively higher expression in J774 macrophages (Figure 3.29A) compared to 
that in RASMCs (Figure 3.29B). Activation of RASMCs with LPS (100 µg/ml) and IFN- 
(100 U/ml) or J774 macrophages with LPS (1.0 µg/ml) failed to show any significant 
change in the basal expression of either phosphorylated TYK2 (Figures 3.30 and 3.31) 
or JAK2 (Figures 3.32 and 3.33) in either suggesting that these proteins may not be 
phosphorylated in these cells when activated. 
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Figure 3.28 Expression of JAK2 in control J774 macrophages and RASMCs. 
Confluent monolayer(s) of J774 macrophages or RASMCs in 6-well plates were 
separately cultured in complete DMEM and incubated for 24 hours. Whole cell lysates 
(40 µg) generated were subjected to western blotting using a JAK2 specific antibody as 
described in the Methods (section 2.13). The bands at 42 kDA show expression levels 
of the house keeping protein, –actin, which was detected using a selective antibody 
targeting this protein. The blot is representative of at least three independent 
experiments. 
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Figure 3.29 Expression of TYK2 in control J774 macrophages (A) and RASMCs 
(B). 
Confluent monolayer(s) of J774 macrophages or RASMCs in 6-well plates were 
separately cultured in complete DMEM and incubated for 24 hours. Whole cell lysates 
(40 µg) were generated from the respective wells and subjected to western blotting 
using a specific anti-TYK2 antibody as described in the Methods (Section 2.13). The 
bands at 42 kDA show expression levels of the house keeping protein, –actin, which 
was detected using a selective antibody targeting this protein. The blot is representative 
of at least three independent experiments. 
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Figure 3.30 Expression of phospho-TYK2 in control and activated RASMCs 
Confluent monolayer of RASMCs in p33 culture dishes were stimulated with both LPS 
(100 µg/ml) and IFN- (100 U/ml) in continued presence of complete DMEM for varying 
time periods as indicated. Equal quantities of lysates (containing 40 µg of protein) were 
subjected to western blotting using a specific anti-phospho-TYK2 antibody as described 
in the Methods (Section 2.13). The bands at 42 kDA show expression levels of the 
house keeping protein, –actin, which was detected using a selective antibody targeting 
this protein. The blot is representative of at least three independent experiments. 
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Figure 3.31 Expression of phospho-TYK2 in control and activated J774 
macrophages 
Confluent monolayer of J774 macrophages in p33 culture dishes were stimulated with 
LPS (1.0 µg/ml) in continuous presence of complete DMEM for varying time periods as 
indicated. Equal quantities of lysates (containing 40 µg of protein) were subjected to 
western blotting using a specific anti-phospho-TYK2 antibody as described in the 
Methods (Section 2.13). The bands at 42 kDA show expression levels of the house 
keeping protein, –actin, which was detected using a selective antibody targeting this 
protein. The blot is representative of at least three independent experiments. 
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Figure 3.32 Expression of phospho-JAK2 in control and activated RASMCs 
Confluent monolayers of RASMCs in p33 culture dishes were stimulated with activated 
with LPS (100 µg/ml) and IFN- (100 U/ml) for varying time periods as indicated. Equal 
quantities of lysates (containing 40 µg of protein) were subjected to western blotting 
using a specific anti-phospho-JAK2 antibody as described in the Methods (Section 
2.13). Lanes 10 represents a positive control for phospho-JAK2 generated from HeLa 
cells treated with IFN-α. The band at 42 kDA shows expression level of the house 
keeping protein, –actin, which was detected using a selective antibody targeting this 
protein. The blot is representative of at least three independent experiments. 
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Figure 3.33 Expression of phospho-JAK2 in control and activated J774 
macrophages 
Confluent monolayers of J774 macrophages in p33 culture dishes were stimulated with 
activated with LPS (1.0 µg/ml) for varying time periods in continuous presence of 
complete DMEM. Equal quantities of lysates (containing 40 µg of protein) were 
generated from the respective wells and subjected to western blotting using a specific 
anti-phospho-JAK2 antibody as described in the Methods (Section 2.13). The band at 
42 kDA shows expression level of the house keeping protein, –actin, which was 
detected using a selective antibody targeting this protein. The blot is representative of 
at least three independent experiments. 
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3.5 DISCUSSION 
 
The studies described in this chapter were aimed at establishing the role of the JAKs in 
the induction of iNOS expression, NO production and L-arginine transport in RASMCs 
and J774 macrophages. These two cell types were chosen because there is evidence 
to show that the induction of iNOS is predominantly localised to the smooth muscle 
cells within the vasculature (Cohen et al., 1998). Macrophages on the other hand 
express high levels of iNOS as part of our host defence mechanisms (Annane et al., 
2000) but were used in these studies partly for comparative purposes. In any case, for 
both cell types, an understanding of the mechanisms that regulate iNOS gene 
expression is important since this would provide strategies for regulating its expression 
and thus overproduction of NO in disease states. 
 
There are currently a wide range of stimuli capable of inducing iNOS expression and 
NO production in various cell systems. These have been reported to include, depending 
on the cell type, LPS (Kim et al., 2007), Granulocyte macrophage colony –stimulating 
factor (GM-CSF) (Vital et al., 2003), erythropoietin (Epo) (Genc et al., 2006), growth 
hormone (GH) (Argetsinger et al., 1993) and a range of cytokines including IFN-, TNF-
 and interleukins amongst others (Kleinert et al., 2004). The induction of iNOS may 
subsequently result in or contribute to the pathogenesis fo inflammatory disease states 
such as in septic shock (Bultinck et al., 2006; Mastronardi et al., 2011; Thiemermann et 
al., 1990; Titheradge, 1999; Zhang et al., 1998b) and in atherosclerosis (Behr-Roussel 
et al., 2000; Knowles et al., 1994; Perrotta et al., 2011). 
 
To initiate the studies outlined in this thesis, the model for inducing iNOS in the two cell 
systems had to be developed and this was established using previous protocols in our 
laboratory. This involved using a combination of LPS and IFN- for smooth muscle cells 
and LPS alone for macrophages at predetermined concentrations. As demonstrated in 
this thesis, a combined exposure to both LPS and IFN- induced iNOS in RASMCs 
while LPS alone was sufficient to induce macrophages. This suggests cell type 
specificity in the induction of iNOS expression. These results are consistent with our 
previous findings (Baydoun et al., 1998; Baydoun et al., 1993a; Baydoun et al., 1993b; 
Baydoun et al., 1999; Hsiao et al., 2003) and with studies in other cell types such as 
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astrocytes where both LPS and IFN- are required for iNOS induction (Bolanos et al., 
1997; Nicoletti et al., 1998). 
 
In addition to the above we also demonstrated in this thesis that there was no iNOS 
expression in either cell types under control conditions but strongly induced following 
treatment of cells with the appropriate stimuli. In both cell types this was associated with 
a significantly distinct and elevated NO production accompanied by the parallel 
induction of L-arginine transport as previously demonstrated (Baydoun et al., 1993a; 
Baydoun et al., 1990). The induction of iNOS in both cell types was time-dependent 
though the pattern of induction in macrophages had a much longer lag time compared 
to RASMCs. These observations are again consistent with previous findings from our 
group (Baydoun et al., 1998; Baydoun et al., 1993b; Wileman et al., 2003) as well as 
from other studies (Fleming et al., 1991; Kang et al., 1999; Kolyada et al., 1996; 
Wileman et al., 2003). 
 
Nitrite due to its bactericidal effects on pathogenic microorganisms and in addition 
provide a compensatory role in maintaining vascular homeostasis (Yan et al., 1996). In 
contrast, the high NO production has also been implicated in endothelial dysfunction, 
hypotension, multiple organ failure and eventual death (Cauwels et al., 2011; Hon et al., 
1998; Thiemermann et al., 1990; Titheradge, 1999) due to deleterious effects 
associated with high amounts of NO within biological systems. 
 
In view of the results obtained it is likely that in RASMCs, the combined signalling 
mediated by LPS and IFN- are a necessary pre-requisites for the optimum induction of 
iNOS protein expression, NO production and of L-arginine transport. Further to this, it 
has also been reported that cells primed by IFN- become more sensitive to other 
stimuli such as LPS in potentiating induction of inflammatory genes such iNOS (Kamijo 
et al., 1994; Xie et al., 1993). There are other additional reports which suggest that IFN-
 may also act to stabilize the mRNA levels for iNOS thereby prolonging its half-life 
(Weisz et al., 1994). Thus, for prolonged and sustained expression of iNOS in smooth 
muscle cells both LPS and IFN-are critical and the two may synergize to enhance the 
transcription of the iNOS gene. 
 
 162 
In summary, in RASMCs the combined exposure to both LPS and IFN- is essential for 
iNOS induction while in macrophages, LPS alone is required. The precise reasons for 
these differences in the requirements of respective stimuli are not entirely clear but it is 
worth noting that the promoter region of the iNOS gene for different species may vary 
and this could have implications in the requirements for the induction of iNOS. 
 
Although the promoter region of both RASMCs and J774 macrophages contain 
common elements, the composition of NF-B subunits and associated induction 
patterns (Spink et al., 1995; Xie et al., 1994) are critical factors in delineating the 
differences between both cell types. In murine macrophages evidence suggest that the 
ratio of p50:p65 was much lower in macrophages compared to RASMCs (Zhang et al., 
2001). In addition, the associated oxidative status of the respective cells following 
induction of iNOS, are possible basis for the differences in the regulation of iNOS. Also 
the NF-B transcription element located downstream of the mouse promoter is the 
critical promoter propagating the responses following cytokine stimulation. In contrast in 
RASMCs the critical NF-B promoter sequence is located further upstream of the iNOS 
promoter (Spink et al., 1995; Xie et al., 1994). Also, consistent with current evidence, 
our data suggest that macrophage mediated induction of iNOS is only plausible via LPS 
stimulation while both LPS and IFN- are required for iNOS induction in RASMCs. 
 
With regards to the stimuli used in our studies, both LPS and IFN- have been 
extensively used for the induction of iNOS either independently or in combination in 
many different cell systems. Signalling via LPS is mainly mediated through binding with 
LPS binding protein (LBP) present in the blood and subsequent association with CD14 
(Wright et al., 1990) in protein complex formation. The latter, binding to TLR-4, initiates 
activation of a cascade of signalling pathways (see below and also highlighted in the 
introduction) which may vary in individual cell systems but may eventually resulting in 
activation of transcription factors which can induce protein synthesis including iNOS. In 
a recent study the cis-regulatory element, octomer within the iNOS gene promoter has 
also been reported to be critical for maximum iNOS transcription by LPS (Lu et al., 
2009). In contrast IFN- signalling is mediated via IFN- receptor chains  and  (Bach 
et al., 1997; Boehm et al., 1997). Both type I IFNs (IFN-/) and type II IFNs (IFN-) are 
important for innate and adaptive immune responses (Pestka et al., 1987). As earlier 
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discussed in the introduction, IFN- signalling  which is actively secreted from activated 
T cells and macrophages is critical in NO production (Lorsbach et al., 1993). Current 
evidence suggest that two of the most important signal transduction pathways by which 
IFN- induces its inflammatory responses include the JAK/STAT pathway (Yu et al., 
2012) which is mostly responsible for its anti-viral and growth inhibitory properties and 
the NF-kB activation (Chang et al., 2011; Stempelj et al., 2007). 
 
Within the JAK family, there are reported differences in their responses to different 
cytokines. For example, while the biological responses to IFN- requires JAK1 and 
JAK2 (Muller et al., 1993; Silvennoinen et al., 1993a; Velazquez et al., 1992; Watling et 
al., 1993) that to IFN- is mediated largely by JAK1 and TYK2. In addition, report 
suggests that type I IFN responses which also includes IFN- amongst others is 
dysfunctional though not completely abrogated in TYK2-/- mice (Karaghiosoff et al., 
2000). Our results following JAK inhibitor treatment of both cell types clearly showed a 
concentration dependent decrease in responses to LPS and IFN- stimulation. A 
modulating role for TYK2 is also further supported by the specificity of STAT-1 
activation in this thesis and its subsequent downregulation following JAK inhibitor I pre-
treatment. 
 
To establish which JAK may be required in the cell systems used in this thesis, 
experiments were carried out using pharmacological compounds known to inhibit the 
JAK pathways. The compounds investigated were AG490, a synthetic tyrphostin 
derived from benzylidine malononitrile, and JAK inhibitor I, pyridine-containing 
tetracycle. Of the two, AG490 is reported to selectively block JAK2 activation (Levitzki, 
1992; Meydan et al., 1996) but has also been shown to inhibit JAK3 (Kirken et al., 
1999) while JAK inhibitor I shows potent inhibitory activity against JAK1 (IC50 = 15 nM), 
JAK2 (IC50 = 1 nM), JAK3 (Ki = 5 nM), and Tyk2 (IC50 = 1 nM) (Thompson et al., 2002). 
However, in our studies, AG490 was without effect on induced iNOS expression, nitrite 
production or L-arginine transport, thus strongly eliminating JAK2 and indeed JAK3 as 
potential critical kinases for the induction of these processes. This conclusion however 
contradicts reports implicating a critical role for JAK2 in the induced expression of iNOS 
(Dell'Albani et al., 2001; Doi et al., 2002; Nakashima et al., 1999). For instance, in a 
dendritic cell line AG490 is reported to inhibit LPS stimulated NF-B activation and 
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iNOS induction (Cruz et al., 2001). In addition, JAK2 has also been demonstrated to 
phosphorylate IkB subsequent to NF-B activation (Steffan et al., 1995) which can lead 
to iNOS expression. The reasons for these discrepancies with AG490 are unclear and 
require further investigation but could reflect in part cell type differences. 
 
In contrast to AG490, our results with JAK inhibitor I have demonstrated a 
concentration-dependent inhibition of iNOS expression, NO production and L-arginine 
transport. These observations indicate that, potentially, a JAK family member other than 
JAK2 or JAK3 may be involved and of the two remaining, JAK1 can be eliminated on 
the grounds that kinase negative mutants are capable to sustaining IFN- production 
and Th1 cell differentiation. This therefore leaves TYK2 as the potential candidate but 
TYK2 appears to be more involved with IFN-/ rather than IFN- signalling 
(Karaghiosoff et al., 2000). However, as already noted in the introduction chapter, apart 
from the interferons, JAK mediated biological response can be initiated by other stimuli 
including LPS (Kovarik et al., 1998), erythropoietin (Epo) (Witthuhn et al., 1993) and 
growth hormone (GH) (Argetsinger et al., 1993). In particular, LPS can activate JAKs 
including TYK2 which has been implicated in the induction of iNOS and subsequently 
septic shock in mice (Strobl et al., 2011). Thus even if IFN- does not recruit JAKs such 
as TYK2 their activation by LPS could indicate a potential involvement for the induction 
of iNOS in our cell systems. The observed effects with JAK inhibitor I would corroborate 
this assumption. However, the effects produced were only partial, thus suggesting that 
activation of additional pathways other than the JAKs may be required. Other kinases 
also implicated include the MAP kinases p42 (ERK2), p44 (ERK1) (Meng et al., 1997), 
p38 (Huang et al., 2004b) and c-Jun kinase (JNK) (Chan et al., 2001b). These have 
been highlighted in the introduction chapter and a full discussion of their role is beyond 
the scope of this thesis. 
 
One concern raised by the findings discussed above is whether the failure of AG490 to 
exert any effect in either RASMCs of J774 macrophages is due to the lack of 
expression or activation of JAK2 and/or TYK2 in these cells. Both these proteins are 
however known to be present in macrophages (Zhu et al., 2013) and in smooth muscle 
cells (Liu et al., 2012). This is indeed consistent with the western blot data obtained 
showing expression when lysates for the J774 macrophages and the RASMCs were 
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probed for JAK2 and TYK2 using selective antibodies for each. Thus, the next issue 
was to confirm whether these JAKs are in fact activated through phosphorylation 
following activation of cells with either LPS and IFN- (RASMCs) or LPS alone (J774 
macrophages). In these studies neither JAK2 nor TYK2 appeared to be phosphorylated 
in response to stimulation as the western blots produced failed to show any phospho-
proteins, suggesting that neither was activated by LPS and IFN- or LPS alone. This 
was an unexpected finding especially since there is a plethora of published data 
showing that JAK2 is phosphorylated in response to IFN- (Bhat et al., 1998; Ihle, 1995; 
Kakar et al., 2005; Kitamura et al., 1996; Silva et al., 1994; Taniguchi, 1995). In addition 
both JAK2 and TYK2 are phosphorylated in response to LPS (Cruz et al., 2001; 
Karaghiosoff et al., 2000; Ohmori et al., 2001; Okugawa et al., 2003; Vadiveloo et al., 
2000) and especially of the later, of type one interferon response in vivo (Prchal-Murphy 
et al., 2012; Shimoda et al., 2002).. At present it is not clear why the phospho-proteins 
were not detected and this cannot be attributed to failed experiments since a positive 
control for JAK2 was picked up. The only reasonable conclusion at this stage is that 
neither protein is activated under our experimental conditions. This would at least 
account for the lack of effects with AG490 and would indicate that other signalling 
pathways other then the JAKs may mediate the actions of LPS and of IFN-. 
 
Apart from the effects observed on iNOS and NO production, L-arginine transport was 
also regulated by JAK inhibitor I but not by AG490. Transport of L-arginine is often co-
induced with iNOS but very little is currently known about its regulation, especially by 
JAK signalling. Indeed this is the first report to show that induced uptake of L-arginine is 
susceptible to inhibition by JAK inhibitor I. However, from the discussions above, it is 
still not clear whether this might the result of action on the JAKs, nor confirmation that 
the latter are required for induced transporter activity.  
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Chapter 4. Confirmation of the role of JAK2 in the induction of iNOS, NO 
and L-arginine transport in RASMCs using JAK2 selective siRNA 
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4.1 INTRODUCTION 
The exact role of the JAKs particularly JAK2 in mediating cytokine induced iNOS 
expression in our cell systems still remains unclear. Our earlier approach using 
pharmacological inhibitors failed to confirm that JAK2 may be required for this process 
as its selective inhibitor, AG490, was without effect. These findings, as discussed, 
contrast with reports, suggesting that JAK2 activation was critical for induced iNOS 
expression in other cell systems. The reason for the discrepancies between our data 
and that published in the literature is unclear. However, to ensure that we can support 
the conclusions from our pharmacological experiments, we have extended our studies 
in this chapter using a siRNA approach by targeting JAK2 to elicit a knockdown and 
establish unequivocally whether induction of iNOS in RASMCs requires JAK2 
activation. In these studies, specific siRNA nucleotide sequences targeting JAK2 were 
synthesised and transfected into cells prior to activation with LPS and IFN-. In pilot 
studies, the efficiency of transfection of the nucleotides was initially optimised and 
changes in JAK2 protein expression determined by western blotting. This was then 
followed by monitoring changes in both iNOS expression and NO production in 
subsequent experiments. These studies were limted to RASMCs as it was difficult to 
transfect the J774 macrophages. Moreover there was only limited time available 
towards the end of the registered study period and there was not enough time available 
to conduct detailed stuidies in the macrophages. 
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4.2 AIM 
The aim of this chapter was to confirm indisputably whether JAK2 activation is indeed 
essential for the induction of iNOS in RASMCs. The studies were carried out using a 
more specific molecular approach that exploited JAK2 selective siRNA nucleotides to 
knockdown JAK2 expression in the cells. 
 
 
4.3 METHOD 
 
4.3.1 Cell culture 
Rat aortic smooth muscle cells were cultured to confluency as described in the 
methods. Prior to transfection RASMCs were trypsinized and diluted in Opti-MEM 
antibiotic free media and seeded at an optimal density of 2.5 x 106 cells/ ml in both 96-
well (100 µl) and in 12-well (500 µl) plates for greiss assays and western blotting 
respectively. Cells were allowed to grow up to 70% confluency within 72 hours. The 
culture medium of each well or plate was replaced after 24 hours with fresh antibiotic 
free media for a further 24 hours. 
 
4.3.2 Transfection Studies; Optimization of siRNA knockdown in RASMCs 
For the selective suppression of JAK2 expression, RASMCs were transfected with ON-
TARGET-plus small interfering RNA (siRNA) targeting JAK2 at optimal cell density and 
appropriate lipid mediated DharmaFect2 concentrations. To aid in this task, we used 
siGLO Green (Dharmacom, UK), a fluorescent oligonucleotide which when utilised, is 
retained in the nucleus to ensure an unambiguous visual confirmation of uptake and the 
optimal transfection conditions for siRNA. It however does not ensure the successful 
confirmation of knockdown. 
 
Monolayer of adherent RASMCs were transfected with siRNA (100 nM final 
concentration) using the lipid mediated transfection reagent, DharmaFect2 as per 
manufacturer’s instructions. Control transfection and optimization of transfection 
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conditions (i.e. plating density, concentration range of DharmaFect2) conditions using 
ON-TARGET-plus siRNAs targeting CYCLOPHILIN B with DharmaFect2 were also 
investigated in parallel. 
 
Prior to transfection, a transfect mix containing 2 µM siRNA solution diluted in 1X siRNA 
buffer and DharmaFect2 were separately prepared in appropriate volumes of serum 
free Opti-MEM media (containing deoxyribonucleosides, L-glutamine ribonucleosides, 
without ascorbic acid,- Invitrogen, UK) in complete absence of antibiotics as per 
manufacturer’s instructions. Briefly in Tube 1, 17.5 µl of 2 µM siRNA with 17.5 µl of 
serum free Opti-MEM media were incubated for 5 min at room temperature. In a 
separate tube (Tube-2), 1.4 µl of DharmaFect2 with 33.6 µl of serum free Opti-MEM 
were mixed and incubated for 5 min at room temperature. The contents of both tube 1 
and 2 were mixed gently and further incubated for another 20 min at room temperature. 
Transfection mix (from combined contents from both tubes 1 and 2) were subsequently 
mixed gently (by pipetting up and down) with 280 µl of complete Opti-MEM media 
(without antibiotics). Old media were aspirated off cells and 100 µl of the transfection 
mix with complete media were added onto adherent cells (in triplicate) in 96-well plate. 
In a further study semi confluent 24-well plate containing RASMCs were cultured for 
western blotting. Transfection mix were prepared as previously described and 
respective volumes scaled up by a factor of 1.5 and aliquoted into designated wells. 
 
Prior to transfection, spent media from culture plates were aspirated off and the above 
prepared transfection mix in combination with an appropriate volume of Opti-MEM 
media were added onto the monolayer of adherent RASMCs. Cells were incubated for 
a further 24 hours in an incubator at 37 °C in 5% CO2. Transfection media was replaced 
with fresh antibiotic free media (Opti-MEM) 24 hrs after signs of cell toxicity were 
observed in the culture flask. Lysates wre subsequently generated and subjected to 
western blotting for JAK2 expression. 
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TABLE 4.1. ON TARGET plus JAK2 siRNA nucleotide sequences 
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4.3.3 Effect of JAK2 siRNA on JAK2 expression in RASMCs 
To assess the level of knockdown following siRNA treatment for 48 hours, media was 
firstly carefully aspirated off the plate and adherent cells lysed in lysis buffer (x1) 
followed by brief centrifugation at 12,000g for 1 min at room temperature. Protein 
concentrations were determined by BCA assay as previously described and equal 
amounts (40 µg protein/lane) were electrophoresed using 8% SDS PAGE. Separated 
proteins were transferred to PVDF membrane by semi-dry electroblotting and then 
blocked in 5% non-fat milk followed by primary incubation with a JAK2 specific antibody 
for an overnight incubation at 4 °C. The PVDF membrane was washed three times with 
wash buffer (containing 0.1% Tween-20 in Tris buffer) followed by a one hour 
incubation with a horseradish-peroxidase-conjugated secondary antibody at room 
temperature. Detection of JAK2 protein bands was by ECL chemiluminescence system. 
 
4.3.4 Effect of JAK2 knockdown on nitrite production in RASMCs 
The effect of silencing JAK2 on LPS (100 µg/ml) and IFN- (100 U/ml) induced NO 
production was assessed by determining changes in accumulated nitrite levels at the 
end of each incubation period using the Griess assay as described in Section 2.9 
(Chapter 2). 
 
 
4.4 STATISTICAL ANALYSIS 
 
All experiments were performed three times and data expressed as means ± SEM as 
indicated. For data with multiple comparisons, statistical analysis was carried out with 
Graph Pad Prism (Graph Pad software, USA) and analyzed by using one-way ANOVA 
followed by Dunnett’s test (in order to compare each treatment to control value). Where 
required, Student’s t-tests were used for single comparisons between treated and 
control groups. Statistical significance was established at P<0.05. 
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4.5 RESULTS 
 
4.5.1 Effect of different culture media on nitrite production in RASMCs  
Because the transfection studies had to be carried out in a different media (opti-MEM) 
to that used previously in activating the cells (ie DMEM) it was important to establish 
whether the change in media affected nitrite production or detection. Cells were 
therefore activated with LPS and IFN-for 24 hras in previous studies. As shown in 
Figure 4.1, there was comparable basal production of nitrite in the absence of any 
stimulation. The induction of nitrite production, although marginally low in cells cultured 
in opti-MEM, was not significantly different between the two conditions. Thus, the 
change in culture media does not alter the ability of cells to respond to LPS and IFN- in 
expressing iNOS. 
 
 
4.5.2 Effects of the transfection reagnets on nitrite production in RASMCs 
In parallel studies, the effect of the transfection agent DharmaFect2 used in delivering 
siRNA into cells was investigated on nitrite production. This was to establish whether 
this agent on its own has the ability to regulate iNOS expression and/or function and 
thus nitrite production. As shown in Figure 4.2, DharmaFect2 caused no statistically 
significant change in nitrite production either in controls or in activated cells over the 
concentration range of 0.05 to 0.125 nM subsequently used in the transfection studies. 
Similarly, DharmaFect 2 did not cause any statistically significant change in cell viability 
except at the highest concentration of 0.5 nM (Figure 4.3). 
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Figure 4.1. Effects of culture media on nitrite production in RASMCs  
Confluent monolayers of RASMCs were incubated in two separate 96-well plates 
containing antibiotic free complete DMEM in one and Opti-MEM media in the other. 
Cells were stimulated with a combination of LPS (100 µg/ml) and IFN- (100 U/ml) for a 
24-hour incubation period. Controls were incubated in complete culture medium alone. 
Nitrite produced in the medium was analysed using the Greiss assay as described in 
Method (Section 2.9). Open bars indicate control samples whilst black filled bars 
indicate activated samples. Data represent the mean ± S.E.M. from three independent 
experiments, each performed in triplicates. Statistical differences between means were 
determined using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data. P>0.05 confirmed there was no significant 
difference in the levels of nitrite produced by cells cultured in DMEM compared to that 
in opti-MEM. 
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Figure 4.2. Effects of DharmaFect 2 on nitrite production in RASMCs 
Semi- confluent (90 %) monolayers of RASMCs in 96-well plates were pre-treated in 
antibiotic free full OptiDMEM with different concentrations DharmaFect2 for 60 minutes 
prior to activation. Cells were activated with a combination of LPS (100 µg/ml) and 
IFN (100 U/ml) in the absence and continued presence of DharmaFect2 for 24-hours. 
The stable NO metabolite, nitrite, present in the medium was analysed using the Greiss 
assay as described in the Methods (section 2.9). The data is presented as percentage 
of nitrite by activated cell without DharmaFect2 treatment (activated control). Data 
represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. 
P>0.05 confirmed there was no significant difference when compared to non activated 
control. 
 
  
 175 
 
 
 
 
Figure 4.3. Effects of DharmaFect2 on the viability of RASMCs 
Semi- confluent (90 %) monolayers of RASMCs in 96-well plates were pre-treated in 
antibiotic free full OptiDMEM with different concentrations DharmaFect2 for 60 minutes 
prior to activation. Cells were activated with a combination of LPS (100 µg/ml) and 
IFN (100 U/ml) in the absence and continued presence of DharmaFect2 for 24-hours. 
MTT metabolism by cells was determined colorimetrically as described in the Methods 
(Section 2.12). The data is presented as percentage in cell viability of activated cell 
without DharmaFect2 treatment (activated control). Data represent the mean ± S.E.M. 
from three independent experiments, each with six replicates. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. P>0.05 
confirmed there was no significant difference when compared to non activated control. 
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4.5.3 Optimization of siRNA delivery in RASMCs 
The successful and efficient delivery of siRNA into the nucleus is essential for effective 
knockdown of the targeted gene. To achieve this, experiments were initially conducted 
to optimise the efficiency of transfection of cells using the dye siGLO. As shown in 
Figure 4.1, treatment with siGLO together with the transfection agent DharmaFect2 
according to manufacturer’s protocol resulted in high uptake and accumulation of siGLO 
in the nucleus of the cells (Figure 4.4C) which was not observed in the absence of 
DharmaFect2. 
 
4.5.4 Assessment of knockdown of JAK2 following JAK2 siRNA 
treatment 
Having established that cells could be transfected efficiently with siGLO using 
DharmaFect2 the next stage was to investigate whether the JAK2 siRNA could be 
successfully transfected into cells and whether depleted JAK2 protein expression 
and/or regulated iNOS expression and NO production. Because of time limitations, 
changes in L-arginine transport or in transporter expression were not investigated. 
These studies are however clearly needed and could form part of any future studies 
carried out by the group. 
 
In the present studies, RASMCs were treated independently with the different JAK2 
siRNA sequences (all at 100 nM final concentration) in the absence and presence of 
DharmaFect2 at a concentration of 0.125 nM. As shown in Figure 4.5, JAK2 expression 
clearly detectable in control non-transfected cells was significantly attenuated in cells 
transfected with siRNA. 
 
In order to assess knockdown we used western blot as a means to ascertain the effects 
of JAK2 down-regulation. Assessment of knockdown using target protein following SDS 
PAGE are influenced by a number of factors such as half-life of target protein, the role 
of constitutive protein expression versus transient protein expression. Following siRNA 
transfection, knockdown was expected to last for up about 72 hours. 
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Our western blot results as shown in Figure 4.7 and densometrically illustrated in Figure 
4.8 demonstrated that in untransfected cells (Lane 1, 2, 3 and 4) there was noticeably 
lack of any significant change in JAK2 expression. In addition, there was no change in 
JAK2 expression in cultured RASMCs induced with DharmaFect-2 mediated CYC 
siRNA as a positive control (i.e.Lane 4). In JAK2 siRNA treated cells however there 
were significant down-regulation in JAK2 protein expression in all the four sequences 
specific TargetPlus JAK2 siRNA tested but to varying extent. Densitometric analysis of 
our western blots bands as shown in Figure 4.8 demonstrated the following levels of 
down-regulation as listed below; 
 
Lane 5 - JAK2 siRNA-[9] down regulated to 31.33 ± 4.49 % 
Lane 6 - JAK2 siRNA-[10] down regulated to 12.11 ± 2.99 % 
Lane 7 - JAK2 siRNA-[11] down regulated to 21.94 ± 4.37 % 
Lane 8 - JAK2 siRNA-[12] down regulated to 38.52 ± 8.44 % 
 
JAK2 siRNA-[12] was the least potent whiles JAK2 siRNA-[10] was the most potent in 
down regulating JAK2 protein expression. 
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Figure 4.4. Micrographs of RASMCs stained with siGLO in the absence and 
presence of DharmaFect 2. 
Cells were seeded at 2500 cells/well for at least 30 hours prior to transfection with 50 
nM siGLO Green for a further 24 hours in the absence and presence of DharmaFect2 at 
final concentration of 0.125 µg/ well. After 24 hours, cells were visualized under a 
confocal microscope. Figure A represents control where cells were treated with siGLO 
alone in the absence of DharmaFect2 and B are cells treated with siGLO and DAPI 
without DharmaFect2. Figure C show cells treated with siGLO together with 
DharmaFect 2 and D represent cells treated with DAPI and DharmaFect2. These 
results are representative of at least three independent experiments. 
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Figure 4.5. Expression of JAK2 in both control and siRNA treated RASMCs. 
Semi-confluent monolayers of RASMCs in 12-well culture plates were cultured in either 
complete Opti-MEM alone (Lane 1), complete Opti-MEM + DharmaFect2 (Lane 2), 
complete Opti-MEM induced with siRNA targeting JAK2 gene (Lane 3), complete Opti-
MEM induced with DharmaFect2 and control siRNA targeting CYC gene (Lane 4). 
Lanes 5 to 8 represent cells transfected with complete Opti-MEM induced with 4 
different sequences specific TARGETplus siRNAs targeting different regions of JAK2 
gene. Cells were harvested and 40 µg of protein lysates resolved on SDS-PAGE gel. 
Western blotting was performed as described in Methods (Section 2.13). The blot is 
representative of three experiments. The bands at 42 kDa show expression levels of 
the –actin to confirm equal loading. 
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Figure 4.6. Densitometry of JAK2 knockdown in both control and siRNA treated 
RASMCs. 
Densitometric quantification of JAK2 protein levels (obtained by western blotting) in 
siRNA transfected RASMCs in knockdown studies shown in Figure 4.5. Data are 
presented as a percentage of relative expression normalized to the -Actin and 
compared to the positive control (as shown in lane 4). Data represent the mean ± 
S.E.M. from three independent experiments. Statistical differences between means 
were determind using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparisons test of the normalized data. There was a very significant change 
in JAK2 protein expression in siRNA tranfected RASMCs. * & ** denotes P<0.05 and 
P<0.01 respectively when both are compared to positive control (bar 4). 
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4.5.5 NO production in JAK2 knockdown RASMCs following siRNA 
treatment. 
Treatment of RASMCs with LPS (100 µg/ml) and IFN- (100 u/ml) resulted in significant 
increases (p<0.05) in NO production. When untransfected cells were pre-treated with 
either DharmaFect-2 alone (Figure 4.9; Bar 2) or with siRNA targeting JAK2 gene alone 
(Figure 4.9 Bar 3) for 60 minutes prior to activation with both LPS and IFN-and in 
complete absence of transfection reagent, there was no significant differences in the 
levels of nitrite produced. More importantly, treatment of cells with siRNA in the 
presence of the transfection reagent also failed to cause anysignificant change in basal 
or induced nitrite levels. This was indeed the case even when different siRNA 
oligonucleotides targeting different regions of the JAK2 gene were used. 
 
In summary there was no significant difference in the levels of nitrite despite 
transfection mix containing siRNA targeting different regions of the JAK2 gene. 
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Figure 4.7. Nitrite production in both control and siRNA treated RASMCs. 
Semi-confluent monolayer of RASMCs in 96 well plates, in the absence and presence 
of transfection mix containing siRNA targeting different regions of the JAK2 gene and 
DharmaFect2 at final concentration of 0.125 µg/ well for 60 minutes prior to activation. 
Cells were activated with a combination of LPS (100 µg/ml) and IFN- (100 U/m) for a 
24-hour incubation period. The stable NO metabolite, nitrite, present in the medium was 
analysed using the Greiss Assay as previously described in the Methods (Sections 2.9). 
The data is presented as percentage of nitrite production by activated control. Data 
represent the mean ± S.E.M. from three independent experiments, each performed with 
6 replicates. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. P> 0.05 confirmed there was no significant difference in nitrite 
production between siJAK2 transfected cells (i.e. bars 5, 6, 7 and 8) and positive control 
(bar 4). 
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4.6 DISCUSSION 
In view of the findings in Chapter 3, further experiments were carried out using siRNA 
as a selective tool to unequivocally establish the role of JAK2 in the induction of iNOS in 
RASMCs. 
 
As an evolving technology, the role of siRNA in RNA interference (RNAi) pathway is a 
fast emerging molecular approach to study gene function by specific inhibition of gene 
expression. Current application of gene knockdown involve the use of short (21 to 23 
nucleotides) small interfering RNA (siRNA) (Moffat et al., 2006; Shen, 2004; Zhou et al., 
2003). They are synthetic double stranded RNA duplexes designed to inhibit gene 
expression by inducing gene sequence-specific degradation of homologous mRNA 
(Elbashir et al., 2001a; Fire et al., 1998; Tuschl et al., 1999). To date a number of 
studies have shown that siRNA can significantly suppress gene expression when 
delivered into mammalian cells in vitro (Elbashir et al., 2001a; Fish et al., 2004; 
McManus et al., 2002). 
 
In this thesis, sequences of pre-designed siRNA oligonucleotides were first examined 
by comparing their sequences to the entries of the rat GenBank database through the 
use of the BLASTN program which is available on the National Centre for Biotechnoloy 
Information web page (http://www.ncbi.nlm.nih.gov/) 
 
The procedure for depleting genes such as JAK2 in cells is dependent on the 
sequence-specific, post transcriptional gene silencing of the JAK2 gene initiated by 
constructing, a 19-25 bp RNA duplex with complete sequence homology to the target 
(Shankar et al., 2005). However the delivery of synthetic siRNA duplex into cells in 
general has been a major obstacle for its application (Zhang et al., 2007). Earlier 
approaches of siRNA delivery into primary cells especially have largely proved 
unsuccessful due to cytoxicity, size and nature of sequence (Whitehead et al., 2009). In 
this thesis we set out, first and foremost to maximize siRNA delivery while minimizing 
cellular toxicity under miniaturized (96-well plate) format. We chose the lipid mediated 
transfection reagent DharmaFect2 on the basis of its previous use in rat derived cells 
including smooth muscle cell line (A7R5), rat fibroblast (RAT2), rat kidney fibroblast 
(NRK-49F) amongst others. Though the use of this transfection reagent represents the 
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most common approach, it is often associated with problems of cytotoxicity and its 
incompatibility with siRNA delivery into suspension and primary cells. We therefore 
optimized conditions for an effective delivery of a dose-dependent DharmaFect2 into 
our primary cells to enable high efficiency of siRNA delivery whiles still mindful of a low 
toxicity target. Other studies suggest that such delivery effects are likely to induce 
interferon response (Reynolds et al., 2006) when not correctly used. Using 
DharmaFect2, we were able to confirm assessment of siRNA mediated knockdown 
following the introduction of the stable, fluorescent, non-targeting control siRNA with 
RISC-free modification, siGLo into the cells. As shown in our results when used in 
addition to DAPI stain, we demonstrated a high degree of efficiency which was not 
possible without this transfection reagent, thus confirming successful transfection of 
cells. Moreover, this was achieved with concentrations that caused little or no 
cytotoxicity to cells. In addition as with other reports (Elbashir et al., 2001a; Lee et al., 
2002) we optimized and subsequently maintained siRNA concentration to about 1.25 
nM and this did not alter the silencing effect, suggesting that siRNA by the nature of 
their design and sequence content were effective at concentrations several orders of 
magnitude below that of a conventional antisense gene-targeting experiment 
(Kehlenbach et al., 1998). 
 
To ensure that the experimental conditions did not interfere with the detection of nitrite 
produced, further controls were carried out including establishing the effects of different 
media on accumulated nitrite levels. The results obtained showed that using Opti-MEM 
in place of DMEM did not cause any significant change in nitrite levels, thus ruling out 
any artifacts resulting from the change in media conditions. 
 
A critical observation from our results also showed that when primary RASMCs were 
treated separately with four sequence-specific siRNA for JAK2, there was suppression 
of JAK2 protein expression. In addition, the degree of the knockdown was very much 
dependent on the sequence specific designed construct delivered into the cells. To 
address the difference in level of knockdown we conducted a Basic Local Alignment 
Search Tool (BLAST) analysis (National Center for Biotechnology Information, NIH) for 
each of the four siRNA constructs. In order to identify the target region within the JAK2 
gene, the BLAST tool enabled an alignment between homologous regions of both the 
target gene and each of the sequence specific siRNA constructs used. Each sequence 
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designed siRNA was aligned against the cDNA of the JAK2 gene, (1q52, Genomic 
Size: 58769 bp) NM_031514.1. An alignment of the siRNA primers to JAK2 genome 
revealed regions targeted by each of the siRNA constructs used as shown in the 
schematic representation below (Figure 4.10). 
 
 
 
 
 
Figure 4.10 JAK2 siRNA constructs in sequence-specific homology with JAK2 
gene 
Schematic representation of JAK2 gene showing designated regions in the JAK2 Locus 
that were functionally inactivated by TARGETplus sequence–specific siRNA constructs 
(Dharmacon) that were transfected into RASMCs. JAK2 gene was functionally rendered 
inactive. 
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Western blotting analysis on lysates generated after 48 hours post transfection revealed 
clearly the expression of JAK2, thus suggesting this protein had a long half-life. 
Previous comparable experiments have found that measuring the mRNA of target 
genes were more reliable in assessing silencing efficacy compared to their protein 
levels. In addition it was significant to note that transfection of RASMCs with RNA 
duplexes as short as 19 bp could still cause detectable silencing as demonstrated in our 
results following western blot analysis. Our results are therefore consistent with other 
investigators that have used comparably much longer (22-25 bp) sequence specific 
siRNA targets with reported high efficiency and the added insignificant loss of potency. 
The much shorter duplex used in the thesis suggests that much of the effectiveness or 
potency of the silencing trigger might be attributed to the sequence specific design 
used. 
 
We are the first to report JAK2 mediated siRNA knockdown in RASMCs in order to 
examine its role in JAK/STAT mediated iNOS expression. There is some consensus in 
acknowledging that effective gene silencing efficiency of siRNA is largely reliant on the 
local mRNA of the target region. Current strategies for effective silencing is still reliant 
on designing several siRNAs (more than three) against different regions of the same 
target gene of interest (Elbashir et al., 2001a; Harborth et al., 2001; Semizarov et al., 
2003). 
 
We did not assess the efficacy of respective siRNAs provided but important parameters 
in assessing such knockdowns from reports have included the nature of secondary 
structure of the target mRNA in determining its accessibility (Luo et al., 2004b; Zuker, 
2003) to binding domains or receptors, duplex-end thermodynamic stability (Khvorova 
et al., 2003; Schwarz et al., 2003), sequence specific motifs (i.e. predominance of A or 
U bases in the 5’ end of antisense) (Haley et al., 2004; Ui-Tei et al., 2004), 21mer 
targets, low GC-content and TT overhangs (Harborth et al., 2003) to target sites. 
Results obtained in this study demonstrate how the variability in position of sequence 
specific siRNA site impacts on the efficacy in target degradation in our JAK2 model. 
Though we are unable to characterize the nature of each specific siRNA construct used 
in this thesis, our results showed variability in the knockdown effect. To date, strategies 
in designing effective siRNAs include the development of motif based algorithms (Pei et 
al., 2006). Designing of such algorithms from previous studies (Amarzguioui et al., 
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2004; Reynolds et al., 2004) have included the use of low G-C content and secondary 
structure prediction in their design algorithms in assessing the efficacy of potential site 
for optimal siRNA/target sequence degradation. Other stringently applied criteria or 
parameters such as low internal stability on the sense strand at the 3’ termini, lack of 
inverted repeats and specific positional sense strand base preference of construct in 
the design algorithm have all greatly improved efficacy of some selected and potent 
siRNAs (Reynolds et al., 2004) by Dharmacon. Thus there may be other factors 
affecting RISC activity but these are yet to be discovered. 
 
There was a high degree of efficiency in our transfected cells as demonstrated in our 
studies (Figure 4.1) with DharmaFect2. Also we were able to introduce siGLo and DAPI 
into cells with a high degree of efficiency which was not possible without this reagent, 
thus confirming successful transfection of cells. In addition this was achieved with 
concentrations that caused little or no cytotoxicity to cells. To ensure that the 
experimental conditions did not interfere with the detection of NO produced further 
controls were carried out including establishing the effects of different media on 
accumulated nitrite levels and the results obtained showed that using Opti-MEM in 
place of DMEM did not cause any significant change in nitrite levels thus ruling out any 
artefacts resulting from the experimental conditions. 
 
To further address the role of JAK2 in cytokine mediated iNOS expression we 
successfully induced gene specific silencing by using four sequence specific siJAK2 
constructs in transfecting RASMCs. When used, siRNA for JAK2 caused suppression of 
JAK2 protein expression but the degree of knockdown was very much dependent on 
the sequence construct used. Thus our results are consistent with previous publications 
(Jayasena, 2005; Zamore et al., 2000) in confirming that different siRNA synthesized for 
various positions vary in their gene silencing effectiveness. Reasons for these 
differences as earlier highlighted varies but there is evidence to suggest that even 
though target recognition is highly sequence specific, the 5’ end of the siRNA beginning 
with A-T pair, rather than a G-C pair with its complement is most effective in inducing 
cleavage compared to either the center or the 3’ end of the target RNA (Elbashir et al., 
2001b). Aside from these parameters there is also the possibility of off-target effects or 
regulation. That is, siRNA may degrade or render ineffective other genes whose 
sequences are similar to that of the target gene. In designing the most effective siRNA 
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for specific targets, various authors (Takasaki, 2010; Xingang et al., ; Yamada et al., 
2005) have designed predictive mathematical algorithms incorporating some of the 
above parameters and in addition including specific base preferences at certain 
locations within the siRNA duplex (Reynolds et al., 2004). 
 
Despite above 80 % average knockdown of JAK2, comparative analysis showed that 
there was still no significant change in nitrite production in RASMCs following 
stimulation with LPS and IFN-, supporting the pharmacological data with AG490, that 
JAK2 may not be essential for iNOS expression. Since there was no significant change 
in nitrite levels (Figure 4.7) further studies examining iNOS protein expression was not 
conducted. We therefore conclude from these findings that despite the implication of 
JAK2 in other studies (Doi et al., 2002; Kim et al., 2007; Nishiya et al., 1995) this kinase 
may not be directly relevant for iNOS expression at least in RASMCs under our 
experimental conditions. Several reports have shown that other pathways including p38 
MAPK and the JNK may also be implicated iNOS expression (Chan et al., 2001a; Da 
Silva et al., 1997) but these were not investigated in this thesis. The lack of TYK2 
specific inhibitors precludes verification of its role in this seemingly complex process. 
 
In conclusion studies carried out in this thesis have further demonstrated that JAK2 may 
not be directly implicated in the signaling of cytokine stimulated NO production in both 
J774 macrophages and RASMCs. This is because prior treatment of two cell models 
with AG490, the specific JAK2 inhibitor did not completely inhibit cytokine-stimulated 
NO production in both cell models. In addition, transport studies also confirmed that 
JAK2 is unlikely to be a major mediator of cytokine-stimulated L-arginine transport in 
both models. Also the lack of phosphorylated JAK2 expression in the cytokine induced 
serum starved cells in both cell models further suggests a lack of any role for JAK2 in 
our studies. These conclusions however contrast with other investigators suggesting a 
positive role for this pathway in human epithelial-like colon carcinoma DLD-1 cells 
(Marrero et al., 1998). In these cells, cytokine induction of iNOS is blocked by the JAK2-
specific inhibitor, AG490 or tyrphostin B42. Also, JAK inhibitor I, which potently inhibits 
all four JAK family members (Thompson et al., 2002) blocked the induction of iNOS and 
NO synthesis suggesting a role for a JAK in these processes. However our findings 
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suggest, under our experimental conditions, there was lack of a direct JAK2 effect on 
iNOS induction, NO production or L-arginine transporter activity. 
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Chapter 5. Expression of phosphorylated STAT-1 and role of GTPases in 
the induction of the inducible L-arginine-NO pathway in J774 macrophages 
and rat cultured aortic smooth muscle cells 
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5.1 INTRODUCTION 
The findings discussed in Chapters 3 and 4 have strongly indicated that the JAKs and 
in particular JAK2 may not be required for the induction of iNOS and/or L-arginine 
transport in either RASMCs or J774 macrophages. This was based on observations 
from cells pre-treated with AG490 (an inhibitor routinely used as a potent JAK2 inhibitor 
(Meydan et al., 1996) or with siRNA targeted at JAK2. In both cases, there were no 
significant modifications of induced NO synthesis or enhanced L-arginine transport 
rates in activated cells. As previously discussed, these results contrasted with other 
findings that have implicated JAK2 for iNOS induction (Cruz et al., 1999; Nakashima et 
al., 1999; Tsoyi et al., 2008). 
 
To confirm whether other components of the JAK/STAT pathway may be involved in our 
system, studies were conducted to examine whether STAT-1 was activated through 
phosphorylation in cells exposed to LPS alone or in combination with IFN- in J774 
macrophages and RASMCs respectively. In these experiments, changes in the 
expression profile of phosphorylated-STAT-1 (pSTAT-1) were determined by western 
blotting using a phospho-specific anti-STAT-1 antibody. Changes in expression of the 
activated (phosphorylated) protein were also determined in the absence and presence 
of AG490 or JAK inhibitor I and correlated with changes in nitrite production, iNOS 
expression and in L-arginine transport. More importantly, studies were also aimed at 
establishing whether STAT-1 may be activated directly and independently of the JAKs. 
 
In this regard, it has been suggested that STAT-1 may be phosphorylated possibly by 
upstream GTPases (Pelletier et al., 2003) and by nuclear pore targeting complex 
formation, independent of JAK mediated activation (Sekimoto et al., 1997). Following 
from these observations parallel experiments were therefore conducted to examine 
whether inhibitors of GTPase signalling regulated iNOS expression and induced L-
arginine transport. The studies were also extended by investigating whether STAT-1 
could be activated directly by the small GTPase Rho and independently of the JAKs. 
These studies are relevant as it has been reported that STAT-1 can be phosphorylated 
directly by Rho, independent of JAK activation (Pelletier et al., 2003). Additionally, some 
evidence has implicated Rho GTPase in modulating iNOS expression in airway 
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epithelial cells (Kraynack et al., 2002) and in smooth muscle cell (Yamamoto et al., 
2003) under inflammatory conditions. 
 
To determine whether Rho plays any role in the induction of iNOS and/or L-arginine 
transport in RASMCs and J774 macrophages, additional experiments were carried out 
using atorvastatin, an HMG CoA inhibitor. The pleiotropic cellular effects for this class of 
statins on vascular endothelial and macrophages are usually direct (Takemoto et al., 
2001) and the mechanism is said to restrict or abrogate isoprenylation and farnesylation 
of small GTPases, particularly the Rho and Ras proteins. This reaction is known to 
down-regulate activities of the GTPases and thus modulate events further downstream 
(Liao et al., 2005; Mason, 2003). Parallel studies were carried out using Y-27632, a 
prenyltransferase inhibitor reported to specifically inhibit Rho activity (Uehata et al., 
1997). These studies were conducted to determine whether STAT-1 phosphorylation 
was mediated through Rho signalling independent of the JAKs. 
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5.2 METHODS 
 
5.2.1 Experimental conditions 
 
5.2.1.1 Cell culture 
Confluent monolayers of RASMCs or J774 macrophages in T-75 culture flasks were 
trypsinized as described in the methods and seeded into 96-well or 6-well plates for L-
arginine transport measurement and Western blotting respectively. Cells were allowed 
to grow to between 80 to 90% confluent over 72 hours before being used in the 
experiments. 
 
5.2.1.2 Activation of cells 
To determine the time course of activation of STAT-1, initial experiments were carried 
out using cells in 6-well plates in which RASMCs were activated with LPS (100 µg/ml) in 
combination with IFN- (100 U/ml) and J774 macrophages activated with LPS alone 
(1.0 µg/ml). Incubations were for 0, 5, 10, 15, 30, 60, 120 and 180 min. Cell lysates 
were separately generated for each cell type for western blotting as described in 
Methods (Section 2.9 and 2.11). 
 
5.2.2 Treating of cells with Rho-inhibitors 
Confluent monolayers of cells in 6 or 96-well plates were washed twice with PBS (X1) 
at 37 ºC. This was immediately followed with incubation of cells with atorvastatin (1 to 
100 µM) or with Y-27632 (0.01 to 10.0 µM) for 30 minutes prior to activating with LPS 
(100 µg/ml) in combination with IFN- (100 U/ml) in RASMCs or LPS alone (1.0 µg/ml) 
in J774 macrophages. Cells were then incubated for a further 24 hours before 
determining levels of nitrite produced. 
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5.2.3 Determination of nitric oxide production 
Nitric oxide production was measured in the culture medium by the standard Greiss 
assay as described in Method (Section 2.9). Supernatant (100 µl) from sub-confluent 
culture was mixed with an equal volume of Greiss reagent and absorbance was read at 
540 nm. 
 
5.2.4 Protein assay 
Protein content in cell lysates was determined using the BCA assay as described in the 
Methods (Section 2.11). Cell lysates (10 µl) from sub-confluent cultures was mixed with 
100 µl of BCA reagent and absorbance read at 630 nm. 
 
5.2.5 Western blot analysis 
Western blotting procedure was carried out as described in the Methods (Section 2.13). 
STAT-1 protein and its phosphorylated form in lysates were determined using rabbit 
polyclonal anti-STAT-1 or phosphor-STAT-1 antibody and a goat polyclonal antibody to 
rabbit IgG as a secondary antibody. 
 
5.2.6 Cell cytoxicity assay 
Changes in cell viability following exposure to the inhibitors were determined in parallel 
experiments where the medium was removed after 24 hr incubation for nitrite 
measurements and the cell monolayer incubated with 0.5 mg/ml MTT for 4 hours. 
Levels of formazan produced were determined as described in the Methods (Section 
2.12). 
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5.3 STATISTICAL ANALYSIS 
All experiments were performed at least three times and data expressed as mean ± 
SEM as reported. For multiple comparisons, statistical analysis was carried out with 
Graph Pad Prism (Graph Pad software, USA) using one-way ANOVA followed by 
Dunnett’s test (in order to compare each treatment to control value). Where required, 
Student’s t-tests were used for single comparisons between treated and control groups. 
Statistical significance was established at P<0.05. 
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5.4 RESULTS 
 
5.4.1 Detection of phosphorylated STAT-1 protein in both RASMC and 
J774 macrophage cultures 
Prior to carrying out a detailed study of the phosphorylation of STAT-1, a pilot 
experiment was carried out to determine whether the phospho protein could be 
detected. The results as shown in Figures 5.1 and 5.2 indicate that in both RASMCs 
and J774 macrophages, pSTAT-1 protein was expressed when cells were respectively 
stimulated with a combination of LPS (100 µg) and IFN- (100 U/ml) or LPS (1.0 µg) 
alone. The level of phosphorylated protein expression was much higher in RASMCs 
than in J774 macrophages. There was however no phosphorylated STAT-1 expression 
in control non-activated cells. 
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Figure 5.1 STAT-1/ tyrosine phosphorylation in control and activated J774 
macrophages. 
Confluent monolayers of J774 macrophages in 6-well plates were either incubated in 
DMEM alone or stimulated with LPS (1.0 µg/ml) in continued presence of complete 
DMEM for. Cell lysates were generated and equal quantities of protein (40 µg) 
subjected to western blotting as previously described in Methods (Section 2.13) using a 
pSTAT-1 specific antibody. The above Western blot insert is a representative of at least 
three independent experiments with bands showing STAT-1 as the target protein and -
actin as a loading control. 
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Figure 5.2 STAT-1/ tyrosine phosphorylation expression in both control and 
activated expression in RASMCs 
Confluent monolayers of RASMCs in 6-well plates were cultured in complete DMEM 
alone or stimulated with both LPS (100 µg/ml) and IFN- (100 U/ml) in continued 
presence of complete DMEM for. Cell lysates were generated and equal quantities of 
protein (40 µg) subjected to western blotting as previously described in Methods 
(Section 2.13) using a pSTAT-1 specific antibody. The above Western blot insert is a 
representative of at least three independent experiments with bands showing STAT-1 
as the target protein and -actin as a loading control. 
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5.4.2 Time-dependent phosphorylation of STAT-1 in RASMCs and J774 
macrophages 
 
 Following the observations above further experiments were carried out to examine the 
time course of STAT-1 phosphorylation in the respective cells following exposure to 
LPS (J774 macrophages) or LPS and IFN- (RASMCs). Since IFN- has been reported 
to associate with the JAKs as its primary mode of signalling, we also further examined 
phosphorylation of STAT-1 in the presence of inhibitors, JAK-inhibitor-I and AG490. 
 
Results from this time course study demonstrated that in RASMCs, there was a time–
dependent increase in the expression of STAT-1 phosphorylation (Figure 5.3) following 
activation with a combination of IFN- (100 U/ml) and LPS (100 µg/ml). This was 
induced within 5 minutes of activation, reaching a peak after 30 minutes and was 
followed by a sharp decline thereafter. There were no expressions of phosphorylated 
STAT-1 in non-activated cells (Figure 5.3). 
 
In contrast, results with J774 macrophages showed a different pattern of STAT-1 
phosphorylation (Figure 5.4) following activation with LPS (1.0 µg/ml). There was hardly 
any detectable phosphorylated protein within the first 30 minutes of activation. There 
was however marginal expression of phospho-STAT-1 at 60 minutes and the level of 
expression were sustained up to 120 minutes post activation. In addition there was very 
little change in intensity of expression over the stated period (see Figure 5.4). 
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Figure 5.3 Time-dependent phosphorylation of STAT-1 expression by a 
combined IFN- (100 U/ml) and LPS (100 µg/ml) in RASMCs 
Confluent monolayer of RASMCs in 6-well plates were incubated in complete DMEM 
alone (Control; Lane 1) or stimulated with both LPS (100 µg/ml) and IFN- (100 U/ml) in 
continous presence of complete DMEM at the indicated time points. Cell lysates were 
generated and equal quantities of protein (40 µg) were subjected to western blotting as 
previously described in Methods (Section 2.13) using a phospho-STAT-1 specific 
antibody. The above western blot (Figure A) is representative of at least three 
independent experiments. Intensity of protein bands were quantified by densitometric 
analysis and normalized to -actin protein (Figure B). The data is expressed as a 
percentage of the value obtained from peak activated time (at time=30 min). A 
representative blot of at least three experiments is shown above.  Data represents the 
mean ± SEM from three independent experiments. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data. * & ** denotes P<0.05 and 
P<0.01 respectively when compared to untreated activated controls. 
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Figure 5.4 Time-dependent phosphorylation of STAT-1 expression by LPS (1 
µg/ml) activation of J774 macrophages 
Confluent monolayers of J774 macrophages in 6-well plates were incubated in 
complete DMEM alone (Control; Lane 1) or stimulated with LPS (1.0 ug/ml) in continous 
presence of complete DMEM at the indicated time points. Cell lysates were generated 
and equal quantities of protein (40 µg) were subjected to western blotting as previously 
described in Methods (Section 2.13) using a phospho-STAT-1 specific antibody. The 
above western blot (Figure A) is representative of at least three independent 
experiments. Intensity of protein bands were quantified by densitometric analysis and 
normalized to -actin protein (Figure B). The data is expressed as a percentage of the 
value obtained from peak activated time (at time=120 min). Data represent the mean ± 
S.E.M. from three independent experiments. Statistical differences between means 
were determined using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparisons test of the normalized data.  * & ** denotes P<0.05 and P<0.01 
respectively when compared to the highest peaked activated time. 
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5.4.3 Effect of AG490 and JAK inhibitor I on STAT-1 phosphorylation 
To evaluate the possible inhibitory effects of both AG490 and JAK inhibitor I on STAT-I 
phosphorylation (pSTAT-1), cell were pre-treated with different concentrations of 
AG490 (0 to 10 µM) or JAK inhibitor I (0 to 10 µM) for 30 minutes prior to activation. 
Cells were then activated with LPS (1 µg/ml) alone (for J774 macrophages) or with a 
combination of LPS (100 µg/ml) and IFN- (100 U/ml) (for RASMCs) in serum starved 
(0.1% FBS) DMEM for a further 24 hr. 
 
The results obtained showed that JAK inhibitor I caused a concentration dependent 
decrease in pSTAT-1 expression in RASMCs (Figure 5.5). The decrease in expression 
were significant (p<0.001) with 10 µM of the drug causing approximately about 80% 
reduction in p-STAT-1 expression over non treated activated control. Similarly in J774 
macrophages, there was a much greater significant decrease in pSTAT-1 expression 
where, as shown in Figure 5.7, a 10 µM of JAK-inhibitor I pre-treatment resulted in over 
90 % reduction in p-STAT-1 expression over non treated activated control. 
 
In contrast to JAK inhibitor I, pre-treatment of RASMCs with AG490 resulted in a very 
marginal decrease in pSTAT-1 expression but this was not statistically significant when 
compared to the non-drug treated cells (Figure 5.6). Similarly, in J774 macrophages 
there was no significant change in p-STAT-1 expression following pre-treatment with 
AG490 (Figure 5.8). 
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Figure 5.5 Effect of JAK-inhibitor I on phosphorylated STAT-1 expression 
following activation in RASMCs. 
Confluent monolayers of RASMCs in 6-well plates were were pre-treated with complete 
DMEM alone (Controls) and complete DMEM with different concentrations of JAK 
inhibitor I (0.01 to 10 µM) for 30 minutes prior to activation. Cells were activated with 
both LPS (100 µg/ml) and IFN- (100 U/ml) in the absence and continued presence of 
JAK inhibitor I. After 24 hours cell lysates were generated as previously described in the 
Methods (Section 2.13). Equal quantities of lysates (60 µg) were subjected to western 
blotting using a phospho-STAT-1 specific antibody. The above western blot (Figure A) 
is representative of at least three independent experiments. Respective protein band 
intensities were quantified by densitometric analysis and normalized to -actin protein 
(Figure B). The data is presented as a percentage of relative intensity of phospo-STAT-
1 protein expression in absence of inhibitor. Data represent the mean ± S.E.M. from 
three independent experiments. Statistical differences between means were determined 
using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data. * & ** denotes P<0.01 and P<0.05 
respectively when compared to untreated activated control. 
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Figure 5.6 Effect of AG490-inhibitor on expression of phosphorylated-STAT-1 
expression following activation in RASMCs. 
Confluent monolayers of RASMCS in 6-well plates were were pre-treated with complete 
DMEM alone (Controls) and complete DMEM with different concentrations of AG490 
(0.01 to 10 µM) for 30 minutes prior to activation. Cells were activated with both LPS 
(100 µg/ml) and IFN- (100 U/ml) in the absence and continued presence of AG490. 
After 24 hours cell lysates were generated as previously described in the Methods 
(Section 2.13). Equal quantities of lysates (60 µg) were subjected to western blotting 
using a phospho-STAT-1 specific antibody. The above western blot (Figure A) is 
representative of at least three independent experiments. Respective protein band 
intensities were quantified by densitometric analysis and normalized to -actin protein 
(Figure B). The data is presented as a percentage of relative intensity of phospho-
STAT-1 protein expression in absence of inhibitor. Data represent the mean ± S.E.M. 
from three independent experiments. Statistical differences between means were 
determined using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data. P>0.05 confirmed there was no significant 
difference when compared to untreated activated control. 
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Figure 5.7 Effect of JAK inhibitor I on phosphorylated-STAT-1 expression 
following activation in J774 macrophages. 
Confluent monolayers of J774 macrophages in 6-well plates were were pre-treated with 
complete DMEM alone (Controls) and complete DMEM with different concentrations of 
JAK inhibitor I (0.01 to 10 µM) for 30 minutes prior to activation. Cells were activated 
with LPS (1.0 µg/ml) in the absence and continued presence of JAK inhibitor I. After 24 
hours cell lysates were generated as previously described in the Methods (Section 
2.13). Equal quantities of lysates (60 µg) were subjected to western blotting using a 
phospho-STAT-1 specific antibody. The above western blot (Figure A) is representative 
of at least three independent experiments. Respective protein band intensities were 
quantified by densitometric analysis and normalized to -actin protein (Figure B). The 
data is presented as a percentage of relative intensity of phospo-STAT-1 protein 
expression in absence of inhibitor. Data represent the mean ± S.E.M. from three 
independent experiments. Statistical differences between means were determined 
using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data.* & ** denotes P<0.05 and P<0.01 respectively 
when compared to untreated activated control. 
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Figure 5.8 Effect of AG490 inhibitor on phosphorylated-STAT-1 expression 
following activation in J774 macrophages. 
Confluent monolayers of J774 macrophages in 6-well plates were were pre-treated with 
complete DMEM alone (Controls) and complete DMEM with different concentrations of 
AG490 (0.01 to 10 µM) for 30 minutes prior to activation. Cells were activated with LPS 
(1.0 µg/ml) in the absence and continued presence of AG490. After 24 hours cell 
lysates were generated as previously described in the Methods (Section 2.13). Equal 
quantities of lysates (60 µg) were subjected to western blotting using a phospho-STAT-
1 specific antibody. The above western blot (Figure A) is representative of at least three 
independent experiments. Respective protein band intensities were quantified by 
densitometric analysis and normalized to -actin protein (Figure B). The data is 
presented as a percentage of relative intensity of phospo-STAT-1 protein expression in 
absence of inhibitor. Data represent the mean ± S.E.M. from three independent 
experiments. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. P>0.05 confirmed there was no significant difference when compared 
to untreated activated control. 
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5.4.4 Role of small GTPases in the induction of iNOS 
To determine whether Rho plays any role in the induction of iNOS and/or L-arginine 
transport in RASMCs and J774 macrophages, experiments were carried out using 
atorvastatin, a liphophilic HMG CoA inhibitor known to inhibit isoprenylation of small 
GTPases, particularly the Rho and Ras proteins and thus able to regulate their activity 
(Liao et al., 2005; Mason, 2003). In addition, parallel studies were carried out using Y-
27632, a prenyltransferase inhibitor reported to specifically inhibit Rho activity (Uehata 
et al., 1997). These studies were conducted to determine whether STAT-1 
phosphorylation could be mediated through Rho signalling independent of the JAKs. 
 
 
5.4.5 Effect of atorvastatin on nitrite production and inducible nitric oxide 
expression in RASMCs and J774 macrophages 
In RASMCs, the profile in nitrite production following pre-treatment with atorvastatin 
was biphasic. Low concentrations of atorvastatin (0.0 to 1.0 µM) had no significant 
effect (p>0.05) on accumulated nitrite levels when compared to activated control cells. 
In contrast, cells pre-treated with atorvastatin at 3 μM and 10 μM caused a significant 
(p<0.05) increase in nitrite production by 72.6±9.3% and 144.3±12.1% respectively 
above that induced in activated controls. Incubation of RASMCs with 30 μM and 100 
μM atorvastatin however resulted in a concentration dependent decrease in nitrite 
production, resulting in an overall bell-shaped curve as shown in Figure 5.9. In addition 
atorvastatin did not cause any significant change in basal nitrite levels indicating that it 
acts to modulate the effects mediated by LPS and IFN- and does not itself have any 
direct effect on the induction of NO production. 
 
Production of nitrite in J774 macrophages also showed a biphasic profile (Figure 5.10). 
Nitrite production by activated cells showed an initial concentration dependent increase 
which peaked at 3.0 μM of atorvastatin but declined thereafter. The change in nitrite 
production caused by atorvastatin was 45.0±9.3% higher than the activated control 
responses. As in RASMC controls, there was no significant change in nitrite production 
in non-activated J744 macrophages (Figure 5.10). 
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Figure 5.9 Effects of atorvastatin on nitrite production in both control and 
activated RASMCs. 
Confluent monolayers of RASMCs in 96-well plates were were pre-treated in complete 
DMEM alone (Controls) and in complete DMEM with different concentrations of 
atorvastatin (1 to 100 µM) for 30 min prior to activation. Cells were activated with both 
LPS (100 µg/ml) and IFN- (100 U/ml) for 24 hours. Nitrite accumulation in the culture 
medium was analyzed using the Greiss assay as previously described in the Method 
(Section 2.9). Open bars represent controls and black closed bars represent activated 
cells. Data represent the mean ± S.E.M. from three independent experiments with five 
replicates in each. Statistical differences between means were determined using one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of 
the normalized data. * & ** denotes P<0.05 and P<0.01 respectively when compared to 
untreated activated control. 
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Figure 5.10 Effects of atorvastatin on nitrite production in both control and 
activated murine J774 macrophages. 
Confluent monolayer of J774 macrophages in 96-well plates were were pre-treated in 
complete DMEM alone (Controls) and in complete DMEM with different concentrations 
of atorvastatin (1 to 100 µM) for 30 min prior to activation. Cells were activated with LPS 
(1.0 µg/ml) for 24 hours. After a 24 hour incubation period, the stable NO metabolite, 
nitrite, present in the medium was analyzed using the Greiss Assay as previously 
described in Method (Section 2.9). Open bars represent controls and closed black bars 
represent activated cells. Data represent the mean ± S.E.M. from three independent 
experiments, each performed in five replicates. Statistical differences between means 
were determined using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparisons test of the normalized data. * denotes P<0.01 when compared to 
untreated activated control. 
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5.4.6 Effects of atorvastatin on iNOS protein expression in both RASMCs 
and J774 macrophages 
 
To determine whether atorvastatin affects iNOS expression, cells were pre-treated with 
different concentrations of the inhibitor for 30 min prior to activation. The results 
demonstrated that iNOS expression was not significantly altered by atorvastatin in 
either RASMCs (Figure 5.11) or J774 macrophages (Figure 5.12) despite the significant 
increase in NO production (as shown in Figures 5.9 and 5.10).  
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Figure 5.11 Effect of Atorvastatin on iNOS protein expression in both control 
and activated RASMCs. 
Confluent monolayer of RASMCs in 6-well plates were pre-treated with either complete 
DMEM alone (Controls) and/ or complete DMEM with different concentrations of 
Atorvastatin (1 to 100 µM) for 30 minutes prior to activation. Cells were activated with 
LPS (100 µg/ml) and IFN- (100 U/ml) in the absence and continued presence of 
Atorvastatin. After 24 hours cell lysates were generated and equal quantities of (60 µg) 
protein were subjected to western blotting using a specific anti-iNOS antibody antibody 
as described in the Methods (Section 2.13). The above western blot (Figure A) is 
representative of at least three independent experiments. Respective protein band 
intensities were quantified by densitometric analysis and normalized to -actin protein 
(Figure B). The data is presented as a percentage of relative intensity of iNOS protein 
expression compared to the control responses without atorvastatin treatment. Data 
represent the mean ± S.E.M. from three independent experiments. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. 
P>0.05 confirmed there was no significant difference when compared to untreated 
activated control. 
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Figure 5.12 Effect of Atorvastatin on iNOS protein expression in both control 
and activated J774 macrophages. 
Confluent monolayer of J774 macrophages in 6-well plates were pre-treated with either 
complete DMEM alone (Controls) and/ or complete DMEM with different concentrations 
of Atorvastatin (1 to 100 µM) for 30 minutes prior to activation. Cells were activated with 
LPS (1.0 µg/ml) in the absence and continued presence of Atorvastatin. After 24 hours 
cell lysates were generated and equal quantities of (60 µg) protein were subjected to 
western blotting using a specific anti-iNOS antibody as described in the Methods 
(Section 2.13). The above western blot (Figure A) is representative of at least three 
independent experiments. Respective protein band intensities were quantified by 
densitometric analysis and normalized to -actin protein (Figure B). The data is 
presented as a percentage of relative intensity of iNOS protein expression compared to 
the control responses without atorvastatin. Data represent the mean ± S.E.M. from 
three independent experiments. Statistical differences between means were determined 
using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data. P>0.05 confirmed there was no significant 
difference when compared to untreated activated control. 
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5.4.7 Effects of atorvastatin on L-arginine transport in both RASMCs and 
J774 macrophages 
In order to examine the role of atorvastatin on transporter activity, cells were pre-treated 
with different concentrations of the drug for 30 min prior to activation with LPS (1.0 
µg/ml) alone or a combination of LPS (100.0 µg/ml) and IFN- (100.0 U/ml) in J774 
macrophages and RASMCs respectively. Confirmation of activation and protein content 
were assessed using Greiss and BCA assays after 24 hours as described in the 
Methods (Section 2.9 and 2.11 respectively). 
 
Activation of RASMCs with LPS (100.0 µg/ml) and IFN- (100.0 U/ml) was able to 
enhance L-arginine transport and this was further potentiated in a concentration 
dependent manner when co-induced with atorvastatin. As shown in Figure 5.13, there 
was a 1.6 fold increase in transport (p<0.01) which peaked at 30 μM atorvastatin. Lower 
concentrations of 1.0 µM or below had no significant effect (p>0.05) despite the 
downward trend in profile. At the highest concentration of 100 µM, atorvastatin reduced 
L-arginine transport back to the levels shown in activated controls. There was no 
significant change in L-arginine transport in non activated controls. 
 
In J774 macrophages, L-arginine transport following atorvastatin treatment also showed 
a biphasic or bell shaped response which peaked at 3 µM to about 2 fold over that in 
non treated activated control. This was followed by a concentration dependent decease 
in L-arginine transport with increased atorvastatin concentration. At the highest 
administered atorvastatin concentration (100 µM) transport rate was reduced to about 
more than 40% of the untreated activated control values. Similarly, as demonstrated in 
RASMCs, the rate of L-arginine transport in control macrophages showed no significant 
change (P>0.05; Figure 5.14). 
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Figure 5.13 Concentration dependent effect of atorvastatin on L-arginine 
transport in controls activated RASMCs. 
Confluent monolayers of RASMCs in 96-well plates was pre-treated in either complete 
DMEM alone (Controls) or in complete DMEM with different concentrations of 
atorvastatin (1 to 100 µM) for 30 min prior to activation. Cells were activated with both 
LPS (100.0 µg/ml) and IFN- (100.0 U/ml) in the absence (as control) and/or continued 
presence of atorvastatin. After 24 hour, nitrite and protein content in respective wells 
were assessed using the Greiss and BCA assays as described in the Methods (Section 
2.9 & 2.11 respectively). Transport of 3[H]-L-arginine was initiated and monitored over 2 
min in both control and activated cells as described in the Methods (section 2.10). Open 
bars represent controls and closed grey bars represent activated cells. Data are 
presented as percentage of 3[H] L-arginine transport by activated controls without 
inhibitor. Data representthe mean ± S.E.M. from three independent experiments, each 
with five replicates. Statistical differences between means were determined using one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of 
the normalized data. * denotes P < 0.01 when compared to untreated activated 
controls. 
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Figure 5.14 Concentration dependent effect of atorvastatin on L-arginine 
transport in control and activated J774 macrophages. 
Confluent monolayer of J774 macrophages in 96-well plate was pre-treated in either 
complete DMEM alone (Controls) or in complete DMEM with different concentrations of 
atorvastatin (1 to 100 µM) for 30 min prior to activation. Cells were activated with LPS 
(1.0 µg/ml) in the absence (as control) and/or continued presence of atorvastatin. After 
24 hour, nitrite and protein content in respective wells were assessed using the Greiss 
and BCA assays as described in the Methods (Section 2.9 & 2.11 respectively). 
Transport of 3[H]-L-arginine was initiated and monitored over 2 min in both control and 
activated cells as described in the Methods (section 2.10). Open bars represent 
controls and closed grey bars represent activated cells. Data are presented as 
percentage of 3[H] L-arginine transport by activated controls without inhibitor. Data 
represent the mean ± S.E.M. from three independent experiments, each with five 
replicates. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. * denotes P < 0.05 when compared to untreated activated controls. 
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5.4.8 Effects of atorvastatin on cell viability 
There was no significant difference in viability between control and activated RASMCs 
(Figure 5.15) or J774 macrophages (Figure 5.16) when exposed to atorvastatin at 
concentrations of 1.0, 10, 30 and 100 µM. Although there was a very small decrease in 
MTT metabolism at the higher concentrations in both cell types, these differences were 
not statistically significant. 
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Figure 5.15 Concentration dependent effects of atorvastatin on viability of both 
control and activated RASMCs 
Confluent monolayers of RASMCs in 96 well plate were pre-treated treated with either 
complete DMEM alone (Controls) or with different concentrations of treated with either 
complete DMEM alone (Controls) or with different concentrations of atorvastatin (1 
to100 µM) for 30 minutes prior to activation. Cells were activated with both LPS (100 
µg/ml) and IFN- (100 U/ml) for a 24 hour in the continued presence of atorvastatin. 
MTT metabolism by cells was determined colorimetrically as described in the Methods 
(Section 2.12). Open bars represent controls and closed grey solid squares represent 
activated cells. The data is presented as the percentage of viable cell as compared to 
the control without atorvastatin treatment. Data represent the mean ± S.E.M. from three 
independent experiments, each with five replicates. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data. P>0.05 confirmed there 
was no significant difference when compared to untreated controls 
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Figure 5.16 Concentration dependent effects of atorvastatin on viability of both 
control and activated murine J774 macrophages. 
Confluent monolayer of J774 macrophages in 96 well plates were pre-treated treated 
with either complete DMEM alone (Controls) or with different concentrations of treated 
with either complete DMEM alone (Controls) or with different concentrations of 
atorvastatin (1 to100 µM) for 30 minutes prior to activation. Cells were activated with 
LPS (1.0 µg/ml) for a 24 hour in the continued presence of atorvastatin. MTT 
metabolism by cells was determined colorimetrically as described in the Methods 
(Section 2.12). Open bars represent controls and closed grey solid squares represent 
activated cells. The data is presented as the percentage of viable cell as compared to 
the control without atorvastatin treatment. Data represent the mean ± S.E.M. from three 
independent experiments, each with five replicates. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data. P>0.05 confirmed there 
was no significant difference when compared to untreated controls 
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5.4.9 Effects of Y-27632 on nitrite production in RASMCs and J774 
macrophages 
To further establish the role of Rho kinase additional experiments were carried out 
using Y-27632 inhibitor. The latter specifically targets ROCK by inactivating 
p160ROCK, a principal subunit of this kinase reported to regulate NO synthesis (Laufs 
et al., 2002). 
 
As shown in Figures 5.17 and 5.18, there was the expected enhanced nitrite production 
in RASMCs activated with both LPS and IFN-  macrophages activated 
with LPS alone for 24 hours at 37°C. A 30 min pre-incubation of cells with different 
concentrations of Y-27632 prior to activation, resulted in a concentration-dependent 
enhancement of induced nitrite accumulation which in RASMCs increased over the full 
concentration range of Y-27632 used (0.01 μM to 10 μM; Figure 5.17) while in J774 
macrophages the increase peaked at 0.1 μM, declining thereafter (Figure 5.18). The 
lower concentrations of the inhibitor caused no statistically significant change (all 
p>0.05) in nitrite production when compared to levels in non-drug treated activated 
control cells.  
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Figure 5.17 Concentration dependent effect of Y-27632 inhibitor on nitrite 
production in both control and activated RASMCs. 
Confluent monolayer of RASMCs in a 96-well plate was pre-treated with different 
concentrations of Y-27632 inhibitor (0.01 to 10.0 µM) in complete DMEM for 30 min 
prior to activation. Cells were activated in the continued presence of Y-27632 inhibitor 
with both LPS (100 µg/ml) and IFN- (100 U/ml). After 24 hour incubation period, nitrite 
accumulation in the culture medium was analyzed using the Greiss assay as previously 
described in the Method (Section 2.9). Clear bars represent controls and closed black 
bars represent activated cells. Data indicates the percentage of viable cell as compared 
to controls without Y-27632 inhibitor treatment. Data represent the mean ± S.E.M. from 
three independent experiments, each with five replicates. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. * denotes 
P<0.01 when compared to untreated controls. 
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Figure 5.18 Concentration dependent effect of Y-27632 inhibitor on nitrite 
production in both control and activated murine J774 macrophages. 
Confluent monolayer of J774 macrophages in a 96-well plate was pre-treated with 
different concentrations of Y-27632 inhibitor (0.01 to 10.0 µM) in complete DMEM for 30 
min prior to activation. Cells were activated in the continued presence of Y-27632 
inhibitor with LPS (1.0 µg/ml). After 24 hour incubation period, nitrite accumulation in 
the culture medium was analyzed using the Greiss assay as previously described in the 
Method (Section 2.9). Clear bars represent controls and closed grey bars represent 
activated cells. Data indicates the percentage of viable cell as compared to controls 
without Y-27632 inhibitor treatment. Data represent the mean ± S.E.M. from three 
independent experiments, each with five replicates. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data.* denotes P<0.01 when 
compared to untreated controls. 
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5.4.10 Effect of Y-27632-inhibitor on L-arginine transport in both 
RASMCs and J774 macrophages 
Activation of RASMCs with a combination of LPS (100.0 µg/ml) and IFN- (100.0 U/ml) 
or J774 macrophages with LPS alone (1.0 µg/ml) was able to enhance L-arginine 
transport as shown in Figures 5.19 and 5.20 respectively. When pre-treated with Y-
27632 prior to activation, there was a concentration-dependent increase in transport of 
L-arginine in both cell types. However the observed changes in RASMCs were less 
pronounced when compared to that in J774 macrophages. Moreover, responses in the 
latter cell type peaked at 0.01 μM to 1 μM and declined thereafter. 
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Figure 5.19 Concentration dependent effect of Y-27632 inhibitor on L-arginine 
transport in both control and activated RASMCs. 
Confluent monolayer of RASMCs in 96-well plate was pre-treated in either complete 
DMEM alone (Controls) or in complete DMEM with different concentrations of Y-27632 
inhibitor (0.01 to 10.0 µM) for 30 min prior to activation. Cells were activated with both 
LPS (100.0 µg/ml) and IFN- (100.0 U/ml) in the absence (as control) and/or continued 
presence of of Y-27632 inhibitor. After 24 hour incubation period, nitrite and protein 
content of sample wells were assessed by the Greiss and BCA assays respectively as 
described in the Methods (Sections 2.9 and 2.11 respectively). Transport of 3[H] L-
arginine was assessed over 2 min in both control and activated cells as described in the 
Methods (Section 2.10). Open bars represent controls and closed bars represent 
activated cells. Data are presented as percentage of 3[H] L-arginine transport by 
activated controls without inhibitor. Data represent the mean ± S.E.M. from three 
independent experiments, each with five replicates. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data. P>0.05 confirmed there 
was no significant difference when compared to untreated controls. 
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Figure 5.20 Concentration dependent effect of Y-27632 inhibitor on L-arginine 
transport in both control and activated murine J774 macrophages. 
Confluent monolayer of J774 macrophages in 96-well plate was pre-treated in either 
complete DMEM alone (Controls) or in complete DMEM with different concentrations of 
Y-27632 inhibitor (0.01 to 10.0 µM) for 30 min prior to activation. Cells were activated 
with LPS (1.0 µg/ml) in the absence (as control) and/or continued presence of of Y-
27632 inhibitor. After 24 hour incubation period, nitrite and protein content of sample 
wells were assessed by the Greiss and BCA assays respectively as described in the 
Methods (Sections 2.9 and 2.11 respectively). Transport of 3[H] L-arginine was 
assessed over 2 min in both control and activated cells as described in the Methods 
(Section 2.10). Open bars represent controls and closed bars represent activated cells. 
Data are presented as percentage of 3[H] L-arginine transport by activated controls 
without inhibitor. Data represent the mean ± S.E.M. from three independent 
experiments, each with five replicates. Statistical differences between means were 
determined using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test of the normalized data. * denotes P<0.05 when compared to 
untreated controls. 
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5.4.11 Effect of Y-27632 inhibitor on cell viability 
The cytotoxic effects of Y-27632 inhibitor were assessed by measuring the 
mitochondrial dependent reduction of MTT to formazan as earlier described in Methods 
(Section 2.12). As shown in Figure 5.21, there was no significant difference in viability 
between control and activated RASMCs treated with up to 10.0 µM Y-27632 inhibitor. 
 
In J774 macrophages (Figure 5.22) there was no significant difference between control 
and activated cells across the concentration range under investigation. Treatment of 
macrophages with up to 10 µM of Y-27632 did not cause any significant effect on cell 
viability in controls and activated cells. 
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Figure 5.21 Concentration dependent effect of Y-27632 inhibitor on viability of 
both control and activated RASMCs 
Confluent monolayer of RASMCs in 96 well plates was pre-treated in complete DMEM 
alone or with different concentrations of Y-27632 inhibitor (0.01 to 10.0 µM) for 30 
minutes prior to activation. Cells were activated in the continued presence of Y-27632 
inhibitor with LPS (100 µg/ml) and IFN- (100 U/ml) for 24 hours. MTT metabolism by 
cells was determined colorimetrically on a 96-well microtiter plate as described in the 
Methods (Section 2.12). Open bars represent controls and closed grey bars represent 
activated cells. Data represent the mean ± S.E.M. from three independent experiments, 
each with five replicates. Statistical differences between means were determined using 
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test 
of the normalized data. P>0.05 confirmed there was no significant difference when 
compared to untreated controls. 
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Figure 5.22 Concentration dependent effect of Y-27632 inhibitor on viability of 
both control and activated J774 macrophages 
Confluent monolayer of J774 macrophages in 96 well plates were pre-treated in 
complete DMEM with different concentrations of Y-27632 inhibitor (0.01 to 10.0 µM) for 
30 minutes prior to activation. Cells were activated in the continued presence of Y-
27632 inhibitor with LPS (1.0 µg/ml) for a further 24 hour incubation period. MTT 
metabolism by cells was determined colorimetrically on a 96-well microtiter plate as 
described in the Methods (Section 2.12). Open bars represent controls and grey filled 
bars represent activated cells. Data represent the mean ± S.E.M. from three 
independent experiments, each with five replicates. Statistical differences between 
means were determined using one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test of the normalized data. P>0.05 confirmed there 
was no significant difference when compared to untreated controls. 
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5.5 DISCUSSION 
 
To further confirm our findings in  chapters 3 and 4 and the proposal that JAK2 may not 
be critical for the expression of the inducible L-arginine-NO pathway in RASMCs and 
J774 macrophages, we extended our studies by examining whether STAT-1 is indeed 
activated by LPS and IFN- in RASMCs or by LPS alone in the macrophages. In 
addition, studies were also aimed at establishing whether the activation of STAT-1 is 
independent of or linked to the activation of the JAKs. This is because STAT-1 is a 
downstream target for IFN- (Silvennoinen et al., 1993; Watling et al., 1993; Levy et al., 
1990). Originally identified to mediate actions of IFNs (Bromberg et al., 1996; Darnell, 
2007; Darnell, 1997) STATs are now reported to be involved in a diverse range of 
cellular activities including proliferation, differentiation, growth and apoptosis amongst 
others (Bromberg et al., 2000; Ihle, 1996). Tyrosine phosphorylation on Tyr701 residue 
near to the carboxyl end (Meraz et al., 1996) by JAKs results in STAT-1 activation (Ihle, 
1996). However, STAT-1 activation and translocation is caused by independent tyrosine 
phosphorylation of the JAKs (Fukuzawa et al., 2003; Schneider et al., 2013). 
Additionally, there is evidence (Blanchette et al., 2003b; Wen et al., 1995; Zhang et al., 
1995) to suggest a requirement of a second phosphorylation event at Ser727 residue 
for maximum activation. Thus, apart from the JAKs other upstream mechanisms may 
activate STAT-1 resulting in gene transcription including that for iNOS and this will be 
discussed below. 
 
The results obtained revealed that induction of RASMCs with LPS and IFN- or J774 
macrophages with LPS caused a time dependent phosphorylation of STAT-1. This 
result confirmes that STAT-1 is indeed expressed in both cell types and can be 
activated by the stimuli used to induce iNOS and L-arginine transport. However, the 
time course was different between the two cell types. In RASMCs the optimum time 
course of STAT-1 activation peaked at 30 min while in J774 macrophages the 
phosphorylation of STAT-1 was comparatively delayed and prolonged after LPS 
stimulation. The reason for this observed trend is unclear but may reflect cell type 
differences or could be due to the different stimuli used and may suggest differences in 
the mechanisms that activate STAT-1. What is most significant and unexpected is the 
fact that phosphorylation of STAT-1 in either cell type was not blocked by AG490, the 
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potent JAK2 inhibitor. This is an interesting observation which confirms that activation of 
STAT-1 in our cell systems is not directly linked to JAK2 and can occur independently 
of the latter. This further supports the notion that JAK2 does not directly mediate the 
effects of IFN- and/or LPS in inducing iNOS in our cell systems. 
 
In contrast to AG490, results from studies with JAK inhibitor I showed a significant 
concentration dependent decrease in STAT-1 phosphorylation in both RASMCs and 
J774 macrophages. Since this inhibitor is effective agains all JAK family members it is 
therefore likely that at least one of these kinases may mediate the actions of IFN-
and/or LPS in inducing iNOS. However, both current and previous data from our 
laboratory seem to rule out JAK2 based on data obtained with AG490. Similarly, JAK3 
can also be discounted because AG490 has been shown to inhibit this isoform (Luo et 
al., 2004a; Nielsen et al., 1997; Wang et al., 1999) but was without effect on iNOS 
expression, NO production of L-arginine transport. Thus, it is not unreasonable to 
suggest that neither JAK2 nor JAK3 may be critical for LPS-stimulated nitrite production 
in J774 macrophages. The other potential candidate JAK1 is susceptible to inhibition by 
JAK inhibitor I but a kinase-negative mutants of this protein can sustain IFN--inducible 
gene expression (Briscoe et al., 1996) suggesting that it may not be required for IFN- 
signalling. This however remains to be established in our cell system. 
 
Based on the above process of elimination, the likely JAK family member that may be 
required is therefore TYK2. This kinase has been implicated in LPS signalling by 
several groups (Kamezaki et al., 2004; Karaghiosoff et al., 2003) and appears to be 
involved in the signalling pathway of autocrine/paracrine secreted IFN-β (Colamonici et 
al., 1994a; Colamonici et al., 1994b; Domanski et al., 1995) in macrophages treated 
with high levels of LPS (Fujihara et al., 1994; Zhang et al., 1994). It is not clear whether 
TYK2 itself can be activated directly by IFN- and there is very little to suggest that it 
may be expressed in smooth muscle cells. Further studies were therefore carried out in 
Chapter 4 examining not only the expression but also the phosphorylation of TYK2 in 
both RASMCs and J774 macrophages. The data generated showed clearly that the 
protein is expressed under control conditions but does not seem susceptible to 
activation by either LPS alone or in combination with IFN-. This conclusion is based on 
data showing that the phospho protein could not be detected by western blotting using 
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a selective phospho-specific antibody. Thus, the effects of JAK inhibitor I may be 
mediated by an action on another target protein other than the JAKs. At present it is not 
clear what the target is but it has been reported that STAT-1 can be phosphorylated by 
the GTPases independently of the JAKs (Gundogdu et al., 2010). This is of relevance to 
this thesis and to confirm whether this might be the case, additional experiments were 
carried out investigating the effects of GTPase inhibitors on nitrite production and L-
arginine transport. In these studies two GTPase inhibitors were used: atorvastatin and 
Y-27632, a specific Rho kinase inhibitor (Uehata et al., 1997). 
 
Atorvastatin is a synthetic HMG-CoA Reductase inhibitor commonly called statin and is 
used clinically in hypercholesterimic patients to reduce circulating cholesterol levels in 
the body. In addition, substantial outcomes from large clinical trials have demonstrated 
considerable improvements in both primary and secondary prevention of heart disease 
of patients following statin therapy. Also, statins have been reported to regulate eNOS 
expression although the majority of such effects have been attributed to statins acting 
as inhibitors of HMG-Co-A enzymes and lowering cholesterol biosynthesis (Laufs et al., 
2002). Statins have also been reported to cause alterations in tetrahydrobiopetrin 
synthesis (Hattori et al., 2002), a cofactor in iNOS function. Such effects may involve 
regulating signaling pathways associated with the expression of iNOS. The pleiotropic 
actions of statins, mediated by antioxidant effects have been demonstrated in other 
studies (Laufs et al., 2003; Takemoto et al., 2001; Tanaka et al., 2013) in which statins 
have also been reported to inhibit the activation of GTPases by inhibiting the synthesis 
of isoprenoids (farnesyl pyrophosphate and geranylgeranyl pyrophosphate) which are 
responsible for the post-translational modification of various proteins including small 
GTPases such as Rho and Ras. These drugs can therefore regulate downstream 
pathways which may feed into the nucleus to regulate iNOS expression. To confirm 
this, experiments were carried out examining the effects of atorvastatin on STAT-1 
phosphorylation and on both NO production and L-arginine transport. 
 
In these studies LPS plus IFN- induction of RASMCs following atorvastatin pre-
treatment caused a significant concentration dependent increase in NO production 
which peaked at 10 µM. This trend was then followed by a decline thereafter suggesting 
a biphasic response to the drug. Interestingly, iNOS expression was not altered 
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suggesting that the actions of the statin were not a consequence of changes in iNOS 
protein expression. This would contrast with studies using MCF-7 cells which have 
demonstrated that statins inhibit geranylgeranylation of prenylated intermediates and 
thereby dose-dependently induce iNOS protein expression (Kotamraju et al., 2007). In 
the present studies, atorvastatin may not regulate the GTPase pathway but could exert 
its effects by directly regulating NO production. One potential explanation for this effect 
is that because atorvastatin has anti-oxidant properties (Chen et al., 2012; Wassmann 
et al., 2002) it may be able to prevent the interaction of NO with superoxide radicals 
thus enhancing the levels which can be detetected by the Griess assay. This however 
remains to be established to account for the present findings in this thesis. 
 
In both cell systems, transport of L-arginine appeared to be enhanced by atorvastatin 
but only in activated cells. This effect was more pronounced in J774 macrophages and 
the pattern was also different between the two cell types in that the peak stimulation 
caused by atorvastatin in RASMCs was at 30 µM while in J774 macrophages it was at 3 
µM. This may reflect subtle differences in the action of the drug which remains to be 
determined. Transport rates in controls however remained largely unaltered. Because 
of time limitations it was not possible to establish whether the increases were 
associated with changes in transporter gene expression as these studies remain 
critical. Similarly, westerns for changes in CAT protein expression could not be carried 
out because of lack of commercially available antibodies. However, it is likely that 
atorvastatin enhances L-arginine transport through changes in induction of the key 
carrier proteins. This is an interesting proposal that would be necessary to confirm in 
future studies. 
 
Similar to atorvastatin, treatment of either RASMCs or J774 macrophages with Y-27632 
prior to activation resulted in a concentration dependent increase in NO production with 
that in the macrophages declining above 1 µM whilst peaking at 10 µM in the RASMCs. 
The inducble NOS expression was not examined because of time limitations but studies 
on L-arginine transport confirmed a relatively similar trend to that seen with atorvastatin. 
Thus taken together, it would appear that both compounds may exert their effects via a 
similar mechanism which could involve inhibition of the GTPases but we cannot rule out 
that atorvasatatin may also have the added anti-oxidant effects. 
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In summary, the results of this chapter have shed further light on the potential role of 
the JAK proteins or rather their lack of involvement in the induction of iNOS, NO 
production and L-arginine transport. Although further definitive studies may be needed 
we can speculate from the present findings that LPS either alone or together with IFN- 
signal independently of the JAKs to induce the above processes. Whether this action is 
linked to the GTPases as was initially thought is debatable. This is because the data 
obtained for the latter suggests that GTPases suppress expression of the inducible L-
arginine-NO pathway and their inhibition results in further stimulation. It is likely 
therefore that signaling through the GTPases is distinct from the signaling activated 
LPS and IFN- for the induction of iNOS, NO and L-arginine. What is missing and could 
not be completed in time for submission of the thesis is whether the GTPases directly 
activate STAT-1. These experiments are critically needed. 
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Chapter 6. Expression profile of Transporters in RASMCs and J774 
macrophages 
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6.1 INTRODUCTION 
 
The use of both in vitro (Chen et al., 1994) and in vivo (Allman et al., 1996) animal 
models has further reinforced the suggestion that synthesis of NO by iNOS is 
predominantly dependent on extracellular L-arginine (Bogle et al., 1992b). In addition, 
the main source of L-arginine is mainly acquired from diet and is reported to be actively 
transported into the cell through transporter carrier systems (Closs et al., 2000; Closs et 
al., 2004; Deves et al., 1998c; Wileman et al., 1995). The main transporter systems 
implicated include the SLC7 family which is further divided into two main subgroups; the 
cationic amino acid (CAT family – SLC7A1 -A4) and the glycoprotein-associated amino 
acid transporters (the gpaAT family (also called hetero-(di)-meric amino acid transporter 
family) – SLC7A5 –SLC7A11). The former are the high affinity carrier, y+ (CAT) system 
with secondary contributory role by the gpaAT system including y+L, b+ and bo,+ (Deves 
et al., 1998a; Deves et al., 1998b). 
 
Results from our earlier experiments in this thesis and additionally by other 
investigators (Baydoun et al., 1993a; Bogle et al., 1992b; Durante et al., 1995; Wileman 
et al., 1995) have demonstrated that activation of RASMCs and J774 macrophages with 
pro-inflammatory mediators including LPS and cytokines (IFN-) cause an up-regulation 
of L-arginine transport which parallels the induction of iNOS. This observation has led to 
the proposal that transport of L-arginine may be critical for the activity of iNOS and 
makes the transporters potential targets for regulating the overproduction of NO. 
However, the expression profile of CATs may be tissue specific and the degree of 
participation of each carrier in mediating entry of L-arginine into cells is not completely 
understood especially under cytokine mediated inflammatory conditions. A clear 
understanding of the nature and cellular profile of expression of CATs is therefore 
essential. Thus, in this chapter, experiments were carried out to determine the profile of 
expression of CATs in RASMCs and in J774 macrophages and further to establish how 
these may be regulated by pro-inflammatory mediators. 
 
The hetero-dimeric amino acid transporters (also called glycoprotein associated amino 
acid-(gpaAT)) are reported to participate in the transport of L-arginine and could 
therefore contribute to substrate supply for iNOS. The latter has however not been 
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addressed and there are few studies that have demonstrated the regulation of these 
carriers by pro-inflammatory mediatiors. This was therefore examined as part of the 
studies for this chapter. The investigated transporters included y+LAT1 (SLC7A5), 
y+LAT2 (SLC7A6) and b0,+ (SLC7A9). 
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6.2 METHODS 
 
6.2.1 cDNA synthesis from extracted RNA 
 
Separate flask containing 80-95 % confluent monolayers of RASMCs or J774 
macrophages were respectively activated with a combination of LPS (100 µg/ml) and 
IFN- (100 U/ml) or LPS (1.0 µg/ml). After 24 hour incubation, total RNA was extracted 
using RNASTAT-60 as described in the Method (Chapter 2) and subsequently treated 
with Turbo DNase-free (Ambion, UK) following manufacturers’ instructions to remove 
any contaminating DNA. The total RNA in all samples was quantified using a 
spectrophotometer (Biophotometer, Germany). The resulting purified RNA was reverse 
transcribed using the ImProm-II reverse transcription system (Promega, UK) by 
following the manufacturer’s instructions. Briefly the RT step of priming the first-strand 
cDNA synthesis was carried out using the following reaction mixtures: 
 
RNA (up to 1.0 µg/rxn) 
Random (Hexamer) primer (up to 0.5 µg/ reaction) 
Nuclease-free water 
ImProm-II 5X Reaction Buffer 
MgCl2 (final concentration 1.5 – 8.0 mM) 
dNTP mix (dGTP, dCTP, dATP and dTTP; each at a concentration of 500 µM) 
RNasin Ribonuclease inhibitor (0.4 U/µl) - optional 
ImProm-II reverse transcriptase ((up to 1.0 ug/20 µl-reaction) 
 
Reverse transcription reactions in a final reaction volume of 20 µl containing the above 
were subjected to initial primer incubation (i.e. RNA and Hexamer random primer only) 
at 25 ºC for 5 minutes, then at 42 ºC for 60 minutes. A final reaction is a thermal 
inactivated step of the reverse transcriptase enzyme by incubating the reaction mixture 
at 70 ºC for 15 minutes and cooled to 4 ºC prior to storage at -80 ºC. 
 
 
 
 238 
6.2.2 Primer Design 
 
The sequences of oligonucleotide primers (both Forward and Reverse) were designed 
to amplify the genes encoding the CATs, y+L, b0+ and iNOS. Sequences of the 
investigated transcripts were retrieved from both murine and rat GenBank and Genome 
Browser databases. With the aid of both FASTPCR and Molecular Beacon primer 
design programmes, primers for the respective transporters, iNOS and two house 
keeping genes were designed as shown in Table 6.1. Other software programmes such 
as BLAST, Oligonucleotide calculator were used to aid in the design and selection of 
the most appropriate primers.  Designed primer sequences were compared with those 
on GenBank using BLAST 2 sequences software and this showed that all designed 
primers had 100% identities with the GenBank database sequences as listed in Table 
6.2. General primer design parameters were followed as described in the Methods 
(Section 2.17). 
 
6.2.3 Reference gene Normalization 
6.2.3.1 Internal control gene 
 
Housekeeping genes (HKGs) are expressed in most cells under a wide range of 
conditions. Generally they are regarded as having ubiquitous expression in virtually all 
tissues with the primary role being to maintain normal but essential metabolic and 
cellular functions. Aside from this, it has been proposed that some HKGs may play a 
significant role in the regulation of important developmental pathways. In contrast, 
tissue specific genes carry out specific functions and are implicated in growth, 
differentiation, apoptosis and other developments (Butte et al., 2001). 
 
Gene expression assays require internal controls (Siebert et al., 1992) that exhibit a 
constant basal level of expression to normalise with. Traditionally, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and β-actin (BACT) have been the most 
commonly used HKGs in normalising q-PCR experiments. Although under certain 
circumstances they may be superior to other HKGs, several publications have indicated 
that GAPDH (Deindl et al., 2002; Glare et al., 2002) and -actin (Selvey et al., 2001) 
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may vary considerably and are therefore unsuitable as HKG for gene expression 
studies. To this end, we examined the variability in expression profile of eight randomly 
chosen HKGs (see Table 6.1). These included several of those commonly used in both 
RASMCs and J774 macrophages. The analysis was carried out in one reaction to 
enable both the gene of interest (GOI) and housekeeping gene to be subjected to the 
same conditions and therefore achieve the main goal of identifying the ideal HKG for 
normalisation. 
 
To identify the most stable expressed housekeeping genes under our experimental 
conditions, transcript expression for target genes were investigated under varying 
conditions in our cell models. In J774 macrophages three main treatment conditions 
were used; Control, LPS (1.0 µg/ml) or IFN- (100 U/ml). In RASMCs, four conditions 
were used: Control, IFN- (100 U/ml) only, LPS (100 ug/ml) only or a combination of 
both LPS (100 µg/ml) and IFN- (100 U/ml). Two of the most stably expressed genes 
that were unaffected by the treatment conditions and could therefore be used for 
normalising target gene expression were chosen as HKGs. 
 
 
 
 
 
 
 
 
 
 240 
Table 6.1. Housekeeping genes analysed for use in normalising target gene expression 
 
§ Prmers designed in house (see primers). All other HKGs were provided by PrimerDesign (UK) Ltd.
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Table 6.2. Primers for transporter genes and HKGs evaluated 
 
 
 
 
 
 
GENES  
 
 
GenBank (accession nos.)/ 
Chromosomal Band (Chr) 
MOUSE 
 
 
GenBank (accession nos.)/ 
Chromosomal Band (Chr) 
RAT 
 
 
CAT-1 (SLC7A1) 
 
 
NM_007513.4  
 
 
5qG3 
 
 
NM_013111.2 
 
 
 
12p11 
 
 
CAT2A (SLC7A2) 
 
 
NM_007514.3  
 
 
8qA4 
 
 
NM_001134686.1  
 
16q12.1 
 
CAT2B (SLC7A2) 
 
 
NM_007514.3  
 
 
8qA4 
 
 
NM_001134686.1  
 
16q12.1 
 
yLAT1 (SLC5A1) 
 
 
NM_011405.3 
 
14qC2 
 
NM_031341.1  
 
15p13 
 
yLAT2 (SLC5A1) 
 
 
NM_178798.3 
 
8qD3 
 
NM_001107424.1 
 
19q12 
 
b0
+
AT1 (SLC5A9) 
 
 
NM_001199015.1 
 
7qB2 
 
 NM_053929.1 
 
1q21 
 
iNOS (or NOSII) 
 
 
NM_010927.3 
 
 
11qB5 
 
NM_012611 
 
10q25 
 
GAPDH 
 
NM_008084 
 
6 
 
NM_017008 
 
 
4q42 
 
2 Microglobulin 
 
 
 
NM_009735.3 
 
 
2 
 
NM_012512.2 
 
3q35 
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6.2.4 Complementary DNA (cDNA) synthesis and real time; PCR 
analysis 
Prior to cDNA synthesis total RNA was treated with RNase-free DNase (Ambion, 
UK) according to manufacturers instruction to eliminate all traces of DNA. 
Complementary–DNA synthesis was carried out with purified RNA using the 
ImProm-II™ Reverse Transcription System (Promega, UK) kit by enabling annealing 
of first strand synthesis reaction of RNA and random hexamer primers at 25°C 
followed by an incubation step at 42°C for 60 minutes in the presence of 1 U/µl 
rRNasin ribonuclease Inhibitor and 4mM MgCl2. The reaction mixture was then 
subjected to thermal inactivation of the reverse transcriptase at 90°C for 5 min. The 
resulting 20 µl reaction mixture was diluted fivefold and stored at -70 °C until 
required in all subsequent q-PCR reactions. 
 
Using Sybr Green q-PCR detection methodology, the transcriptional profiling of all 
eight HKGs and all transcripts for transporters in addition to that for iNOS were 
assessed. All Ct values generated from each assay run were determined at fixed 
threshold fluorescence value. 
 
6.3 STATISTICAL ANALYSIS 
 
6.3.1 GeNORM Analysis 
 
The stability of the selected genes was analysed using the GeNorm software which 
provides a measure of gene stability by introducing two key parameters, an 
expression stability value, M and a mean pairwise variation, V. 
 
Following q-PCR, CT values for the HKGs under investigation were transformed into 
relative quantification data using the delta CT method (Livak et al., 2001). Replicates 
Ct values were first transformed into geNorm data followed by the determination of 
the arithmetic mean of the replicates. In geNorm, the measures of stability of the 
chosen HKGs were based on geometric averaging of expression levels. Using the 
geNorm analysis software, data were imported from the transformed Ct values 
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generated in Excel (with macros enabled). GeNorm charts were generated following 
importation of data into the programme. The first of three charts (see Figures 6.4 & 
6.6 - J774 macrophages and RASMCs respectively) generated indicated the 
average stability value (M) of the HKG at each step during a stepwise exclusion of 
the least stable expressed HKG. The least stable HKG for J774 macrophages is 
shown on the left (B2M) with the most stable on the right (UBC & RPL13A) as 
illustrated in Figure 6.4. Similarly, the least stable HKG for RASMCs is shown on the 
left (B2M) with the most stable on the right (CYC & RPL13A) as shown in Figure 6.6. 
 
The second chart (Figure 6.5 & 6.7) following geNorm analysis was used as a guide 
for determining the optimal number of HKGs required in the assay. It therefore 
served as an illustration of the levels of variation in HKG stability and is known as the 
pairwise variation V, with an average score of 0.15 as the recommended ideal target. 
Standard curve were generated for each gene following serial dilution of the stock 
DNA against Ct of each gene. All the genes showed a linear correlation coefficient 
(R2) of 0.980 – 0.099 with efficiency of assay in the range of 96 – 104%. All Ct 
values of the respective genes were within the range of the Standard curve. 
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6.4 RESULTS 
 
6.4.1  Confirmation of quantity and quality of RNA isolated 
In order to ensure high quality RNA was used in the studies, the purity of isolated 
RNA samples was routinely checked using an agarose gel electrophorysis. The 
result as shown in Figure 6.1 demonstrated that the samples obtained from RASMCs 
were free of contaminants (mostly DNA) and were intact. This is based on the fact 
that there were clear 28S and 18S ribosomal RNA fragments identified with little or 
no smear. Similar blots were also obtained using total RNA isolates from J774 
macrophages. 
 
 
Figure 6.1 A representative agarose gel electrophoresis of RNA isolated 
from both untreated (control) and activated RASMCs. 
Total RNA samples extracted from confluent untreated control or a combined LPS 
(100.0 µg/ml) and IFN- (100.0 U/ml) stimulated RASMCs were mixed with 
bromophenol blue (1:1) and subjected to gel electrophoresis at 5 V/cm for 
approximately 45 minutes on a 1% agarose gel. The gel was transferred into a 
chamber with TBE buffer containing 10µg/ml ethidium bromide for 15 to 20 minutes. 
Gels were visualized under a transilluminator. The Figure above is a representative 
gel of at least three independent experiments showing 28s and 18s ribosomal bands 
with very little evidence of contamination in the samples. 
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6.4.2 Expression patterns of HKGs in J774 Macrophages and RASMCs 
In J774 macrophages the eight chosen HKGs showed marked differences in their 
expression levels from the highest median Ct of 21.31 for Ubiquitin C (UBC) to the 
lowest median Ct of 14.54 for the ACTB gene (Figure 6.2). All but three HKG genes 
(CYC, UBC and RPL13A) had median Ct values above 20 whiles the remaining five 
genes (YWHAZ, CANX, ACTB, GAPDH and B2M) had median Ct values below 20. 
Similarly, in RASMCs there was a demonstrable wide range in expression of HKGs. 
As shown in Figure 6.3, all but two HKGs (CYC and YWHAZ) had median Ct values 
above 20 whiles the remaining six genes (CANX, UBC, RPL13A, ACTB, GAPDH 
and B2M) had median Ct values below 20. 
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Figure 6.2 Raw qualitative RT-PCR of Threshold cycle (Ct) for eight 
candidate HKGs in control and activated J774 macrophages  
Confluent monolayer of J774 macrophages were cultured in either complete DMEM 
alone (as Control) or stimulated with LPS (1 µg/ml) in continued presence of 
complete DMEM. After 24 hour incubation period, nitrite content of the culture 
medium was assessed by the Greiss assay as described in the Methods (Section 
2.9) to confirm activation of the cells. Total RNA was isolated from adherent cells 
and DNAse treated. Purified RNA was then subsequently reversed transcribed to 
cDNA and real-time Sybr green based q-PCR analysis was performed as described 
in the Methods (Section 2.15 to 2.19). These results are the mean expression levels 
of transcripts in both activated and control cells and are representative of at least 
three independent experiments, each performed in tiplicates. HKGs investigated 
include; CYC: Cyclophilin C; YWHAZ: Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide; CANX: Calnexin; UBC: 
Ubiquitin C; RPL13A: Ribosomal protein L13a; ACTB: -Actin; GAPDH: 
Glyceraldehyde-3-phosphate dehydrogenase; B2M: 2-Micrglobulin 
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Figure 6.3 Raw of Threshold cycle (Ct) for eight candidate HKGs in control 
and activated RASMCs. 
Confluent monolayer of RASMCs were cultured in either complete DMEM alone (as 
Control) or stimulated with both LPS (100.0 µg/ml) and IFN- (100.0 U/ml) in 
continued presence of complete DMEM. After 24 hour incubation period, nitrite 
content of the culture medium was assessed by the Greiss assay as described in the 
Methods (Section 2.9) to confirm activation of the cells. Total RNA was isolated, 
DNAse treated, purified before being reversed transcribed to cDNA and used in Sybr 
green based q-PCR reactions as described in Methods (Sections 2.15 to 2.19). 
These results are the mean expression levels of transcripts in both activated and 
control cells and are representative of at least three independent experiments, each 
performed in tiplicates. HKGs investigated include; CYC: Cyclophilin C; YWHAZ: 
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
polypeptide; CANX: Calnexin; UBC: Ubiquitin C; RPL13A: Ribosomal protein L13a; 
ACTB: -Actin; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; B2M: 2-
Micrglobulin. 
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6.4.3 Optimisation and selection of the most stable HKG under  
experimental conditions 
The amplification of each target HKG was carried out using the complementary DNA 
(cDNA). To ensure there was comparability between all the eight reference genes 
and the genes of interest, PCR efficiencies for all genes were undertaken. To 
evaluate the stability of the HKGs, geNorm (VBA) analysis software (Vandesompele 
et al., 2002) was used with the incorporation of two key parameters which were an 
average expression stability value designated M and a pairwise variation, V. All 
reactions were performed in duplicates and a control using double distilled water was 
used for comparison. The threshold cycle (Ct) was automatically determined by 
using the Quansoft software (Techne). 
 
Results from our q-PCR data showed varying ranges of stability for all the 
housekeeping genes examined in both control and in different activated conditions in 
RASMCs. Particularly, transcripts specific for CYC and RPL13A were the most 
stable, followed by CANX, GAPDH, YWHAZ, UBC and ACTB with B2M being the 
least stable. This trend in stability was determined by establishing the Ct value for 
each gene and normalising values in activated cells against controls (Table 6.1). The 
normalization factor produced was computed using the GeNorm analysis tool to 
determine the M values which were then plotted in Figure 6.4, clearly showing the 
trend in stability. Normally, M values of <1.5 indicate stable genes and in our screen 
all but one housekeeping gene fell below this with the most stable showing a M value 
of 0.152. 
 
By comparison, the most stable genes in J774 macrophages were UBC and RPL13A 
with an M value of 0.026. The other stable genes in order of decreasing stability 
were: CANX, CYC, GAPDH, ACTB, YWHAC and B2M (as shown in Table 6.2 and in 
Figure 6.5). 
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Table 6.3. Stability of housekeeping genes based on their respective 
Ct values in RASMCs 
 
 
 
This Table was generated by the geNorm analysis software which also generates a 
normalization factor required for the determination of M values for each gene. S1 
represents studies in control cells; S2, IFN- treated cells; S3, LPS treated cells and 
S4, a combined LPS and IFN- treated cells. 
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Figure 6.4 Average expression stability values of various housekeeping 
genes in RASMCs. 
Confluent monolayer of RASMCs in T-25 flasks were cultured in complete DMEM 
alone (as Control) or stimulated with IFN- (100 U/ml) or LPS (100 µg/ml) or a 
combination of both IFN- (100 U/ml) and LPS (100 µg/ml) in continued presence of 
complete DMEM for 24 hours. Total RNA was isolated, DNAse treated, purified 
before being reversed transcribed to cDNA and used in Sybr green based q-PCR 
reaction as described in Methods (Sections 2.15 to 2.19). Stability of the eight 
selected HKGs was undertaken to assess the most stable gene and assigned a 
stability value M, using the geNorm approach. Resulting data is plotted against the 
respective gene as shown above. This figure is representative of at least three 
independent experiments with both CYC and RPL13A having the lowest M value. 
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Table 6.4. Stability of housekeeping genes based on their respective 
Ct values in J774 macrophages 
 
 
 
This Table was generated by the geNorm analysis software which also generates a 
normalization factor required for the determination of M values for each gene. S1 
represents studies in control cells; S2, IFN- treated cells and S3 LPS treated cells. 
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Figure 6.5 Average expression stability (M) values of the HKGs in J774 
macrophage using the geNorm program. 
Confluent monolayer of murine J774 macrophages in T-25 flasks were cultured in 
complete DMEM alone (as Control) or stimulated with IFN- (10 U/ml) or LPS (1.0 
µg/ml) in continued presence of complete DMEM for 24 hours. Total RNA was 
isolated, DNAse treated, purified before being reversed transcribed to cDNA and 
used in Sybr green based q-PCR reactions as described in Methods (Sections 2.15 
to 2.19). Stability of the eight selected HKGs was undertaken to assess the most 
stable gene and assigned a stability value M, using the geNorm approach. Resulting 
data is plotted against the respective gene as shown above. This figure is 
representative of at least three independent experiments with both UBC and 
RPL13A having the lowest M value. 
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6.4.4 Profile of L-arginine Transporter expression in RASMCs and J774 
macrophages. 
As previously demonstrated (Baydoun et al., 1993a; Baydoun et al., 1994b; Kakuda 
et al., 1999; Schott et al., 1993b), L-arginine transport in this thesis increased in J774 
macrophages following activation with LPS alone. Similarly, there was a comparative 
increase in L-arginine uptake in RASMCs when induced with both LPS (100 µg/ml) 
and IFN- (100U/ml). To determine which transporter may be critical for this change 
gene analysis of CAT expression was carried out comparing the relative expression 
of CAT transporters against the relevant housekeeping gene determined as 
described above. In RASMCs these were CYC and RPL13A and in J774 
macrophages we used UBC and RPL13A. In addition, amplification of iNOS was 
also conducted and used for comparative purposes to determine how the induction 
of the enzyme correlates with the induction of CATs. This should help shed light on 
which CAT may be critical for substrate supply to iNOS by correlating profiles of 
increases with changes in function (ie NO production and L-arginine transport). A 
representative amplification plot of a ten-fold serially diluted iNOS cDNA showing a 
change in fluorescence (ΔRn) as a function cycle numbers in iNOS transcript is 
shown in Figure 6.6 (RASMCs) and Figure 6.7 (J774 macrophages) below. This was 
first determined to basically establish that the reaction conditions resulted in efficient 
amplifications of the target gene. 
 
In relation to CAT expression, primers of CAT genes had amplification slopes in the 
range of –3.19 to –3.56, corresponding to amplification efficiencies of 93 to105%. In 
RASMCs, all target genes achieved a correlation coefficient (R2) of between 0.965 – 
0.999 (Data not shown). The average cycle threshold (AvCt) values indicate signals 
in single PCR reactions. Each Ct point represents an average of three replicates. 
Similarly, in J774 macrophages, target genes achieved a correlation coefficient (R2) 
of between 0.96 and 0.989 (Data not shown). The average cycle threshold (AvCt) 
values indicate signals in single PCR reactions. Each Ct point represents an average 
of three replicates. 
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Figure 6.6 Amplification curve of iNOS gene in RASMCs 
Confluent monolayer of RASMCs in T-25 flasks were cultured in complete DMEM 
alone (as Control) or stimulated with LPS (100.0 µg/ml) and IFN- (100.0 U/ml) in 
continued presence of complete DMEM for 24 hours. Total RNA was isolated, 
DNAse treated, purified before being reversed transcribed to cDNA and used in Sybr 
green based q-PCR reactions as described in Methods (Sections 2.15 to 2.19). A 
representative linear regression of the amplification plot of 10 fold serially diluted 
cDNA (in DNase free water) is shown in Figure A. Figure B is a representative 
amplification profile plot generated from the Quantica thermocycler software 
(Quansoft) with non-treated (green) and activated (red) serially diluted iNOS cDNA 
showing relative fluorescence (ΔRn) as a function cycle numbers in the iNOS 
transcript. 
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Figure 6.7 Amplification curve of iNOS gene in J774 macrophages 
Confluent monolayer of J774 macrophages in T-25 flasks were cultured in complete 
DMEM alone (as Control) or stimulated with LPS (1.0 µg/ml) in continued presence 
of complete DMEM for 24 hours. Total RNA was isolated, DNAse treated, purified 
before being reverse transcribed to cDNA and used in Sybr green based q-PCR 
reactions as described in Methods (Sections 2.15 to 2.19). A representative linear 
regression of the amplification plot of 10 fold serially diluted cDNA (in DNase free 
water) is shown above (Figure A). Figure B is a representative amplification profile 
plot generated from the Quantica thermocycler software (Quansoft) showing non-
treated (green) and activated (red) serially diluted iNOS cDNA showing relative 
fluorescence (ΔRn) as a function of cycle number in the iNOS transcript. 
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The presence of expected PCR products (transcript of transporter mRNA) was 
confirmed by melt-curves analysis which indicated amplification of a single product in 
the SYBR Green based q-PCR reaction assay. As shown in Figures 6.8 (RASMCs) 
and 6.9 (J774 macrophages) each of the targeted gene (i.e. CAT-1, CAT2A, CAT2B, 
y+LAT1, y+LAT2 and b0,+) had a single unique peak indicating a single product and 
thus confirming a successful reaction and target specificity. More importantly, basal 
expressions of these transporters were found in all cells in the absence of IFN- 
and/or LPS. In control RASMCs, CAT-1 was the most highly expressed while CAT2A 
the least expressed transcript (Figure 6.10). By comparison, CAT2B was the most 
highly expressed transcript in J774 macrophages with CAT2A again showing the 
least expression. Following induction RASMCs showed significantly enhanced 
expression of CAT2B (3.14±0.35) while both CAT-1 and CAT2A were only 
moderately enhanced, showing 1.59 and 6.23 fold increases respectively. However 
neither of these increases were significantly different to control levels due to the 
large variations between experiments (p>0.05) (Figure 6.10). In the macrophages, 
CAT2A did not appear to be induced and was in fact reduced by LPS (0.47 ± 0.007) 
but the large variations between experiments suggest the changes were not 
statistically different to control. Both CAT-1 and CAT2B were however significantly 
enhanced with the latter being the most predominant in LPS-activated cell (Figure 
6.11). The fold change in CAT2B expression was on average 24.98 ± 3.48 and that 
of CAT-1 was 10.9± 1.3. These changes were much higher when compared to 
similar changes in RASMCs. In addition the expression of iNOS mRNA also 
increased very significantly to over 3081 ± 14.91 fold compared to control cells.  
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Figure 6.8 Specificity of targeted gene expression in RASMCs 
Confluent monolayer of RASMCs in T-25 flasks were cultured in complete DMEM 
alone (as Control) or stimulated with both LPS (100 µg/ml) and IFN- (100 U/ml) in 
continued presence of complete DMEM for 24 hours. Total RNA was isolated, 
DNAse treated, purified before being reversed transcribed to cDNA and used in Sybr 
green based q-PCR reactions as described in Methods (Sections 2.15 to 2.19). Each 
Melting curve represents respective profile of the investigated carrier transport 
transcripts which includes CAT-1, CAT2A, CAT2B, y+LAT1, y+LAT2, b0+ and HKGs 
CYC (HKG1), RPL13A (HKG2) and CANX (HKG3). 
 
 
 
 258 
6.4.5 Specificity in expression profile of CAT members in the murine 
J774 macrophages 
 
Figure 6.9 Specificity of targeted gene expression in J774 macrophages 
Confluent monolayer of J774 macrophages in T-25 flasks were cultured in complete 
DMEM alone (as Control) or stimulated with LPS (1.0 µg/ml) in continued presence 
of complete DMEM for 24 hours. Total RNA was isolated, DNAse treated, purified 
before being reversed transcribed to cDNA and used in Sybr green based q-PCR 
reactions as described in Methods (Sections 2.15 to 2.19). Each Melting curve 
represents respective profile of the investigated carrier transport transcripts which 
includes CAT-1, CAT2A, CAT2B, y+LAT1, y+LAT2, b0+ and HKGs UBC (HKG1), 
RPL13A (HKG2) and CANX (HKG3). 
  
 
 259 
 
Figure 6.10 Effect of IFN- and LPS on the expression of CATs in RASMCs 
Confluent monolayer of RASMCs in T-25 flasks were cultured in complete DMEM 
alone (as Control) or stimulated with both LPS (100 µg/ml) and IFN- (100 U/ml) in 
continued presence of complete DMEM for 24 hours. Total RNA was isolated, 
DNAse treated, purified before being reversed transcribed to cDNA and used in Sybr 
green based q-PCR reactions as described in Methods (Sections 2.15 to 2.19). 
These results are mean expression levels of transcripts in both activated and non-
activated cells normalized to HKGs, CYC and RPL13A. Open white bars represent 
controls and closed black filled bars represent activated cells. Data represent the 
mean ± S.E.M. from three independent experiments, each performed in three 
replicates. Statistical differences between means were determined using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test of the 
normalized data. * denotes P<0.01 when compared to untreated controls. The 
highlighted insert is an adjusted normalized expression profile of data below 0.150 
units in order to optimize visualization of lowly expressed transcripts. 
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Figure 6.11 Effect of LPS on the expression of CATs in J774 macrophages 
Confluent monolayer of J774 macrophages in T-25 flasks were cultured in complete 
DMEM alone (as Control) or stimulated with LPS (1.0 µg/ml) in continued presence 
of complete DMEM for 24 hours. Total RNA was isolated, DNAse treated, purified 
before being reversed transcribed to cDNA and used in Sybr green based q-PCR 
reactions as described in Methods (Sections 2.15 to 2.19). These results are mean 
expression levels of transcripts in both activated and non-activated cells normalized 
to HKGs, CYC and RPL13A. Open white bars represent controls and closed black 
filled bars represent activated cells. Data represent the mean ± S.E.M. from three 
independent experiments, each performed in three replicates. Statistical differences 
between means were determined using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons test of the normalized data. * denotes 
P<0.01 when compared to untreated controls. The highlighted insert is an adjusted 
normalized expression profile of data below 0.150 units in order to optimize 
visualization of lowly expressed transcripts. 
6.4.6 Effect of Lipopolysaccharide and IFN- on the expression of 
heterodimeric amino acid transporter in cultured RASMCs and in murine 
J774 macrophages 
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In parallel studies to the above, changes in the expression profile of y+LAT1 
(SLC7A5), y+LAT2 (SLC7A6) and b0,+ (SLC7A9) were also examined. With the 
exception of b0,+ basal expression of each transporter was identified in both cell 
types in the absence of IFN- and LPS. In RASMCs, all transcripts present in 
controls were moderately enhanced following activation; with y+LAT1 and y+LAT2 
showing 3.17 and 2.21 fold increases respectively over control transcript levels 
(Figure 6.12). Although b0,+ was not expressed in controls, stimulation with both LPS 
and IFN- resulted in detectable levels of expression albeit at very low levels. In J774 
macrophages the results (Figure 6.13) showed increased expression in all three 
transcripts following stimulation with LPS. Increased expressions on y+LAT1, y+LAT2 
and b0+ were on average, 44.4 ± 0.02, 27.7 ± 0.08 and 1.16 ± 0.01 fold respectively. 
As in RASMCs the expressions of transporters in control cells were very low. 
 
A summary table of the changes in expression of all the transporters is shown in 
Table 6.5. 
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Figure 6.12 Effect of IFN- and LPS on the expression of glycoprotein 
associated amino acid transporters in RASMCs 
Confluent monolayer of RASMCs in T-25 flasks were cultured in complete DMEM 
alone (as Control) or stimulated with both LPS (100 µg/ml) and IFN- (100 U/ml) in 
continued presence of complete DMEM for 24 hours. Total RNA was isolated, 
DNAse treated, purified before being reverse transcribed to cDNA and used in Sybr 
green based q-PCR reactions as described in Methods (Sections 2.15 to 2.19). 
These results are mean expression levels of transcripts in both activated and non-
activated cells normalized to HKGs, CYC and RPL13A. Open white bars represent 
controls and closed black filled bars represent activated cells. Data represent the 
mean ± S.E.M. from at least three independent experiments, each performed in 
three replicates. Statistical differences between means were carried out using one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test 
of the normalized data. * denotes P<0.01 when compared to untreated controls. The 
highlighted insert is an adjusted normalized expression profile of data below 0.150 
units in order to optimize visualization of lowly expressed transcripts. 
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Figure 6.13 Effect LPS on the expression of glycoprotein associated amino 
acid transporters in J774 macrophages 
Confluent monolayer of J774 macrophages T-25 flasks were cultured in complete 
DMEM alone (as Control) or stimulated with LPS (1.0 µg/ml) in continued presence 
of complete DMEM for 24 hours. Total RNA was isolated, DNAse treated, purified 
before being reversed transcribed to cDNA and used in Sybr green based q-PCR 
reactions as described in Methods (Sections 2.15 to 2.19). These results are mean 
expression levels of transcripts in both activated and non-activated cells normalized 
to HKGs, UBC and RPL13A. Open white bars represent controls and closed black 
filled bars represent activated cells. Data represent the mean ± S.E.M. from at least 
three independent experiments, each performed in three replicates. Statistical 
differences between means were determined using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test of the normalized data. * 
denotes P<0.01 when compared to untreated controls. The highlighted insert is an 
adjusted normalized expression profile of data below 0.001 units in order to optimize 
visualization of lowly expressed transcripts. 
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Table 6.5. Comparison of relative expression between levels of arginine transporters in RASMCs  
and J774 macrophages 
 
 
HK GENES RAT SMOOTH MUSCLE 
CELLS (RASMCs)
FOLD EXPRESSION
MURINE J774 
MACROPHAGES
FOLD EXPRESSION
SLC7A1 (CAT-1) 1.59 ± 0.154 10.941 ± 1.252
SLC7A2 (CAT2A) 6.223 ± 0.072 0.473 ± 0.0068
SLC7A2 (CAT2B) 15.736 ± 0.347 24.980 ± 3.488
SLC7A7 (y+LAT1) 3.178 ± 0.0038 44.396 ± 0.0153
SLC7A6 (y+LAT2) 2.208 ± 0.01 27.709 ± 0.0835
SLC7A9 (b0+) - 1.16 ± 0.0098
NOS2 (iNOS) 1.58 ± 0.332 3081.9 ± 14.91
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6.5 DISCUSSION 
 
Housekeeping gene selection by assessing stability following gene 
expression 
 
In comparing the levels of gene expression in different cell types or under 
different physiological conditions it is suggested that the housekeeping genes-
(HKGs, also called reference or normalizer) must be stable and specific in the 
profile they exhibit (Dheda et al., 2004; Thellin et al., 1999). Whether in gene 
micro-array which offers a high throughput or in q-PCR for sensitivity and 
precision, normalization is considered critical to compensate for the subtle 
changes in expression or variability in assays in order to allow accurate 
comparison of data between different samples and under varying condition. It is 
now widely recognized that there is not a single gene that is stable or suitable as 
a control under all experimental conditions (Bustin et al., 2004). In this thesis we 
addressed these short comings by systematically analyzing the stability of a 
panel of HKGs prior to our target gene expression studies. Without these safe 
guards in place there could be misinterpretation of gene expression of target 
genes. Commonly used HKGs in expression studies have in the past included 
beta actin (ACTB), glyceraldeyde-3-phosphate dehydrogenase (GAPDH), beta-2-
microglobulin (B2M), ribosome small subunit (18S) ribsosomal RNA (rRNA), 
Ubiquitin C (UBC), hypoxanthine guanine phosphoribosyl transferase (HPRT), 
succinate dehydrogenase complex, subunit A (SDHA) and Tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
polypeptide (YWHAZ). Previous literature reported that genes such as GAPDH, 
beta-2-microglobulin, 28S RNA and -Actin (ACTB) were widely used in many 
and past investigations and have presently been found to be very unstable under 
some experimental conditions (Deindl et al., 2002; Goidin et al., 2001; 
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Schmittgen et al., 2000; Suzuki et al., 2000) and therefore unreliable. The 
outcomes have therefore rendered such genes unsuitable as HKGs under the 
conditions reported (Dheda et al., 2004; Thellin et al., 1999; Zhong et al., 1999). 
In view of the importance of identifying statistically significant data in this study 
we investigated a panel of 8 commonly used HKGs (as shown in Table 2.) in 
both RASMCs and J774 macrophages under both normal physiological and 
pathophysiological conditions. The pathophysiological conditions were induced 
using LPS alone or LPS+IFN- or IFN- alone. 
 
Secondly the quality of the extracted RNA could impact on the accuracy of our 
data. All extracted RNA was routinely analyzed on both gel electrophoresis to 
detect 28s and 18s bands and additionally analyzed on the spectophotomter for 
the 260/280 ratio (optimum range was between 1.78 and 2.08). These 
parameters were critical in validating our target gene expression studies. RNA 
quality, outside of these criteria was excluded from our final analysis and in 
addition to the presence of non-specific products or primer-dimers in our q-PCR 
assays. It is suggested that these artefacts do limit the dynamic range of the 
desired standard curve as a result of the apparent insufficient reaction 
components due to competition in the amplification cycle (Bustin et al., 2004). 
 
In monitoring the small changes in mRNA expression (Bustin, 2002), q-PCR 
assays combines the sensitivity, reproducibility and a wide quantification range of 
newly synthesized DNA in transcripts (Bustin, 2000). To this end we also 
demonstrated in this thesis the reliability of our q-PCR assays and amplification 
on the required genes being expressed by ensuring that each target gene had a 
representative product specific profile generated in our melt curve analysis after 
the amplification cycle. The melt curve is the first derivative of the plot which 
signifies the rate of change of fluorescence (Sybr Green assay) as a double-
stranded PCR product melts in real time as a function of temperature (dF/dT). 
We further ensured that the product sizes of amplified transcripts in the real time 
PCR assays in this study were directly correlated with respective amplification 
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temperature (Tm). All the target genes in this study had a unique peak as 
demonstrated in the melting curve profiles of all the carrier transporter transcripts 
being expressed using SYBR Green I. 
 
Results from this study using the geNorm approach to select the most stable 
HKG identified RPL13A and UBC as the most stable HKG in J774 macrophages 
with both having geNorm (M) stability values of 0.026. In RASMCs however both 
CYC and RPL13A were shown to be the most stable HKG, both with slightly 
higher geNorm (M) stability values of 0.152. In addition results in this study 
demonstrated a wide range of stabilty in gene expression across the treatment 
conditions used. These suggest that there is species or even cell type specificity 
in stability of housekeeping genes depending on the treatment conditions. 
 
Our results thus confirmed tissue specificity in expression variability of these 
genes. The geNorm analysis (Vandesompele et al., 2002) approach to select the 
most appropriate HKG in both cell models incorporated two key parameter in our 
analysis; an average stability measure (M) and a pairwise variation (V). A low M 
value was indicative of stable expression and with minimum V cut-off value of 
0.15 to require an additional gene in normalizing the gene of interest (GOI) 
(Vandesompele et al., 2002). The selected genes also demonstrated very high 
expression profiles with comparatively reduced expression variability as required 
in current approaches to normalization (Galiveti et al., 2010; Pfaffl et al., 2004; 
Vandesompele et al., 2002). In addition, data analysis from this study 
incorporated the geometric averaging of multiple control genes to improve on 
previous normalization strategies that were based on a single gene which led to 
erroneous results. We assessed the stability of the chosen genes by using the 
geNorm VBA applet (Vandesompele et al., 2002). Although we only used the 
geNorm strategy in this study, similar analytical tools comparable to the geNorm 
approach of gene normalization have been reported. The ‘Best Keeper’ and 
‘NormFinder’ (Andersen et al., 2004; Pfaffl et al., 2004) tools have been reported 
to achieve comparable results. 
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In summary, we have demonstrated in this study the reliability of the RPL13A 
and CYC in J774 macrophages and with RPL13A and UBC in RASMCS as 
stable HKGs to efficiently normalize gene expression studies in mouse and rat 
respectively. Several different investigations when normalizing HKGs have also 
found RPL13A to be a very reliable control gene though under different 
conditions (Curtis et al., 2010; Quiroz et al., 2010). It is however important to note 
that the selected genes could not account as appropriate normalizers for all 
experimental conditions associated with the respective cell models. They 
however represent adequate HKG targets in pro-inflammatory mediated 
conditions in view of their low gene expression variability amongst the HKGs so 
far examined in this thesis. Surprisingly, commonly used HKGs such as GAPDH, 
B2M and ACTB were inadequate HKGs under such pro-inflammatory mediated 
conditions and are therefore best avoided in any future experiments. The use of 
inappropriate HKG could lead to misinterpretation of gene expression pattern of 
the GOI. Given that gene stability is dependent on tissue or cell type specificity in 
addition to the physiological condition, it was imperative to validate chosen HKGs 
before embarking on any gene expression profiling. We have also demonstrated 
the ability of RT/ q-PCR as a platform for adequate assessment of gene stability 
without priori evidence. It is our hope that this study will identify novel genes 
relevant to pathophysiological processes as well as provide an insight into the 
complex regulatory system of iNOS induced nitrite production during 
inflammation. 
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Expression of Transporters responsible for L-arginine uptake: 
y+ system of transporters 
 
Transporters of L-arginine are of particular importance not only as a source of 
essential amino acids but also as a key substrate for NO production in the 
vasculature by maintaining vascular tone, endothelial permeability, cell migration 
and proliferation. Moreover the cellular rate of nitrite production is principally 
dependent on L-arginine availability (Beasley et al., 1991; Bogle et al., 1992a; 
Iyengar et al., 1987; Wileman et al., 1995). Thus the fact that proinflammatory 
mediators also enhance L-arginine transport makes these carrier proteins 
potential targets for regulating induced NO synthesis. 
 
To identify the carrier(s) responsible for substrate supply to iNOS it is important 
to examine the profile of expression of these proteins in different cell systems 
and this was examined in the RASMCs and J774 macrophages used in this 
thesis. In general, L-arginine transportation is mediated by a class of amino acid 
transporters largely characterized by their substrate specificity, relative affinity 
and ion dependency (Deves et al., 1998b). To identify which may be expressed 
in the two cell systems, q-PCR gene expression analysis using the geNorm 
approach was carried out on total RNA isolated from each cell type. The data 
obtained has revealed, for the first time, the expression of transcript for all the 
sodium-independent transporters, (namely y+, y+L and b0+) in both RASMCs and 
J774 macrophages. These observations are interesting because these carriers 
are thought to be selectively expressed in specific tissues. For instance, CAT-1 is 
ubiquitously expressed except in liver, and mediate high affinity (Km: 0.1-0.2 mM) 
transport of L-arginine under normal physiological conditions (Kim et al., 1991; 
Wang et al., 1991). In contrast, CAT2A is thought to be more restricted in its 
expression and present predominantly in liver where it mediates low (Km: 2.1-5.2 
mM) affinity uptake of L-arginine (Closs et al., 1993a; Kavanaugh et al., 1994b) 
Because of this, CAT2A was thought to function only adequately at high 
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extracellular substrate concentrations and has led to the suggestion that it may 
not contribute significantly to L-arginine uptake into cells under normal 
physiological conditions. The present findings from this thesis however showed 
that this transporter is indeed expressed albeit at low mRNA level. 
 
We are not able at present to establish whether the expressions of any of these 
transporters or indeed the increases observed reflect changes in functional 
activity of the respective proteins. It is therefore not clear from these studes as to 
what the significance is of the expression of any of the transporters identified. 
There is presently very little published literature on the regulation of the y+LATs 
or bo,+ by inflammatory mediators and this is the first study to show their 
regulation by IFN- and/or LPS. Further studies looking at the expression of each 
protein both at the transcript and protein levels and correlating with changes in 
iNOS activity are required. In the interim, it is worth noting that some of the 
findings support previous publications which have demonstrated enhanced 
CAT2B expressions in macrophages (Chen et al., 2006; Hammermann et al., 
2000; Liu et al., 2006), lung fibrosis (Niese et al., 2010; Rothenberg et al., 2006) 
and inflammatory induced endothelial cells (Visigalli et al., 2010). The implication 
is that upregulation of this transporter under inflammatory conditions may 
facilitate enhanced substrate supply for sustained NO production in inflammation. 
This however needs further examination for the hypothesis to be substantiated 
unequivocally. 
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CONCLUSION 
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Understanding the signaling pathways, as well as the molecular mechanism 
regulating iNOS expression is very important if novel therapeutic strategies are to 
be developed to modulate the excess production of NO and its deleterious 
consequences in disease states. Strids towards achieving this have been taken 
by many laboratories including ours where the focus has been to identify the key 
signalling mechanisms that mediate the induction by inflammatory mediators of 
both iNOS and L-arginine transport in cultured vascular cells and macrophages. 
In previous studies, the group’s work has focused on the MAP kinases and has 
established a role of the p38 but not the p42/44 MAPKs in these processes 
(Baydoun et al., 1999). In this thesis the focus has been on the JAK/STAT 
pathway largely because of the lack of clarity in the role of the latter in the 
induction of iNOS. As already discussed earlier, there is conflicting data about 
the role of the JAKs in iNOS expression in different cell systems. This is 
highlighted by the fact that in previous studies in our group, they could not 
establish a critical role for JAK2 in the initiation of iNOS expression by LPS and 
IFN- in smooth muscle cells (unpublished observations). As already mentioned 
this contrasts with other published literature and is puzzling since IFN-is widely 
known to signal through JAKs. 
 
The reasons for the discrepancies highlighted above are unclear but may simply 
reflect differences in cell systems or species. A clear approach using both 
molecular and pharmacological interventions was needed to unequivocally 
establish whether activation of the JAK/STAT pathway is indeed relevant for cells 
to express iNOS. Thus in this thesis a strategic approach was taken using two 
known pharmacological inhibitors of the JAKs as well as developing an siRNA 
protocol for knocking down JAK2. These two approaches together have helped 
confirm the group’s preliminary findings and established clearly that activation of 
JAK2 is not a critical signaling protein for iNOS and indeed L-arginine transport. 
The studies were carried out in smooth muscle cells and in J774 macrophages. 
The rational for working with these cell types is because smooth muscle cells 
have been reported to be the predominant cells within the vasculature that 
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express iNOS in inflammatory conditions such as septic shock (Liu et al., 1997) 
and macrophages play a major role in host defense through production of NO 
(Kolyada et al., 1996). 
 
The results in this thesis have confirmed the effective and sustained induction of 
iNOS and L-arginine transport in RASMCs using a combination of LPS and IFN- 
and in J774 macrophages, using LPS alone. These observations are consistent 
with the group’s previous studies (Baydoun et al., 1998; Baydoun et al., 1993a) 
and demonstrates cell specific difference in their stimuli requirement for optimum 
iNOS induction and activity. RASMCs required both LPS and IFN- exposure 
whiles J774 macrophages required LPS alone in order to induce iNOS protein 
expression, NO production and L-arginine transport. This induction pattern is 
consistent with the concept of cell type dependent specificity (Gao et al., 1997; 
Kolyada et al., 1996; Marrero et al., 1998). Current molecular evidence from 
other studies suggests that IFN- primes the induction of iNOS expression by 
stabilizing and thus prolonging the half-life of iNOS mRNA expression (Ozaki et 
al., 2010). This may not be required in macrophages and as such LPS alone is 
sufficient to induce sustained expression of iNOS. 
 
The induction of iNOS in both our cell systems was regulated differentially by the 
two JAK inhibitors used: JAK inhibitor I, a non specific tyrosine kinase inhibitor 
and the specific JAK2 inhibitor, AG490. Our results demonstrated significant 
reduction in iNOS protein expression, NO production and L-arginine transport 
with JAK inhibitor I but not with AG490 in both RASMCs and J774 macrophages. 
The inhibitions in the smooth muscle cells although dose dependent, were only 
partial suggesting that other pathways independent of that inhibited by JAK 
inhibitor I may also be involved. In addition these results suggest that the 
inducible L-arginine-NO pathway is induced by a complex network of more than 
one signaling transduction mechanisms. In contrast, in J774 macrophages the 
reductions following pre-treatment with JAK inhibitor I were much nearer to basal 
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levels in comparisons with that in RASMCs, suggesting that in these cells a JAK 
inhibitor I pathway may be exclusive for the induction of iNOS. 
 
Since JAK inhibitor I is a known inhibitor of the JAKs, it is tempting to conclude 
from the data obtained that a JAK is involved in the actions of IFN- and/or LPS 
in inducing both RASMCs and J774 macrophages. However, the consistent lack 
of effect demonstrated with AG490 would argue against a role for JAK2, the key 
JAK implicated by others as already explained. One hypothesis considered for 
the lack of action of AG490 is the possible lack of expression and/ or 
phosphorylation of JAK2 and TYK2 in RASMCs and J774 macrophages in 
response to IFN- and/or LPS. We therefore next examined the expression of 
these two proteins and further examined whether these were phosphorylated 
following exposure of RASMCs to LPS and IFN- or J774 macrophages to LPS 
alone. The data showed conclusively that both cell types expressed these JAKs 
albeit at different intensities in control cells. In the follow up study we could not 
demonstrate that either JAK2 or TYK2 was phosphorylated following induction of 
cells.These results suggest these JAKs were constitutively expressed in the 
respective cell types examined but not activated/phosphorylated. The reason for 
this unexpected finding is unclear but gives an insight, at least to why AG490 
was without effect. 
 
To have further evidence in eliminating JAK2 as a potential regulator of the 
expression of iNOS, studies were carried out using siRNA targeting knockdown 
of JAK2 in RASMCs. These studies unequivocably established that JAK2 was 
not required since siRNA mediated knockdown of this protein failed to 
significantly change iNOS expression or function. Although similar studies were 
not carried out in the J774 macrophages because of difficulties in transfecting 
these cells, it would not be unreasonable to speculate that the same may apply 
because of the lack of effects with AG490. This however will need to be 
confirmed in similar studies to those carried out in the RASMCs once suitable 
transfection strategies can be developed for macrophages. 
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Other than JAK2, there are three other proteins which are part of the JAK family 
and any one of these could potentially mediate the effects of the interferons. 
However as already argued in Chapter 3, a case could be made to eliminate 
JAK1, JAK3 and Tyk2. The argument given is that JAK3 is also susceptible to 
inhibition by AG490 which was without effect in our studies and JAK1 appears to 
be irrelevant for IFN- signalling. TYK2 on the other hand appears to mediate 
IFN-/ rather than IFN- signalling (Karaghiosoff et al., 2000). Thus, if none of 
the JAKs are involved, the question raised is what could be the target for JAK 
inhibitor I and are any other components of the JAK pathway such as the STATs 
involved? To answer these questions, the studies carried out were extended to 
investigate (i) the role of upstream signalling GTPases and (ii) whether STAT-1 
was indeed activated through phosphorylation following exposure of cells to pro-
inflammatory mediators. The latter study is critical because STAT-1 can be 
activated downstream of the JAKs but more importantly, in the contest of our 
initial findings, can also be activated directly by GTPases and independently of 
the JAKs (Pelletier et al., 2003). Such a mechanism could explain the JAK-
independent induction of iNOS and L-arginine transport. 
 
Western bloting initially carried out to detect STAT-1 expression and its activation 
revealed that this protein was indeed expressed in the cells and could be 
phosphorylated when cells were stimulated with their respective inducers. 
Interestingly, parallel studies carried out established that the expression of 
phospho-STAT-1 could be blocked by JAK inhibitor I but not by AG490 in both 
RASMCs and J774 macrophages. Thus the actions of JAK inhibitor I may be 
mediated via inhibition of STAT-1 activation which may involve inhibition of 
upstream signaling molecules independent of JAKs. At present the precise 
upstream targets for the JAK-independent activation of STAT-1 or indeed for JAK 
inhibitor I are not known and would require further studies in future to be able to 
determine what these are. 
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In terms of earlier signaling events that may feed through STAT-1 to induce the 
iNOS pathway the GTPases stand out as potential targets. The roles of these 
molecules were explored using atorvastatin, a 3 hydroxy 3-methylglutaryl CoA 
(HMG-CoA) reductase inhibitor. Statins reduce the geranylgeranylation and 
farnesylation of small GTPases, particularly the Rho and Ras proteins (Xiao et 
al.). These actions lead to down-regulation of their activities which has direct 
pleiotropic cellular actions, restricting or abrogating isoprenylation and thus 
modulation of events further downstream (Liao et al., 2005; Mason, 2003). 
Parallel studies were also carried out using Y-27632, a prenyltransferase inhibitor 
which specifically inhibits Rho activity (Uehata et al., 1997). These studies were 
initially conducted to determine whether STAT-1 phosphorylation was mediated 
through the GTPases independent of the JAKs. However, because of time 
constraints the experiments eventually carried out were restricted to establishing 
the effects of GTPase inhibitors on iNOS expression, NO production and L-
arginine transport. The results obtained demonstrated that all three parameters 
were regulated by inhibitors of GTPases/Rho. In each case what was interesting 
was the observation that incubating cells with either Y-27632 or atorvastatin 
enhanced IFN- and/or LPS induced effects. These observations suggest that 
GTPases/Rho may suppress the induction of the inducible L-arginie-NO pathway 
and their inhibition enhances the expression and/or function of the latter. This 
would however question whether GTPases in fact feed through STAT-1. Indeed 
western blots showed clearly that STAT-1 was phosphorylated by IFN- and/or 
LPS which coincides with the induction of the inducible L-arginine-NO pathway. 
Moreover, treatment of cells with JAK inhibitor I blocked STAT-1 phosphorylation 
and subsequent expression of iNOS, NO production or enhanced L-arginine 
transport. Thus, if STAT-1 plays a role in our cell system, this would be to induce 
the L-arginine-NO pathway. Because the GTPases appear to suppress this 
process, it is unlikely that they do so by activating STAT-1. Of course they may 
inhibit the latter but this was not what we had hypothesized and would not be in 
line with other published literature. This is however an interesting point which will 
need further investigation in future studies. 
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In the case of atorvastatin, we cannot rule out that this compound may have 
other effects which directly affect the function of the induced proteins. This may 
be particularly true for iNOS since treatment of cells with the statin enhanced 
nitrite production without altering iNOS protein levels. Thus, in this case it is likely 
that atorvastatin regulated the function rather than the expression of iNOS. 
Atorvastatin is also known to have anti-oxidant properties and as a result could 
alternatively have had direct effects on the NO produced, thus preventing its 
interatction with superoxide radicals. In doing so, atorvastatin may be able to 
enhance the amount of nitrite detected even though there was no change in the 
levels of iNOS expressed. Further studies may however be required to fully 
understand the underlying mechanism(s) of action of atorvastatin under our 
experimental conditions. 
 
Because of the critical role of L-arginine transporters may play in sustaining 
substrate supply to iNOS, some time was dedicated in this thesis to examine in 
more detail the intrinsic differences between the different transporters for L-
arginine in both control and under cytokine mediated inflammatory conditions. As 
previously stated, transport of L-arginine into cells is mediated by several classes 
of CATs, characterized on the basis of ion dependency, substrate specificity and 
relative affinity (Deves et al., 1998b). To address any subtle changes in the 
expression profiles in both cell types we used q-PCR, the most sensitive 
technique for gene expression. However, along with its sensitivity and wide 
dynamic range is the risk of data misinterpretation. This may result from 
inadequate sample preparation, inefficiencies in RNA extraction and RT 
procedures as well as amount and quality of RNA material. Other more intrinsic 
factors include poor primer design and inappropriate HKG selection. HKGs are 
used to normalize qPCRs in order to reduce possible sources of errors generated 
during the quantification of gene expression. The current MIQE guidelines 
(Bustin et al., 2010; Bustin et al., 2009) in addition to other independent 
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publications (Becker et al., 2010; Taylor et al., 2010) have been of enormous 
assistance to scientist. 
 
Among the different normalisation strategies reported (Huggett et al., 2005; 
Vandesompele et al., 2002) we chose in this thesis the geNORM approach. Our 
results have identified RPL13A and UBC as the most stable HKGs in J774 
macrophages with both having geNorm (M) stability values of 0.026. In RASMCs 
however both CYC and RPL13A were the most stable HKGs, both with slightly 
higher geNorm (M) stability values of 0.152. Thus even among different cell 
types, there are variations in the HKGs inspite of having the same experimental 
conditions. The most stable HKG across the cell types examined in this thesis is 
RPL13A. 
 
We have also demonstrated that the y+ system of cationic amino acid 
transporters are constitutively expressed in both J774 macrophages and 
RASMCs. In addition in both LPS mediated activated J774 macrophages and 
LPS and IFN- mediated activated RASMCs, the high affinity CAT2B mRNA 
expression was significantly enhanced. Up-regulation of CAT2B mRNA 
expressions in J774 macrophages was significantly much higher in comparison 
to that in RASMCs following activation. CAT2A mRNA expression are however 
down-regulated in J774 macrophages in contrast to its up-regulation in RASMCs 
which may demonstrate contrasting roles of transporters in substrate supply to 
iNOS. How variation in mRNA expression correlates with functional activity 
however remains to be established but only when suitable antibodies for each 
transprter becomes commercially available. At present we are unable to acertain 
or determine whether the increased mRNA levels translate to increased protein 
levels.  
 
 
Apart from the system y+ transporters other experiments examined expression of 
the y+L and b0+ systems. As with the y+ carriers the results from q-PCR analysis 
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showed changes in both y+L and b0+ expressions. The significance of these 
changes or indeed the expression profiles established will need further 
investigation if we are to determine the relevance of each carrier or system of 
carriers for substrate supply to iNOS for sustained NO synthesis. In the intrem, it 
is important to appreciate that both vascular smooth muscle cells and 
macrophages express multiple transporter systems for L-arginine and each may 
be capable of supplying this amino acid into cells, thereby supporting NO 
synthesis. Moreover, these transporters can be upregulated and via signaling 
mechanisms which may overlap with those required for the induction of iNOS. 
 
In conclusion, a series of detailed studies have been carried out as part of the 
programme of work for this thesis which has confirmed that the induction of iNOS 
and L-arginine transport occur in parallel in both smooth muscle cells and in 
macrophages. The induction of these processes appears to be independent of 
the JAKs but dependent on the phosphorylation of STAT-1, a potential 
downstream target for activation by JAKS. However, in our cell systems, it would 
appear that STAT-1 activation may occur independently of the JAKs. At present 
we have not been able to conclusively determine the upstream activator of 
STAT-1 but have established that its phosphorylation may be critical for the 
expression of the inducible L-arginine-NO pathway. In achieving this we have 
also demonstrated or at least given an indication that the so called selective JAK 
inhibitor, Jak inhibitor I, may have actions independent of inhibition of the JAKs. 
In addition, we have demonstrated that potential GTPase inhibitors, including the 
widely used atorvastatin may enhance NO synthesis and this could have 
implications in certain pathologies where it may be beneficial or harmful. 
 
Although these findings and conclusions are supported by the data, it has to be 
acknowledged that power calculations were not carried out for the studies 
conducted and as such it may be possible that these were underpowered. Each 
study was however carried out in at least three independent experiments and in 
some cases with 6 replicates in each. Although the validity of the statistical tests 
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for underpowered studies may be limited, there is confidence that the trends 
obtained are indeed reproducible and consistent with both our previous work and 
with those of many other studies. Thus, the conclusions reached from the 
findings in this thesis would still be considered valid and indicative of the critical 
cellular events that regulate the induction, expression and function of the 
inducible L-arginine-NO pathways in the cell systems investigated. These 
pathways could be targeted in future therapeutic strategies to regulate iNOS 
expression and function and potentially the induction of L-arginine transport. 
Coupled to this, strategies could also be developed, targeting the LPS and/or 
cytokine receptors associated with the induction of these processes. Although 
there is some skepticism about the clinical efficacy of therapies targeting 
cytokines, there is emerging evidence that blockade of TNF-α is beneficial in a 
number of diseases including Rheumatoid Arthritis (Camussi et al., 1998; Maini 
et al., 1995; Reimold, 2003), ankylosing spondylitis (Braun et al., 2002; Mathieu 
et al., 2010), psoriasis (Tobin et al., 2005; Woolacott et al., 2006), and 
inflammatory bowel disease (Milia et al., 2009; Perrier et al., 2011). Furthermore, 
there is growing optimism that blockade of other cytokines such as IL-13, IL-9 or 
IL-4/13 receptors may be beneficial in asthmatics. These findings are beginning 
to set the trend for targeted cytokine/cytokine receptor therapy in disease 
treatment and it is likely that this can be extended to diseases associated with 
the induction of iNOS. 
 
It however remains to be determined if targeting iNOS receptors as a therapeutic 
strategy is useful in the long term management of inflammation and sepsis in 
patients. This view is taken given the fact that iNOS induced nitrite production 
also serves a specific function in host defence against microbial infection and 
tumours. In addition, given the multiple and complex signalling cross-talk 
associated with iNOS induction, further investigations will be required and 
therapeutic strategy astutely devised and diligently evaluated in order to achieve 
a better outcome of disease. 
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FUTURE WORK 
 
The studies carried out in the thesis have generated data which has helped in 
shedding some light on the regulation of expression of the inducible L-arginine-
NO pathway but at the same time raised some questions which will need 
addressing. Thus in developing this project in future the following is proposed: 
The siRNA studies have demonstrated clearly that JAK2 may not be required for 
the induction of expression of the inducible L-arginine-NO pathway. Similar 
studies targeting TYK2 are now required to conclusively establish its role in this 
process. 
 
In parallel with the above, additional studies using TYK2 specific pharmacological 
inhibitors could be used when these become commercially available. Such 
compounds could be used to investigate changes in iNOS expression, NO 
production, L-arginine transport and STAT-1 phosphorylation in both RASMCs 
and J774 macrophages. 
 
Studies establishing whether atorvastatin or Y-27632 regulate GTPAses and thus 
STAT-1 phosphorylation are also needed to confirm whether there is a direct link 
between these two targets. These studies could examine changes in STAT-1 
phosphorylation by western blotting in both RASMCs and J774 macrophages 
treated with either atorvastatin or Y-27632. 
 
The potentiation of nitrite levels by atorvastatin without any significant change in 
iNOS expression would suggest effects of the drug at the functional level or 
indeed throught a direct antioxidant action on the NO generated. Studies are 
therefore needed to establish whether the atorvastatin effects are mediated 
through its antioxidant properties. These could include determining levels of 
reactive oxygen species (ROS) produced under each experimental condition and 
establishing whether ROS generation is altered by atorvastatin and whether this 
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correlates with changes in nitrite levels. Because of time limitations it was not 
possible to establish whether the increases in transport of L-arginine in both cell 
models following pre-treatment with atorvastatin were associated with changes in 
CAT transporter gene expression. These studies remain critical. 
Since Y-27632 has been shown to enhance nitrite levels, experiments confirming 
whether this compound also alters iNOS expression are required. This is 
important since atorvastatin which produced similar effects on nitrite did not 
appear to alter levels of the enzyme.Though our result profile of CAT mRNA 
transporter expression in this thesis has also confirmed previous reports, the 
present lack of available antibodies for the respective transporters examined 
make it difficult to reconcile the changes in mRNA expression to protein 
expression and to functional activity. Further work will be required to address this 
when antibodies become available for these transporters. In addition, the 
implication of an enhanced CAT2B expression is up-regulation of this transporter 
under inflammatory conditions. This may facilitate enhanced substrate supply for 
sustained NO production in inflammation. This however needs further 
examination for the hypothesis to be substantiated unequivocally. 
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